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ABSTRACT 
 
JOSEPH MICHAEL THOMPSON:  Venezuelan Equine Encephalitis Virus Particles:  
Mucosal Vaccine Vectors and Biological Adjuvants 
(Under the direction of Dr. Robert E. Johnston) 
 
 Vaccination is the most effective control measure in the fight against infectious 
diseases, and represents an opportunity to intercede in the spread of dangerous organisms 
through prophylactic intervention.  Viral vectors, including alphavirus vectors, have proven 
to be powerful vaccine delivery vehicles and a promising platform for vaccines against 
multiple pathogens.  Specifically, as demonstrated here, Venezuelan equine encephalitis 
virus (VEE) replicon particles (VRP) induced strong humoral, cell-mediated, and mucosal 
immune responses directed against heterologous antigens expressed from the viral genome, 
as well as against antigens simply mixed with VRP.  These observations established a dual 
function of VRP as both vaccine expression vectors and vaccine adjuvants, demonstrating 
that VRP possess intrinsic immunostimulatory properties.  When utilized as adjuvants, VRP 
systemic humoral adjuvant activity was as strong as the activity of CpG DNA.  In addition, 
the mucosal responses induced by VRP adjuvants were superior to those induced by CpG, an 
effect that was dependent upon VRP RNA replication.   The induction of mucosal immune 
responses is critical for vaccine-mediated protection following challenge with mucosal 
pathogens.  Delivery of antigens directly to mucosal lymphoid tissues, as occurs following 
mucosal delivery, results in the strongest mucosal immune responses. While this has revealed 
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the components of the natural mucosal inductive pathway, little is known regarding the 
lymphoid structures responsible for mucosal immune induction following nonmucosal 
delivery.  Here we demonstrate that following nonmucosal VRP vaccination, several markers 
of mucosal lymphoid tissues were present in the draining lymph node (DLN). This included 
the presence of antigen-specific polymeric IgA antibodies, upregulated expression of the α4β7 
integrin on DLN lymphocytes, expression of the mucosal addressin, MAdCAM-1, and the 
production of IL-6 and other mucosal cytokines.  The presence of these markers is consistent 
with a model in which the DLN is converted by VRP infection into the functional equivalent 
of a mucosal inductive site.  Furthermore, while type I interferon (IFN) signaling was not 
required for VRP adjuvant activity, it was critical for the induction of mucosal IgA responses 
induced by VRP expression vectors.  Together, these findings may significantly improve 
both our knowledge of viral immunology and the efficacy of viral-based vaccines. 
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GENERAL PRINCIPLES OF VACCINATION 
 
Historical Perspective 
 The earliest recorded accounts of variolation, or vaccination, date back as far as 1000 
A.D. in China, where smallpox scabs or pustules from infected individuals were used to 
inoculate unexposed people and afforded a significant degree of protection (207, 294).  It was 
stated that following this procedure, “not one in 10, not one in 100 does not recover.” (98, 
207).  Reports of parenteral smallpox variolation surfaced in India, Asia, and Africa as early 
as the sixteenth century (207, 291).   In eighteenth century Europe, smallpox was a 
devastating illness, responsible for 8-20% of all the deaths in both rural and urban 
populations (8).  It was recognized by physicians and scholars of the time that milkmaids 
often acquired a pox-like infection from cows, and in turn, were spared from the most 
agonizing symptoms of smallpox (98, 207, 339).  However, a direct relationship between the 
mild pox infection and protection from smallpox infection was not established until 1796, in 
the pioneering work performed by Edward Jenner. 
 On May 14, 1796, Jenner inoculated a 13-year-old boy, James Phipps, with the 
cowpox or vaccinia virus obtained from a woman named Sarah Nelmes, who was 
accidentally infected by a cow named Rosebud (8).  James Phipps was deemed “secure” or 
immune to a subsequent smallpox challenge delivered “some months afterwards.” (8, 207).  
Thus, the science of vaccine inoculation (159), or vaccination, as coined by Louis Pasteur 
many years later (207),  was born.  As a result of these discoveries, and as predicted by 
Jenner (8, 207), smallpox has been eradicated from its natural environment in the world by a 
vaccine developed approximately 200 years before (98).   
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The Jennerian approach to vaccination was first deliberately applied by Louis Pasteur, 
following his discovery of the principle of attenuation (291, 294).  Pasteur returned to the 
laboratory following a vacation over the summer of 1881 to find a culture of a Pasteurella 
species, the causative agent of fatal chicken cholera, which had been left out on the bench 
over the summer.    Pasteur discovered that the aged culture was avirulent in chickens, and in 
fact, protected chickens from lethal disease following challenge with fresh cultures (207, 
280, 291).  These results served as the groundwork for the hypothesis that organisms could 
be rendered attenuated by exposure to external insults.  This hypothesis was confirmed by his 
work on anthrax and rabies over the next several years (207, 281, 291), a remarkable 
achievement given the fact that he was unable to cultivate the rabies virus in vitro, as cell 
culture for the purposes of virus growth was not adapted until the middle of the twentieth 
century (379).  The concept of attenuation was applied to a number of organisms over the 
next century (291, 294), including Mycobacterium bovis by Calmette and Guerin (49) and 
yellow fever virus by Max Theiler (357).  To date, live attenuated vaccines still serve as 
some of the most immunogenic vaccines ever produced, most likely due to the fact that they 
most closely mimic the events which occur following a natural infection (109, 179, 260, 
372).   
 
Immunological Correlates of Protection and Vaccines 
 The development of new vaccine technologies in the twentieth century has brought 
about vaccines for lethal diseases such as diphtheria, tetanus, paralytic poliomyelitis, 
pertussis, measles, mumps, rubella, Haemophilus influenzae type b (Hib), and Hepatitis A 
and B [reviewed in (8, 291, 294, 295)].  These vaccines are based on live attenuated 
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vaccines, subunit or whole-cell bacterial vaccines, and/or recombinant production of 
individual vaccine components [reviewed in (8, 291, 294, 295)].  These advances have 
significantly increased overall life expectancy over the last few decades (29, 290), with 
widespread vaccination efforts in infants estimated to save the lives of 3 million children a 
year (8).  Systematic administration of existing vaccines would save millions of additional 
lives worldwide  (7, 384).   
 The overall goal of vaccination is to generate memory B and T cell responses 
sufficient to protect the individual from a natural infection (196).  While the concept of 
protective immunity is a relative quantity/quality of immune induction, much effort has  been 
exerted to define protective factors (288).  The nature and magnitude of the immune response 
required to provide protection clearly varies from pathogen to pathogen (100, 200, 203, 277).  
Knowledge of the correlates of protection for a specific organism is central to the design of 
an efficacious vaccine (288).  In general terms, vaccines activate B cell responses (antibody 
secretion or other activities), CD8+ T cell responses (usually as cytotoxic lymphocytes or 
CTLs), and/or CD4+ T cell responses to provide cytokine help for either B cell responses or 
CD8+ T cell responses (288, 315, 349).   
 
 A role for systemic antibody responses.  Protection from challenge after 
immunization with most traditional vaccines is mediated by the reduction in systemic spread 
of the organism, as manifested by a decrease in serum viremia or bacteremia, in the case of 
viral and bacterial pathogens, respectively.  This is normally facilitated by vaccine-induced 
specific serum IgG antibodies [reviewed by Stanly Plotkin (288)].  Here we provide support 
for the role of vaccine-induced systemic antibody responses in protection.   For example, 
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serum IgG responses directed against hepatitis A virus protect individuals from the onset of 
hepatitis.  In fact, gamma-globulin preparations from naturally-infected patients provides 
protection, allowing the establishment of a minimally protective dose (62, 338).  Studies in 
primates suggested that serum antibodies also protect from the paralytic manifestations of 
polio infection, presumably by limiting viremic spread to the CNS, even though viral 
delivery and replication occur in the gut. (26).  Systemic IgG antibodies also provide various 
levels of immunity to rabies virus infection (289), yellow fever virus infection (222), 
meningococcal polysaccharides (392), pneumococcal polysaccharides (180), and typhoid 
polysaccharides (292).  While controversy exists regarding which component of the pertussis 
vaccine is the dominant protective antigen (54, 242, 293, 360), it is clear that serum IgG 
antibodies play an important role in protection from this important pathogen as well (288).  
Serum IgG responses directed against bacterial toxins have also been shown to provide 
protection; such as is the case for vaccines against both diphtheria and tetanus (227, 228).   
 
A role for local mucosal antibody responses.  The examples provided above clearly 
demonstrate the importance of systemic antibody responses in vaccine-induced protective 
immunity (288).  However, what role do vaccine-induced systemic antibodies play in 
limiting infection at the local mucosal surface?  For example, polio virus replicates in the gut 
epithelium, and delivery of the oral polio vaccine (OPV) induces local mucosal immunity to 
subsequent challenge (348).  Interestingly, parenteral delivery of the inactivated polio 
vaccine (IPV) does not induce equivalent levels of local antibody production in the gut (94, 
253).  However, IPV does appear equally capable as OPV at reducing extraintestinal virus 
titers (219).  The effectiveness of IPV appears to be affected by previous natural or OPV 
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exposure (270, 288).  IPV vaccination only induced mucosal immune responses in previously 
infected individuals (141), suggesting that mucosal antigen delivery is required for the 
induction of mucosal immunity. 
It is also important to consider the relative contributions of both systemic and 
mucosal immunity antibodies in protection from infectious agents that either do not have a 
systemic replication stage in their life cycle, or have a very limited systemic phase.  Such is 
the case for both rotavirus infection as well as influenza virus infection.  The definitive 
correlates  of protection from rotavirus infection are not completely understood; however, 
resistance to natural infection appears to correlate with both systemic IgG and IgA antibody 
production (265).  It is likely that systemic IgA merely serves as a surrogate for mucosal IgA, 
as local IgA antibody production likewise appears to predict outcome of infection (223).  The 
inactivated parenteral influenza vaccine provides a strong degree of protection form 
mortality, although it does not block replication at the local mucosal surface.  Serum anti-
hemagglutinin titers correlate with protection (57, 71, 72, 144); however, it is thought that 
such antibodies are transudated onto the local lung mucosa to mediate protection, as 
influenza does not replicate to substantial levels outside the lung (90).  In a later section of 
this review, the anatomical basis and molecular mechanisms responsible for the induction of 
mucosal immune responses are discussed in detail (see below). 
 
A role for T cell responses.  Many natural infections with organisms and/or vaccine 
strains that replicate systemically and at the local mucosal surface result in the activation of 
efficient CD8+ T responses.  Such is the case with both rotavirus infection (267-269) and 
influenza virus infection (25, 106, 226).  As mentioned above, both antibody and T cell 
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responses may influence the outcome of infection with these mucosal viruses; however, T 
cell immunity alone, in the absence of an antibody response, is necessary and sufficient for 
protection with other pathogens.  The activation of CD4+ T cells and CD8+ T cells are critical 
for protection from Mycobacterium tuberculosis (TB) (69, 70, 274, 288), and the live 
attenuated vaccine (BCG)  is known to induce protective T cell immunity in humans and 
animal models (99, 275).   
T cell responses also play an important role with infections agents other than TB.  
CD8+ T cells are capable of killing virus- and bacterial-infected cells and represent one of the 
most critical clearance mechanisms, especially with chronic infections (83, 93, 208).    Cell-
mediated immune responses provide protective capacity either with primary infection or 
reactivation from latency with several herpesviruses including varicella zoster (13), herpes 
simplex virus type 1 (211), herpes simplex virus type 2 (243), Epstein-Barr virus (48), 
cytomegalovirus (168), as well as other chronic infections such as hepatitis C virus  (305).  
 
Herd Immunity.  This review has focused thus far on the effects of vaccination 
within a given vaccinated individual.  However, when considered on a population level, 
vaccination provides significant benefits even to the unvaccinated individuals within the 
population.  These benefits are manifested in at least 3 separate ways (288).  First, within a 
highly vaccinated population, there are fewer infected individuals, decreasing the likelihood 
of an exposure event.  Secondly, some vaccines, such as the Hib vaccine (245), reduce 
carriage of the organisms, further decreasing the chance of exposure.  Lastly, live vaccine 
strains have the potential to spread to, and directly induce immunity in, unvaccinated 
individuals, as was observed with OPV (154).  While controversy exists regarding the 
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nomenclature for herd immunity (164), the protective effect of vaccination in unvaccinated 
individuals is unquestioned, and should be considered in vaccine design.   
 
The status of human immunodeficiency virus vaccines.  While this review is not 
intended to be comprehensive in terms of vaccine-induced immunity to all human pathogens, 
we would be remiss not to mention the current status of human immunodeficiency virus 
(HIV) vaccine development.  There are approximately 5 million new HIV infections each 
year and the virus is spreading at an increased rate in numerous locales worldwide (203).  
The development of an efficacious vaccine would save the lives of millions of individuals.  
Unlike the scenario described above for many of the infectious agents in which the exact 
correlates of protective immunity are known, definitive correlates of protection from HIV 
infection have not been clearly established (203).  To date, the most promising protective 
efficacy has been demonstrated with live attenuated vaccines in the simian 
immunodeficiency (SIV) and simian human immunodeficiency virus (SHIV) models (190).  
In fact, live attenuated SIV vaccines not only provide protection from systemic challenge, but 
also from challenge by the natural mucosal route (317).  While this approach harbors the 
potential to define immunological correlates, delivery of live viruses is not feasible in 
humans because of the potential of generating a pathogenic revertant virus in vaccinees.   
Conflicting evidence exists regarding the ability of specific immune components to 
provide protection from SIV infections.  For example, passive antibody transfer studies have 
implicated humoral immune responses in protection from SIV following both systemic (128, 
220) and mucosal (221) challenge.  However, B-cell-depleted monkeys displayed normal 
virus clearance at early times following SIV challenge, suggesting that humoral immunity 
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may not play a dominant role (327).  In contrast, SIV was not controlled in monkeys lacking 
CD8+ T cells, directly implicating a role for cell-mediated immunity in protection from SIV 
infection (326).  Additionally, local mucosal immune responses are proposed to play an 
important role in protection as well (241).  As definitive proof regarding precise correlates of 
protection is lacking, a successful HIV vaccine most likely will need to stimulate humoral, 
cell-mediated, and mucosal immunity.   
 
New Vaccine Technologies.   
Traditional vaccine approaches have relied upon parenteral delivery of either live 
attenuated organisms, subunits/proteins derived from infectious organisms, or inactivated 
particles.  While these approaches have resulted in a plethora of efficacious vaccines against 
important human pathogens, it is estimated that infectious diseases still account for almost 
25% of deaths worldwide, particularly in developing countries (192, 272).  The failures 
associated with HIV vaccine development alone exemplify the need for new vaccine 
platforms.  Here we outline several of the promising new techniques currently under 
development at various stages from early preclinical studies to efficacy-stage clinical trials, 
including viral/bacterial gene transfer systems, adjuvants, DNA vaccines, differential 
prime/boost systems, and new delivery methods.  Again, this is not intended to serve as a 
comprehensive list, but instead provide a survey of the state of this new area of vaccinology.   
 
DNA vaccines.  The utilization of plasmid DNA as an antigen delivery system is a 
relatively recent development, first utilized in the 1980s [reviewed in (80, 365)].  Early 
studies with DNA vaccines demonstrated activation of both B cell and T cell responses in 
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small rodents and non-human primates (313, 363).  In humans, DNA vaccines elicit potent T 
cell-mediated immune responses (373); however, they appear inefficient at stimulating an 
antibody response directed against the encoded antigen (66).  DNA vaccines are traditionally 
delivered by the intramuscular (i.m.) route, which results in DNA uptake and antigen 
expression in myocytes.  Myocytes present the expressed antigen in the context of major 
histocompatibility complex (MHC) I molecules on the cell surface; however, as myocytes do 
not upregulate costimulatory molecule expression, other cell types most likely function as 
antigen-presenting cells (APCs) for immune activation (146) [reviewed in (189)]. Both local 
and recruited APCs, especially dendritic cells (DCs), become transfected and activate 
costimulatory molecules for direct activation of CD8+ T cells (389), or activation by cross 
priming (364).  DNA vaccines activate components of the innate immune system through the 
presentation of unmethylated CpG motifs present in bacterial DNA (182).  Bacterial DNA is 
recognized by toll-like receptor (TLR) 9 (see below), and stimulation of this pathway plays a 
pivotal role in the immunogenicity of DNA vaccines (14). 
DNA vaccines may be advantageous under various experimental conditions, 
including as a tool in neonatal or early childhood vaccines, when maternal antibodies are 
present.  Traditional vaccines which are reliant upon the authentic particles initiating 
infection or presenting antigen to the immune system are susceptible to interference by 
placentally-transferred antibodies (334).  As DNA delivery does not deliver any antigens 
which maternal antibodies can recognize, DNA vaccines may circumvent maternal antibody 
interference (333).  DNA vaccines have proven effective in numerous infectious disease and 
cancer models [reviewed in (80, 365)] either alone, or as components of an alternative prime 
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boost system; and therefore may enable the production of safe, efficacious vaccines in the 
future. 
 
Adjuvants.  Adjuvants were originally defined by Ramon as, “substances used in 
combination with a specific antigen that produced a more robust immune response than the 
antigen alone”  (306) [reviewed in (264, 335)].  Adjuvants can function to improve vaccine-
induced immunity in numerous different ways, including 1) increasing immunogenicity of 
weak antigens, 2)  enhancing the speed and/or duration of the immune response, 3)  
modulating antibody avidity, specificity, isotype, or subclass distribution, 4)  stimulating 
cytotoxic T lymphocytes (CTLs), 5)  promoting mucosal immune induction, 6)  increasing 
immunity in immunologically immature or senescent individuals, 7)  decreasing the antigen 
dose in a vaccine required to induce a protective response, or  8)  helping to overcome 
antigen competition in combination vaccines (264, 335).  Here we briefly introduce several 
common and new adjuvant systems and what is known regarding their mechanism/s of 
action. 
 
Alum.  While the adjuvant activity of aluminum-based mineral salts, or alum, was 
discovered over 80 years ago (117), it is, to this day, the only adjuvant approved in licensed 
vaccines by the Food and Drug Administration (FDA) in the United States (174).  It has been 
extremely difficult to precisely determine the mechanism/s of adjuvant activity associated 
with alum, as it has profound effects on numerous systems following in vivo delivery (42).  
The original hypothesis suggested that alum exerted its adjuvant activity by means of a 
“depot” effect, that is the deposition of antigen in the immune system for continued immune 
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stimulation (116); however, this notion has been challenged recently (124).  The major effect 
of alum appears to be the regulation of the Th1/Th2 environment (247) by promoting the 
production of Th2 cytokines, particularly interleukin (IL)-4 (362) and antibodies of the Th2 
IgG subtype, IgG1 (210).  Interestingly, alum still exerted a significant adjuvant effect in IL-
4 knockout (KO) mice (43), IL-13 KOs (43), IL-6 KOs (41), and tumor necrosis factor (TNF) 
receptor KO mice (41).  The production of IL-4 following alum delivery was markedly 
reduced in IL-18 KO animals; however, the production of IgG1 antibodies was not affected 
(296).  Alum has not proven an effective inducer of Th1 cytokines nor activation of delayed 
type hypersensitivity (DTH) reactions (127), consistent with a strong skewing towards Th2 
responses.  Together, these observations typify the complexity of the cytokine networks 
active following adjuvant delivery and underscore the difficulty in attributing adjuvant 
effects to a single immunological mechanism.  
 
Freund’s adjuvant/s.  Similar to the alum story, incomplete Freund’s adjuvant (IFA) 
and complete Freund’s adjuvant (CFA) were discovered over fifty years ago, and the 
mechanism of adjuvant activity remains elusive to this day (101) [reviewed in (22)].  IFA is 
composed of a paraffin oil surfactant mixture that, when mixed with antigen, forms a viscous 
water-in-oil emulsion with antigen in the water phase (101).  CFA also contains preparations 
of heat-killed Mycobacterium (M. tuberculosis and/or others) which play a significant role in 
immunogenicity (22)].  Like alum, CFA and IFA provide a potent adjuvant signal for the 
activation of antibody responses to co-delivered antigens (386).  Interestingly, CFA, but not 
IFA, induces cell-mediated immune responses in addition.  This observation suggests that the 
presence of Mycobacterium preparations drives T cell activation.  This is the case, as 
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cytokine profiles are dramatically shifted towards a Th1 phenotype with CFA as compared to 
IFA (137, 390).  Both CFA and IFA upregulate the  phagocytic activity of APCs (261) and 
have dramatic effects on antigen localization (22).  Interestingly, both CFA and IFA delivery 
appear to trap antigens, at least at early times post delivery, in the subcapsular sinuses of the 
draining lymph nodes, potentially providing an immunological locale for lymphocyte 
activation (177, 209).  This suggests that, unlike the induction of cell-mediated immunity, the 
antigen entrapment function of Freund’s adjuvant is attributable to the oil-in-water emulsion 
alone.   
While IFA and CFA have provided valuable tools as a vaccine adjuvants, there are 
detrimental effects of their use as well.  Both adjuvants are associated with moderate to 
extreme local inflammation in all species tested to date, including small rodents and humans 
(22, 340).  Additionally, both IFA and CFA are associated with the formation of granulomas, 
or tubercles in treated animals, especially following repeated treatments (374).  Granulaoma 
formation was dependent upon adjuvant-induced TNF-α  (176), which may also play a role in 
the adjvanticity of Freund’s (22).  Together, these observations support the notion that 
Freund’s adjuvants are potent immunomodulators and illustrate the balance which must be 
struck between immunogenicity and toxicity for the widespread use of vaccine technologies 
in humans.   
 
TLR ligands.  It has been suggested that the overall goal of adjuvants, in the context 
of vaccines for infectious diseases, is to ensure that the vaccine mimics natural infection 
accurately enough to promote induction of protective immunity (96, 157) [ reviewed in (192, 
279, 301, 335)].  Therefore, stimulation of the receptors which first “sense” natural infection 
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may serve as a potent adjuvant strategy.  TLRs are among the pattern recognition receptors 
(PRRs), which recognize conserved pathogen-associated molecular patterns (PAMPs) (158).  
The Toll proteins were originally discovered in Drosophila, recognized for their role in the 
induction of anti-fungal responses (202).  Eleven different TLRs have been identified to date 
(279), each receptor recognizing a distinct PAMP or set of PAMPS (382):  TLR1 and TLR 2 
recognize ligands from gram-positive bacteria (129, 330, 367); TLRs 4 and 5 recognize 
products from gram-negative bacteria (105, 136, 298); TLR 9 recognizes bacterial DNA 
(353); and TLRs 3, 7, and 8 recognize viral RNA (5, 138).  TLR ligation triggers a complex 
intracellular signaling cascade (266) involving the adaptor molecule myeloid differentiation 
factor 88 (MyD88), ultimately culminating in the activation of the transcription factor NF-kB 
and the release of pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α (3, 352).  
Signaling via TLR3 and TLR4 also utilize additional adaptor molecules to mediate cellular 
responses (387).   
TLR ligands in general have pleiotropic effects following in vivo delivery, and while 
commonalities exist in terms of responses induced by all TLR agonists, stimulation with a 
given TLR agonist may promote a slightly different response than others (301).  For this 
reason, here we consider the adjuvant activity of CpG DNA as a representative TLR agonist, 
mindful that different TLR agonists may regulate immunity to co-delivered antigen in a 
different manner.  Delivery of CpG DNA has dramatic effects in vivo,  including increased 
cellular migration towards the draining lymph node (368), increased costimulatory molecule 
expression on DCs (135), increased cytokine production (156), and increased immunity 
directed towards co-delivered antigen (73, 183).  CpG DNA promotes the production of 
IgG2a antibodies (56), as well as an increase in cell-mediated immune responses (55) 
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directed towards a co-delivered antigen, consistent with a Th1 phenotype.  CpG DNA 
provides a potent adjuvant signal either when used alone, or in combination with other 
traditional adjuvants (153).   
The promising results obtained with CpG DNA as a vaccine adjuvant have raised the 
question of involvement of TLR triggering as a general mechanisms of action of adjuvant 
activity.  Querec et al. recently proposed multiple TLR stimulation as a critical mechanism 
responsible for the efficacy of the yellow fever virus (YFV) 17D vaccine, one of the most 
successful and safe vaccines utilized in humans (304).  Indeed TLR signaling plays a critical 
role in mediating the adjuvant effect associated with CFA, evidenced by the observation that 
T cell proliferation and IFN-γ production were abrogated in MyD88 knockout mice, which 
are defective in TLR-mediated signaling (328).  However, a generalized role for TLR 
signaling with traditional adjuvants has been called into question recently, given the fact that 
some traditional adjuvants including CFA do retain activity in MyD88 knockout animals 
(104).  It is clear TLR ligands in general, and CpG DNAs specifically, possess potent 
immunomodulatory effects which may be harnessed as tools in vaccinology; however, the 
details of how generalized a role TLR signaling plays with traditional adjuvants remains to 
be fully elucidated.   
 
Authentic infections provide adjuvant effects.  As mentioned above, adjuvants have a 
place is vaccinology as a means to more accurately mimic the events which occur following 
natural infection which lead to potent immune induction (96, 157) [ reviewed in (192, 279, 
301, 335)].  Delivery of TLR ligands is an example of a reductionist approach to defining the 
individual components amongst a complex infection environment which are responsible for 
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immune induction, and harnessing them separately for use as immunomodulatory modalities. 
While potentially less satisfying from a definitive mechanistic point of view, it is possible 
that the holistic approach of simply relying on natural infection to provide an adjuvant signal 
may in fact provide an even stronger adjuvant effect that any one constituent alone, as 
proposed for the YFV vaccine (304).  While this principle has not been tested vigorously in 
animal models, it is clear that natural infection with several viruses and bacteria do provide 
an adjuvant signal.   For example, bacterial DNA provides an adjuvant signal in the form of 
CpG DNA described above, as does infection with bacteria from which the DNA was 
isolated.  This is  demonstrated by the observed adjuvant activity of  Mycobacterium 
tuberculosis (22), Corynebacterium parvum (375), and Bacillus firmus (244).   
It is possible that the adjuvant effect observed following bacterial infection is due 
entirely to the presence of CpG DNA present in the bacterial genome; however, such an 
explanation does not account for the adjuvant effect observed following virus infection.  
Various forms of adjuvant effects have been observed with influenza virus (44), poxviruses 
(152), adenovirus (152), oka varicella zoster virus (287), lactic dehydrogenase virus (263), 
and alphaviruses (65, 151).  Interestingly, adjuvant effects were observed with non-
replicating virus particles derived from parvovirus (27) as well as the alphaviruses (142, 
358), suggesting that early events in the virus replication cycle are capable of triggering an 
adjuvant signal.  Consistent with this idea, adjuvant activity in the alphavirus system was 
dependent upon RNA replication (358) and type I interferon signaling (142).   Together these 
examples are supportive of a role for natural viral and bacterial infections as adjuvant tools.   
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Viral expression vectors.  As mentioned above, considerable effort has gone into 
understanding the specific mechanisms by which natural infections promote immune 
induction.  While much is known regarding the general principles, there is paucity of 
knowledge regarding the specifics.    Viruses have evolved highly efficient mechanisms for 
both infecting cells and generating new copies of the viral genome and structural 
components.  While the strategies employed by different viruses vary widely, cell entry and 
genome replication are commonalities of all successful infections.  This concept is exploited 
by live attenuated vaccines as described above.  It is also exploited by viral-based expression 
vector systems.  In this case, molecular genetic approaches are employed to generate 
recombinant viruses which express a heterologous gene as a vaccine antigen [reviewed in 
(40, 84, 198, 337)].  Vaccine expression systems have also been developed based upon a 
number of bacterial genomes [reviewed in (82, 139)]; however, here we focus on viral-based 
delivery systems.  Here we describe the salient features of some of the most promising viral 
expression vector systems. 
 
Poxviruses.  Poxviruses are large, complex viruses which contain a double-stranded 
DNA genome ranging in size from 130-300 kilobases (kb) (165) and exhibit a number of 
advantageous characteristics as vaccine vectors.  First, these vectors are very stable and 
retain effectiveness following lyophilization, a real advantage as cold chain problems 
represent a significant impediment to vaccine distribution, especially in the developing world 
(337).  Second, poxvirus vectors are relatively easy to produce, cost effective, and versatile, 
as they are effective following delivery via multiple routes, including mucosal delivery (see 
below).  Pre-existing immunity, which can be a problem with some vaccine vectors, can be 
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overcome with mucosal delivery (337), as the systemic and mucosal immune systems are 
distinct (145).  The most widely used vectors are based on attenuated strains such as 
modified vaccinia Ankara (MVA) (346), NYVAC (based on the Copenhagen strain of 
vaccinia) (354), as well as viruses which naturally infect alternative species such as 
canarypox (355) or fowlpox (356).   
Poxvirus vectors have proven to be potent inducers of humoral and cellular immunity 
in numerous experimental systems, as well as inducers of mucosal immunity following 
mucosal delivery (see below) (107).  Poxviruses induce measurable protection in several 
infectious disease models including SHIV (6), influenza (347), measles (341), and others.  
Another advantage of the poxvirus system is the ability to incorporate large amounts of 
foreign DNA into recombinant viruses.  Up to 10 kb of heterologous DNA can be inserted; in 
fact, poxvectors induced protection/immunity to up to 3 foreign genes from 3 separate 
pathogens in the same recombinant vector (282).  These observations support the pursuit of 
poxvirus vaccine vectors for improved human vaccines. 
 
Adenovirus.  The adenoviruses (Ad) are members of the Adenoviridae family, and 
have been used extensively as live vaccines in the US Army (337).  Ad contains a double-
stranded DNA genome of approximately 35 kb and display a number of important features 
which promote their use as vaccine vectors including stability, ease of manipulation, 
feasibility of high titer production, and simple purification (337).  As with poxviruses, Ad is 
active following lyophilization and functions as a potent gene delivery vector following 
delivery by the intranasal, oral, intratracheal, intraperitoneal, intravenous, intramuscular, or 
subcutaneous routes, allowing tailored use based upon the specifics of the desired immune 
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response (337).  Replication-incompetent Ad vectors have been engineered which either lack 
structural components required for virion assembly all together or harbor mutations in the 
structural components.  These replication-incompetent constructs are likewise extremely 
immunogenic as vectors (191).   
Potential concerns regarding the use of Ad-based vaccines that have arisen are the 
potential for inhibition by pre-existing immunity to the virus, the relatively small payload for 
heterologous sequence, especially with replication competent vectors, and the virus-induced 
inflammatory response (40, 337).  Strategies to deal with these concerns have been 
developed including the use of alternative strains of Ad to circumvent pre-existing immunity 
and oral delivery to limit the systemic inflammatory reaction (40, 337).  Recombinant Ad 
expression vectors have demonstrated protective efficacy as vaccines for important 
pathogens such as SHIV(332), Ebola (345), measles (323), and  malaria (314).  Ad provide a 
powerful tool in vaccinology and an opportunity to study virus-induced immunity. 
 
Alphaviruses.  Alphaviruses are small, single-stranded RNA viruses of the 
Togaviridae family.  Alphaviruses contain a message sense genome of approximately 12 kb 
and have proven to be effective vaccine vectors.  Expression vectors based on Sindbis virus 
(SIN), Semliki forest virus (SFV), and Venezuelan equine encephalitis virus (VEE) have all 
shown promise in preclinical studies in both infectious disease and cancer models [reviewed 
in (77, 214, 215, 297, 307, 312, 325)].  Both replication-competent and replication-defective 
vector systems have been developed.  Alphavirus vectors are active following many 
parenteral delivery routes as well as following mucosal delivery.  Replication-defective 
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vectors, or replicon particles, have the structural gene cassette replaced with the heterologous 
gene and therefore infect cells, but fail to produce new progeny virions.  (324, 342) 
The alphavirus display numerous advantages as vaccines in that they are simple to 
work with, produce large amounts of heterologous transgene product, target DCs in vivo 
(103, 218) , and induce robust humoral, cellular, and mucosal immunity (77, 214, 215, 297, 
307, 312, 325).  Additionally, as the majority of the human and veterinary population has not 
been exposed to most of the alphaviruses, pre-existing immunity is not predicted to be 
prohibitive.  Protective immune responses have been demonstrated with a number of 
important pathogens such as influenza virus (74, 303, 329), Ebola virus, (302), SIV (75, 
248), as well as a number of bacterial toxins (197, 199).  Alphavirus vectors have 
demonstrated promise as vaccine expression vectors and are under development for vaccines 
in numerous additional model systems.  A more extensive review of alphavirus-induced 
immunity, especially in the context of mucosal immune induction is found in the VEE 
section of this review.   
 
Novel Delivery Techniques 
 As mentioned above, the majority of vaccines are delivered by a parenteral route 
(288).  The most common methods employ either intramuscular or subcutaneous delivery.  
Under these conditions, antigens and vaccines access the skin DC system and are reliant 
upon the function of skin-derived APCs and lymphatics to deliver antigens to the draining 
lymph node/s to initiate immune induction (351).  While parenteral delivery results in 
efficient stimulation of systemic immunity, this technique typically fails to stimulate a 
response that is active at the local mucosal surface (291).  Additionally, parenteral delivery 
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relies on the use of sterile syringes and needles, which can serve as an impediment, 
especially is resource-poor countries.  Still other complications with parenteral delivery exist, 
such as reactogenicity at the injection site, training of vaccinators, and contamination with 
blood after multiple users of the same syringe (108).  Therefore, additional delivery methods 
are under development in an attempt to circumvent some of the pitfalls associated with 
traditional delivery approaches.  For example, mucosal antigen delivery is an efficient 
method for stimulating systemic, but more importantly mucosal immunity, and various 
needle-free delivery techniques are being explored.  Here we briefly summarize some of the 
promising non-parenteral delivery methods in use.   
 
Mucosal immunization.  The term mucosal immunization refers to antigen or vaccine 
delivery across a mucosal surface (252).  The ideal mucosal delivery system should satisfy a 
set of important requirements.  Effective systems should be protected from both physical and 
enzymatic barriers which exist at the mucosal surface, target the vaccine to the appropriate 
mucosal lymphoid environment for immune induction (see below), and orchestrate the 
induction of the appropriate innate signals to fully activate antigen-specific adaptive 
immunity at the mucosal surface (148).  In theory, all mucosal surfaces are equally good 
candidates for mucosal vaccine delivery; however, some practical limitations impede antigen 
delivery across the vaginal and rectal surfaces as well as the conjuctiva (204).  Thus, delivery 
of antigens by the oral and nasal routes represent two of the most promising mucosal delivery 
strategies (205).  Here we discuss some of the successful mucosal vaccines as models of 
mucosal immunization. 
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 Oral vaccines.  Oral vaccine delivery has proven effective in several systems.  The 
most widely used mucosal vaccine is OPV, developed some 45 years ago (348).  Following 
oral delivery, OPV replicates in the gut and efficiently delivers viral antigens to the gut-
associated lymphoid tissue.  This local infection triggers the induction of a strong intestinal 
humoral immune response (81, 170).  Immunogenicity of OPV is one of the factors 
contributing to the largely successful eradication of polio, as is the fact that OPV is simply 
delivered by a single-dose disposable pipette and requires only a single immunization.  These 
characteristics have proven important in the eradication campaign (108).  The success of 
OPV has prompted hope for the development of other oral vaccines  (273).  However, the 
incidence of vaccine-associated paralytic poliomyelitis (VAPP), which causes approximately 
1 case per 2.9 million vaccinations, is cause for caution and signifies the potential dangers of 
live attenuated vaccines (4, 175).   
 Two additional live oral vaccines were developed based on the knowledge gained 
from OPV for vaccines against cholera and typhoid fever (108).  The live attenuated strain 
Salmonella typhi Ty21a was developed in the 1970s and has proven to be well tolerated and 
safe (108).  This vaccine induces protection in 60-80% of vaccinees for at least 5-7 years, 
demonstrating its efficacy as a human mucosal vaccine (81, 206).  Likewise,  a single oral 
inoculation of the cholera strain, CVD 103-HgR, induced 60-100% efficacy and few adverse 
effects (81, 359).  An additional oral vaccine, a human-rhesus rotavirus reassortant was 
developed as a rotavirus vaccine; however, it was withdrawn from the market due to safety 
concerns with vaccine-induced intussusception (254, 255).  While intussusception was 
clearly observed in vaccinees, the incidence was not significantly increased as compared to 
unvaccinated children of the same age group (284).   
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 A number of new technologies have been developed in the arena of oral vaccines.  As 
mentioned above, oral delivery of viral and bacterial expression vectors represents a 
promising area of oral vaccine development.  Additionally, new successful oral vaccine 
technologies have been developed, such as strong mucosal adjuvants like the bacterial 
enterotoxins (149), the development of oral edible vaccine approaches (343, 344), and oral 
delivery of many of the established parenteral vaccines.  The area of mucosal adjuvants will 
be reviewed in the next section in detail.   
 
Nasal Vaccines.  Nasal vaccine delivery is an active area of inquiry, and here we 
highlight one of the more recent success stories.  The traditional influenza vaccine consists of 
a trivalent inactivated preparation which is delivered parenterally.  This vaccine induces a 
strong serum IgG response which protects the lungs from complications associated with 
lower respiratory tract (LRT) infection; however, it does not inhibit virus replication in the 
upper respiratory tract (URT) (57, 71, 72, 144).  Therefore, a cold-adapted influenza virus 
was selected for its ability to grow at the colder temperatures of the URT, but that would not 
replicate at the higher temperatures of the LRT (64).  The cold-adapted vaccine appears to be 
safe and much more immunogenic, due to the fact that it more accurately mimics natural 
infection (1, 64).  Other methods for increasing the immunogenicity of nasal vaccines include 
the use of mucosal adjuvants, as will be discussed below. 
 
Transcutaneous immunization.  Transcutaneous immunization (TCI) refers to a 
novel vaccine delivery technique in which vaccine antigens and adjuvants are delivered 
through the skin using a skin patch [reviewed in (111, 113, 114)].  Recently, the skin has 
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been appreciated not only as a barrier to antigen entry, but also as one of the largest 
immunological organs of the body, and a promising target for vaccine delivery (112, 113).  
The epidermis of the skin contains a significant number of powerful APCs called Langerhans 
cells (LCs), which take up skin derived antigens and transport them to the draining lymph 
node/s for immune induction (155).  The inclusion of strong adjuvants in skin patches 
dramatically increased LC migration and activation (63, 64).  TCI has proven to be a potent 
inducer of humoral and cell-mediated immune responses in numerous experimental systems 
and in rodent and human models (112-115).  Interestingly, TCI also results in potent mucosal 
antibody and T cell induction (17, 89, 118).  The mechanism by which TCI is capable of 
stimulating mucosal immunity in the absence of mucosal delivery is not completely clear; 
however, it is proposed that the TCI-activated skin DCs are induced to migrate to mucosal 
inductive sites to present antigen (17, 89).  TCI represents a promising new delivery 
technique which may enable the production of new efficacious vaccines against multiple 
pathogens, including mucosal pathogens.  
 
Concluding Remarks  
 Here we have highlighted what is known regarding the components of the immune 
system that are activated by vaccines, the immune correlates of protection with a select group 
of important human pathogens, and the current tools under development in vaccinology.  
This is not intended to serve as a complete list in any one of the mentioned areas, but instead, 
to provide a context in which to place the development of new vaccines and vaccine 
technologies.  We hope this affords the reader an appreciation of the simultaneous simplicity, 
and complexity of the interactions between vaccines and the immune system.  The previous 
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studies described here provide a strong foundation for discussion of new vaccine 
technologies, such as those introduced in this dissertation.  Hopefully, these new vaccine 
approaches will provide new tools in the fight against infectious diseases, and their study will 
lead to an improved basic understanding of pathogenesis and immunity associated with 
infectious organisms.   
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ORGANIZATION OF THE MUCOSAL IMMUNE SYSTEM 
 
Overview 
 The mucosal surface is classically defined as the mucus-covered exterior which 
serves as the body’s interface with the external world (231).  The epithelial structures lining 
the respiratory, gastrointestinal, and urogenital tracts as well as the exposed 
cornea/conjuctiva provide simultaneous absorptive and barrier function for nutrient uptake, 
oxygen exchange, and a path for waste excretion (234).  The mucosal immune system is 
charged with the daunting task of protecting the body’s vast mucosal surfaces from invading 
organisms, while simultaneously facilitating the uptake of critical nutrients from food 
particles as well as air exchange (259).  This objective is complicated by the fact that the 
mucosal immune system must differentiate harmful organisms from innocuous food and 
inhaled antigens (251, 257).   
It is estimated that approximately 90% of all human infections are initiated at the 
mucosal surface (234), and the surface area of the mucosa is extensive, at approximately 400 
m2 in humans (67, 150).  In turn, size and cellular makeup define the mucosal immune 
system as the largest immunological organ of the body (234).  The gut alone contains 
approximately 1012 lymphoid cells per meter of small intestine, accounting for the greatest 
number of immunoglobulin (Ig)-secreting cells, more than in all other lymphoid organs 
(spleen, bone marrow, peripheral lymph nodes) combined (234, 236).  IgA antibodies are by 
far the most prominent antibody isotype present in mucosal secretions (37, 231, 232, 237, 
238).  In fact, Conley and Delacroix estimated that adult humans produce between 2 and 4 
grams of IgA per day (61).  
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The activation of adaptive mucosal immune responses, including IgA-producing B 
lymphocytes, occurs within the organized mucosal-associated lymphoid tissue (MALT) 
(259).  Antigen transport into the mucosal lymphoid tissues initiates a complex cascade of 
events which ultimately culminate in the activation of lymphocytes with effector function at 
the mucosal surface (258, 259).  Here we review the anatomical basis of mucosal immune 
induction, with emphasis on the gut immune system, the anatomy and function of mucosal 
antibody responses, the role of mucosal adjuvants in stimulating the natural pathway of 
mucosal immune induction, and the evidence supporting the existence of an alternative 
pathway for mucosal immune induction.   
 
Anatomy of a Mucosal Immune Response 
 Organized mucosal lymphoid tissue.  The mucosal immune system is organized into 
mucosal inductive and mucosal effector sites.  Mucosal inductive sites, include the organized 
mucosal lymphoid tissues and are responsible for the activation of immune responses active 
at the diffuse mucosal surfaces, or the mucosal effector sites (181, 231).  Organized mucosal 
lymphoid tissues are present at all of the mucosal surfaces including in the digestive (276), 
respiratory (16), and genital mucosa (34).  While the specific organization of MALT differs 
between different mucosal surfaces, the aggregates of lymphoid cells at each surface perform 
the same function of directing luminal antigens into the correct anatomical context for the 
activation of antigen-specific immune responses (259).  A commonality amongst the primary 
lymphoid structures at all of the mucosal surfaces is the presence of a specialized epithelial 
surface covering the lymphoid aggregates (181).  In the Peyer’s patches (PPs) of the gut, this 
specialized epithelium is termed the follicle-associated epithelium (FAE) and contains the 
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microfold cells, or M cells, specialized epithelial cells which function to transport luminal 
antigens into the underlying lymphoid compartment (169). 
 The lymphoid cell component underlying the FAE has been studied in a number of 
animal models.  (24, 91, 92).  The follicle contains B cells, T cells, DCs, and macrophages.  
Most B cells in the actual corona of the follicle are surface IgM positive, whereas the B cells 
present in the germinal centers within the follicle have switched to the IgA isotype (195, 
233).  Both CD4+ and CD8+ T cells are localized in the inductive sites; however, the CD4+ T 
cells are predominantly located in the subepithelial dome, while the CD8+ T cells are found 
in the parafollicular zones (24, 91).  Both Th1 and Th2 CD4+ T cells (as defined by IFN-γ 
and IL-5 secretion, respectively) reside within the inductive sites of the mouse intestine; 
however, a greater proportion of Th2 cells exist throughout the lamina propria (181, 350) 
(see below). DCs and macrophages, in addition to M cells, play a critical role in sampling 
luminal antigens; however, the relative contribution of the various APC subsets varies 
significantly based upon the structure of the epithelial cell anatomy at the specific mucosal 
surface (259, 322). 
 
 Diffuse mucosal lymphoid tissue.  Following antigen delivery to the inductive tissues 
and subsequent lymphocyte activation, lymphocytes migrate through the general circulation 
and home to the diffuse mucosal effector tissues of the corresponding mucosal surface 
(reviewed below).  Once present at the mucosal surface, local signals drive further 
differentiation of activated cells where they mediate their effector functions at the local 
surface (91, 181).  Two distinct subsets of lymphocytes exist at the mucosal surface 
according to their specific localization; the intraepithelial lymphocytes (IELs) and the lamina 
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propria lymphocytes (LPLs).  The majority (approximately 80%) of the gut IELs in mice and 
humans are CD8+ T lymphocytes (181).  There are fewer IELs present at the nasal and 
respiratory mucosal surfaces, and a higher proportion of CD4+ T cells (385).  Within the IEL 
population, two distinct subsets of CD8+ T lymphocytes exist based on expression of the 
CD8 molecule.  Both CD8 α/β and CD8 γ/δ T cell populations are present (181).  γ/δ T cells 
are proposed to play a critical role in mediating defense to common bacterial infections in the 
gut (28).   
The second population of gut lymphocytes is the LPLs.  LPLs consist of 
approximately 40% B cells and 25% T cells (mostly CD4+).  Approximately 90% of the LPL 
B cells produce IgA antibodies as well as secrete Th2 cytokines, along with the CD4+ T cells, 
and epithelial cells, promoting IgA class switch (39, 331, 350).  It is thought that Th1 cells in 
the LPL compartment produce IL-2, which activates proliferation of all T cells, including 
Th2 cells, which in turn secrete large amounts of IL-5, IL-6, transforming growth factor beta 
(TGF-β), and other cytokines to orchestrate the efficient IgA class switch signal (224, 336).  
Together, these lymphocyte populations provide the first line of adaptive defense at the local 
mucosal surface, and are critical for protection from mucosal pathogens (35). 
 
The Natural Pathway for Mucosal Immune Induction 
 Mucosal immune responses are most efficiently induced following antigen/pathogen 
delivery at the local mucosal surface (231).  In turn, the natural pathway for mucosal immune 
induction is defined as the cellular mechanism by which adaptive mucosal immune responses 
are activated following mucosal delivery.  Much is known regarding the programming that is 
initiated in mucosal tissues and culminates in the localization of antigen-specific cells at the 
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mucosal surface.  Here we outline those events and the characteristics of mucosal IgA 
antibodies at mucosal surfaces.   
 
Mucosal lymphocyte homing.  Following activation in the mucosal inductive tissues 
lining each mucosal surface, a complex cascade of events is initiated which directs those 
activated cells to migrate back to effector sites at that mucosal surface.  This differs from the 
homing program initiated following antigen encounter in a peripheral lymph node.  In 
general terms, lymphocytes activated in a mucosa-draining lymphoid tissue are programmed 
to migrate back to effector sites at that mucosal surface, whereas lymphocytes activated in a 
non-mucosa-draining lymphoid tissue (i.e. peripheral lymph node or spleen), as occurs 
following parenteral vaccine delivery, are directed elsewhere (46).  In this regard, the 
regulation of homing to the mucosal surface represents a critical checkpoint in the natural 
pathway of mucosal immune induction (187).   
Classical adoptive transfer studies demonstrated the propensity of cells isolated from 
mucosal lymphoid tissues to preferentially repopulate the mucosal compartment following 
adoptive transfer (229, 316).  Since then, many of the mechanisms responsible for 
lymphocyte homing to the mucosal surface have been discovered and recently reviewed (46, 
186, 187).  Here we present an overview of the regulation of mucosal homing by endothelial 
cell-integrin interactions as well as specific chemokines and chemokine receptors (CCRs). 
 
Regulation of mucosal homing by lymphocyte-endothelial cell recognition.  
Transendothelial lymphocyte migration can be broken down into four key steps:  1) initial 
tethering; 2) activation; 3) arrest; and 4) diapedesis (46, 47, 234).  The initial tethering steps 
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are mediated through the interaction of lymphocytes with the high endothelial venules 
(HEVs).  The HEVs of peripheral lymph nodes express peripheral lymph–node addressins 
(PNAd), whereas the HEV of mucosal lymphoid tissues express mucosal addressin cellular 
adhesion molecule-1 (MAdCAM-1) (46, 47, 234).  L-selection (CD62L) is responsible for 
binding to PNAd, while the α4β7 integrin binds to MAdCAM-1.  The tethering and rolling of 
lymphocytes on the endothelium mediated by these interactions serve to slow lymphocyte 
movement and allow the establishment of more permanent interactions (234).  In the gut, 
rolling is mediated by both L-selectin and α4β7 integrin binding to MAdCAM-1 (20, 130).  
The activation stage involves signaling via a number of chemokine-CCR interactions and 
promotes firm arrest on the endothelium (50).  Following the establishment of firm contacts, 
lymphocytes next undergo transendothelial migration by diapedesis into the mucosal 
lymphoid area (46, 47).  This step is also regulated by the activities of a number of factors 
including α4β7 integrin-MAdCAM-1 interactions and numerous chemokines (95, 173, 311).  
Interactions between α4β7 integrin and MAdCAM-1 regulate mucosal homing at numerous 
levels and therefore  are proposed to be critical regulators of mucosal homing, especially in 
the gut (37, 38, 46, 47).   
 
Chemokine regulation of mucosal homing.  Recently, a number of chemokine-CCR 
interactions have been demonstrated to play a role in mucosal homing, especially in the 
recruitment of IgA-secreting cells to the gut mucosa.  Both thymus-expressed chemokine 
(TECK/CCL25)-CCR9 interactions, as well as mucosae-associated epithelial chemokine 
(MEC/CCL28)-CCR10 interactions play a critical role in the recruitment of IgA-secreting 
cells to the gut mucosa (31, 143, 194).  In fact, the α4β7 integrin, TECK, and MEC, all play a 
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role in the local IgA response to an important gut pathogen, rotavirus (97, 185).  Thus, CCR9 
and CCR10 expression, along with α4β7 integrin appear to regulate mucosal homing of IgA-
secreting cells (187, 188).   
 
 Architecture of mucosal IgA antibodies.  The respiratory and gastrointestinal 
surfaces of humans comprise approximately 100m2 and 300m2 respectively (161).  These 
surfaces are vulnerable to attack from various mucosal pathogens and require active effort for 
protection.  A number of innate protective mechanisms play a critical role in protecting the 
mucosal surfaces (300, 320); however, here we focus on the adaptive responses that are 
activated by vaccination and their roles in protection from mucosal challenge.  Secretory IgA 
(SIgA) is the most prominent antibody isotype in mucosal secretions and mediates protection 
of the mucosal surface in a number of experimental systems.  Here we review the structure of 
mucosal IgA, the mechanism by which IgA antibodies are transported into mucosal 
secretions, and the evidence for IgA-mediated protection at the mucosal surface. 
 
 Structure of mucosal IgA.  As mentioned above, IgA antibodies are the most abundant 
antibodies present in mucosal secretions; although IgG and IgM antibodies are also present 
and do play a role in mucosal defense (34, 239).  IgA antibody-secreting-cells (ASCs) 
present at mucosal sites are distinguishable from systemic IgA ASCs, as over 90% of 
mucosal IgA cells concomitantly express the joining chain, or J chain (20).  J chain is a 15 
kilodalton (kDa) protein incorporated into IgA molecules, most likely during trafficking 
through the endoplasmic reticulum, that facilitates the production of dimeric and/or 
polymeric forms of IgA (36, 37, 239).  Intracellular J chain expression has been observed in 
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IgG-secreting-cells as well; however, the J chain is not incorporated into secreted IgG and 
the reason for J chain expression in these cells is unclear (23).  IgA molecules form mostly 
dimers in the presence of J chain; however, trimeric and tetrameric polymers also have been 
observed (369).  
In humans, serum contains between 80-100% monomeric IgA, while dimeric and 
polymeric forms of IgA dominate in mucosal secretions (238, 239).  Increased levels of 
polymeric IgA has been noted in the serum of rodents, although the exact importance of this 
finding is unclear (318).  The importance of J chain in polymeric IgA production is 
evidenced by the observation that J-chain knockout mice exhibited a significant increase in 
the ratio of monomeric-to-dimeric forms of IgA.  J chain is also incorporated into pentameric 
IgM complexes (262).  J-chain-containing IgA and IgM antibodies are preferentially 
transported into mucosal secretions by an active transport mechanism (see below).  Thus, the 
physiological structure of mucosal IgA molecules facilitates their role in mucosal defense. 
 
Transport of IgA molecules into mucosal secretions.  The unique ability of IgA and 
IgM antibodies to polymerize into higher order structures is determined by the ability of the α 
and µ heavy chains to interact with J chain.  Two cysteine residues present in the human J 
chain form a disulfide bridge with the penultimate cysteines in the α and µ chain to form 
polymeric IgA and pentameric IgM respectively (161, 240).  Support for a role of J chain in 
the transport of IgA molecules into mucosal secretions comes from analysis of J chain 
knockout mice.  Decreased levels of fecal IgA antibodies were observed in J chain-deficient 
animals, suggesting that polymeric forms of IgA were transported across mucosal surfaces 
(140).   
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The original description of dimeric IgA at the mucosal surface demonstrated not only 
the addition of the J chain to IgA, but also an 80 kDa protein, designated as the ‘secretory 
piece’ (361).  We now know this component as the secretory component (SC), a proteolytic 
fragment of the poly Ig receptor (pIgR) which is retained in SIgA following transport through 
mucosal epithelial cells.  Much is known regarding the mechanism of IgA transport via the 
pIgR (167, 250).  The pIgR is a 100 kDa protein expressed on the basolateral surface of 
mucosal epithelial cells which binds to IgA in a J chain-dependent manner (162, 249).  The 
polymeric IgA-pIgR complexes are endocytosed and transported to the apical surface of 
mucosal epithelial cells.  During transport, disulphide bridges hold the complex together and 
proteolytic cleavage at the apical surface cleaves off the transmembrane domain of pIgR and 
releases SIgA into the mucosal lumen (10).  Support for the importance of this pathway 
comes from the observation that animals lacking the pIgR have severe defects in the levels of 
IgA and IgM antibodies in mucosal secretions (163).  Analysis of the structure and function 
of mucosal IgA transport suggests a clear relationship between the form and function of IgA 
molecules within the mucosal compartment. 
 
Role of IgA antibodies in mucosal defense.  As mentioned above, mucosal antigen 
delivery is the most efficient method of generating a mucosal IgA response.  Evidence from a 
number of experimental systems has demonstrated a correlation between the appearance of 
IgA antibodies in mucosal secretions and protection from challenge with influenza virus (58), 
rotavirus (63), polio virus (270), and cholera (160) [reviewed in (234, 319)].  While this 
correlation is strong and appears to be broadly applicable, the correlation alone does not 
prove that IgA provides a critical, non-redundant role in protective mucosal immunity.   
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Two lines of evidence support the notion that IgA antibodies provide a critical 
protective effect at the local mucosal surface.  First, systemic passive transfer of IgA 
antibodies is protective in several mucosal challenge models [reviewed in (319)].  Following 
systemic IgA transfer, IgA antibodies can be detected at the mucosal surface, suggesting they 
mediate protection at the local level; however, such antibodies are also present systemically, 
complicating that clear interpretation.  Interestingly, nasal administration of IgA antibodies 
mediated protection from an intranasal influenza challenge in mice (225), and intranasal 
challenge with respiratory syncytial virus in both mice (380) and monkeys (381) provides 
clear evidence for a role for IgA at the local mucosal surface.   
The second line of evidence comes from studies performed in IgA, and/or mucosal 
IgA deficient mouse models.  A number of IgA deficiency models exist including IgA 
knockouts (12), J chain knockouts (217), and pIgR knockouts (388), all of which exhibit 
increased susceptibility to mucosal challenge.  However, compensatory mechanisms exist in 
these models such as increased serum IgA (J chain and pIgR KOs), serum IgG/IgM, and 
increased mucosal IgG, clouding the interpretation of such studies (234).  Further definitive 
evidence for the protective capacity of mucosal IgA comes from an additional model system.  
In an elegant study, Renegar and Small (310) depleted IgA, IgG, and IgM antibodies 
specifically in the URT of influenza virus-immune animals by local delivery of specific anti-
immunoglobulin antibodies prior to/during a nasal influenza challenge.  The local depletion 
of nasal IgA, and not IgG or IgM, abrogated the protection observed in immune animals, 
providing strong evidence that mucosal IgA antibodies directly at the mucosal surface are 
critical for mucosal defense.  Together, these studies are consistent with a model in which 
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IgA antibodies are produced at the local mucosal surface following mucosal delivery, are 
transported into mucosal secretions, and provide a protective effect. 
 
 Stimulation of the natural pathway by bacterial enterotoxins.  In earlier sections of 
this review we have introduced the concepts of adjuvants as well as mucosal antigen 
delivery.  As we have now reviewed the anatomical basis of mucosal immune induction, here 
we summarize what has been learned regarding the natural pathway for mucosal immune 
induction using mucosal delivery of the bacterial enterotoxins: cholera toxin (CT) and labile 
toxin (LT).  The use of CT and LT as mucosal adjuvants has set the benchmark by which 
mucosal immune induction is measured, and serves as the “gold standard” for the evaluation 
of mucosal immunity in new experimental systems (33).  CT is used as an example of the 
mechanisms regulating mucosal immune induction, as well as a further example of the 
paucity of knowledge regarding the critical mechanisms of adjuvant activity.   
 CT, from Vibrio cholerae, is comprised of an A subunit with adenosine-diphosphate 
(ADP)-ribosly-transferase activity, and a pentameric B subunit (CTB) which mediates 
receptor binding to the cellular receptor, GM1-ganglioside (87).  The ADP ribosyl-
transferase activity of the A subunit has dramatic effects on vesicular membrane trafficking 
and organelle integrity in vivo (193).    Adjuvant experiments performed with CT enzymes 
harboring mutations in either the A subunit active site, B subunit active site, or both, 
suggested that both subunits were required to generate a full adjuvant effect (88); however 
other studies have demonstrated adjuvant activity with the B subunit alone, albeit not as 
strong as with the complete enzyme (149). 
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 As mucosal CT delivery is the most potent stimulator of the natural pathway, its 
adjuvant activity is typically studied under the assumption that its immunomodulatory effects 
are likewise the most efficient means of stimulating mucosal immune responses.  Therefore, 
the characterization of CT-induced immunomodulation provides a target level for induction 
with new adjuvants, in lieu of a single mucosal inductive mechanism.   CT, like most 
adjuvants, affects multiple aspects of the immune environment which alone, or in 
combination are responsible for immune induction.  These effects likely occur by multiple, 
overlapping mechanisms, as outline for systemic adjuvants (see above).  CT appears to 
induce a Th2-biased cytokine profile with strong production of IL-4, IL-5, IL-6, IL-10 and 
the production of IgA and IgG1 antibodies (147).  Further analysis has led to the conclusion 
that the B subunit has a more profound effect on Th2 polarization than either the A subunit 
alone, or delivery of the holoenzyme (32).  A role for Th2 cytokines in the adjuvant effect of 
CT is supported by the observation that CT failed to exert a mucosal adjuvant effect in IL-4 
deficient animals (371); however, IL-6 appears not to be necessary, as normal adjuvant 
effects were observed in IL-6 deficient mice (45).  As is true in IgA deficiency models, 
caution must be exercised in the interpretation of adjuvant activity in specific cytokine 
deficient models, as compensatory effects may occur in such animals.   
 In addition to cytokine production, CT induces recruitment and activation of DCs at 
the mucosal surface (9).  These effects may partially explain the strong effect of CT by 
modulating the cellular antigen presentation pathway.  In humans, CT is quite toxic and to 
date is inappropriate for inclusion in human vaccines.  However, much work has gone into 
the development of genetically detoxified mutants which lack the toxic effects while 
retaining adjuvant activity (2, 216).  The utilization of CT as a mucosal adjuvant has shed 
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new light on the mechanisms by which mucosal immune responses are activated, and if non-
toxic mutants still retain adjuvant activity in humans, should enable the development of 
mucosal vaccines in humans.   
 
An Alternative Pathway for Mucosal Immune Induction 
 There is no disputing that, to date, the strongest mucosal immune responses are 
observed following stimulation of the natural pathway for mucosal immune induction.  
Indeed, it has been suggested that localization of antigen to the MALT following mucosal 
antigen delivery is a prerequisite for mucosal immune induction (230-232).  However, 
protection from mucosal challenge, and production of local mucosal immune responses 
following nonmucosal delivery has been demonstrated in a number of experimental systems, 
suggesting the presence of an alternative pathway(s) for mucosal immune induction 
[reviewed in (30, 366)].  Unlike the natural pathway, antigen delivery across a luminal 
barrier appears not to be required for immune induction via this alternative pathway.  Here 
we briefly review the evidence supporting the existence of such a pathway and attempt to 
identify the commonalities amongst the individual examples as a means to determine the 
specific immunological mechanism(s) at work.   
The examples presented here are extremely varied, and a common unifying 
mechanism responsible for mucosal immune induction under all circumstances is not readily 
evident upon initial review.  Both virus infections as well as bacterial infections appear 
capable of promoting mucosal immunity through the stimulation of an alternative mucosal 
inductive pathway.  Peripheral, or nonmucosal delivery of a diverse class of viruses or viral 
vaccine vectors including rotavirus (59, 60), canarypox vectors (256), Venezuelan equine 
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encephalitis virus (51) and replicon particles (131, 212, 358), and Rubella virus (271) results 
in the presence of antigen-specific antibodies in mucosal secretions and/or the activation of 
antigen-specific T cells located at the mucosal surface.  Likewise, bacterial antigens/vectors 
derived from Listeria monocytogenes (285) and Haemophilus influenzae type  b (171) 
stimulate immunity at the mucosal surface following nonmucosal delivery. 
The examples cited above suggest that traditional nonmucosal delivery methods are 
capable of stimulating mucosal immunity.  In addition, several specialized nonmucosal 
delivery approaches have been developed which likewise promote mucosal immune 
induction.  One example is parenteral targeting of mucosal lymphoid tissues by the use of 
anti-MAdCAM-1 antibodies, which dramatically augment mucosal IgA production (235).  
As mentioned above, TCI in the presence of CT also induces potent mucosal immunity 
following delivery through the skin in both mice and humans (113, 115, 391).  Interestingly, 
an approach termed targeted lymph node immunization, which relies on direct antigen 
inoculation into a peripheral lymph node, also stimulates mucosal immunity in non-human 
primates (172, 201).   
Whether mucosal immune induction, following either traditional nonmucosal delivery 
or one of the specialized approaches outlined above, is in fact due to an intrinsic signal 
provided by a direct effect of the infectious agent/antigen itself or, instead, is due to an 
indirect effect, such as the induction of an immunoregulatory agent is unclear at this point.    
A number of candidate immunomodulatory factors have been identified including various 
forms of vitamin D3 (89) as well as a group of specific cytokines and chemokines (85) which 
potentially provide a mechanistic explanation for mucosal immune induction following 
nonmucosal antigen delivery. 
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The exact mechanisms underlying mucosal immune induction following nonmucosal 
antigen delivery have yet to be clearly elucidated.  The identification of such inductive 
mechanisms is an active area of inquiry in our laboratory, as well as several others.  In our 
estimation, the definition of the exact lymphoid tissues which serve as the critical 
components of the alternative pathway for mucosal immune induction is a crucial first step in 
defining the operative mechanisms.  In this report (Chapter 3), we provide supportive 
evidence for the inclusion of the draining lymph node in the alternative pathway for mucosal 
immune induction following footpad delivery of VEE replicon particles.  Whether the 
involvement of this lymphoid tissue in such an alternative pathway is common to the other 
examples remains to be determined.  In the next section of this review, we describe our 
current understanding of a peripherally-induced mucosal inductive pathway, as revealed by  
nonmucosal delivery of alphaviruses and alphavirus-derived vectors (see below).  The 
elucidation of the immunological mechanisms operative in an alternative mucosal inductive 
pathway may allow mucosal immune induction with parenterally-delivered vaccines, and 
therefore more efficacious vaccination protocols.   
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VENEZUELAN EQUINE ENCEPHALITIS VIRUS 
 
Overview 
 VEE is a member of the Togaviridae family and the alphavirus genus.  Further, VEE 
is a member of the New World alphaviruses, along with Eastern equine encephalitis virus 
and Western equine encephalitis virus.  These viruses possess the capability to cause a febrile 
illness and encephalitis in equines and humans (123).  The Old World alphaviruses, including 
SIN, SFV, Ross River virus (RRV), Chikungunya virus, and O’nyong-nyong virus, produce 
an arthritic and/or arthralgic disease characterized by fever and rash in humans (123).  All of 
the alphaviruses are arthropod-borne infections and are transmitted in nature by the bite of an 
infected mosquito (376).    
 VEE is maintained in nature in an enzootic cycle between mostly Culex mosquitoes 
and small rodents in North and south America (377).  Epizootics and epidemics are possible, 
especially with specific subtypes (I-AB and I-C) and can have a dramatic effect on equines, 
including as an amplification host for the generation of a high titer viremia (377).  VEE was 
first identified as the etiologic agent of equine encephalitis in Venezuela in 1938 when it was 
isolated from the brains of fatal cases of encephalitis in horses (184).  The first documented 
cases of naturally acquired human disease was identified in the 1950s in Colombia (321).  
Infection in equines results in a severe disease with mortality rates ranging between 20-80%; 
however; severe disease is much less common in humans with a neurological symptoms 
apparent in 5-15% of infections and mortality in less than 1% (377).  The implementation of 
the TC-83 vaccine, a live attenuated I-AB strain passaged in guinea pig heart cells 83 times 
(18), has gone a long way to curb VEE outbreaks where vaccination of equines is extensively 
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utilized (377).  The potential of epizootic outbreaks, as evidenced by the 1995 epidemic 
which affected up to 100,000 people in South America (378), along with the previous history 
of VEE as a potential agent of biological warfare (377), has stimulated great interest in 
understanding the biology of VEE infection. 
 
Genome Organization and Replication 
 Much of the knowledge of VEE biology and replication has stemmed from 
comparative studies with SIN in cultured cells.  VEE contains a message-sense, single 
stranded RNA genome of 11, 477 nucleotides which contains a 5’ methylguanosine cap and a 
3’ polyadenlyated tail.  The genome has considerable secondary structure and is divided into 
two regions:  the viral non-structural proteins (nsPs 1-4), responsible for RNA replication, 
are encoded at the 5’ two-thirds of the genome, while the structural components, the capsid, 
E3, E2, 6K, and E1 proteins, are encoded at the 3’ one-third of the genome, expressed from a 
separate subgenomic 26S promoter  (342).  The genome is encapsidated into an icosohedral 
nucleocapsid containing 240 copies of the capsid protein with T=4 symmetry (50) following 
specific interactions with the capsid protein and the encapsidation signal found in the nsP1/2  
gene region (102).  The nucleocapsid is engulfed in a lipid bilayer which harbors the viral 
glycoprotein spikes, composed of trimers of E1/E2 heterdimers, also with T=4 symmetry 
(342).   
 The receptor for VEE is currently unknown; however, c-type lectins (178), the 
laminin receptor (213), and heparin sulfate (HS) proteoglycans (21) have all been proposed 
as attachment receptors for VEE.  Binding to HS represents a tissue culture adaptation and 
most likely is not a natural receptor, as HS-binding viruses are all attenuated in vivo (21).  
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Following receptor-mediated endocytosis and fusion of viral and endosomal membranes 
triggered by low pH, or alternatively, the direct release of the genome through the plasma 
membrane after attachment (278), the viral RNA is directly translated by the host translation 
machinery into the precursor P123 or P1234, depending upon a low efficiency read through 
event at an opal termination codon just prior to nsP4 (342).  The P123 precursor and free 
nsP4, the RNA-dependent RNA polymerase, mediate the production of minus sense RNA 
during the first 3-4 hours post infection (342).  Following cleavage of the P123 complex into 
the individual nsP proteins, a shift occurs, driving the production of positive sense messages, 
including 5-10 fold molar excess of the subgenomic RNA over the genomic.  This ensures 
adequate production of the structural components required for assembly of new virions (342).  
Budding of newly assembled virions occurs at the plasma membrane following encapsidaton 
of full length genomic RNA and transport of newly made E1 and E2 glycoproteins through 
the endoplasmic reticulum (342).  Infection has dramatic effects on host cells including 
cessation of host RNA and protein synthesis and eventual apoptosis (119, 123). 
 
Pathogenesis and Control 
 A range of symptoms are exhibited in humans following VEE infection from little or 
no disease, to a fatal encephalitis (377).  A number of factors affect disease severity 
including age and genetic factors of the patient as well as the virus serotype (86).  Infection 
of humans with VEE results in fever, malaise, vomiting, and acute retro-orbital pain, 
following a 2-5 day incubation period.  In most cases, these symptoms subside within one 
week; however, in a minority of cases severe complications develop including convulsions, 
coma, and neurological sequelae.  In the <1% of fatal human cases, disease is accompanied 
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by diffuse congestion, edema with hemorrhage in the brain, lungs, and gastrointestinal tract 
(79, 86).  Interestingly, VEE infection causes a severe lymphopenia in humans, equines, and 
rodents (86, 377), which may result from either lymphocyte apoptosis or lymphocyte 
retention in peripheral tissues.  (79, 86, 377).  
 Several animal models of VEE pathogenesis have been developed over the years 
including macaques (246, 309), rabbits (68), and guinea pigs (68); however, the mouse 
model, in combination with the development of the infectious clone of the Trinidad donkey 
strain (78), has proven the best model to date.  In the mouse model, much like the disease 
course in equines, VEE exhibits a bi-phasic disease, with an early lymphotropic phase 
involving replication in peripheral lymphoid tissues, followed by a neurotropic phase, which 
ultimately culminates in a lethal encephalitis by day 6-8 post-infection (110).  The stepwise 
pathogenesis of virulent VEE, as well as molecularly cloned mutants, was recently 
demonstrated by Johnston and colleagues in the mouse model of VEE disease (11, 76, 121).   
The initial targets of VEE infection following footpad inoculation were identified by 
MacDonald and Johnston as DCs; specifically, LCs (218).  Infected DCs migrated to the 
draining lymph node (DLN) as early as 4 hours post infection (hpi) following footpad 
infection, where viral replication was detected at 6 hpi (121).  Viremia peaked at 12 hpi, and 
by 18 hpi, virus replication was rampant in numerous peripheral organs including the spleen, 
kidney, lung, and heart; although viral RNA was restricted to a subset of these tissues, 
suggesting the VEE serum viremia is a major source of virus at early times (121).  Peripheral 
titers peaked between 24-48 hpi; a time at which the virus begins to seed infection in the 
central nervous system (CNS) (76, 121).  CNS invasion likely occurs through infection of the 
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olfactory neuroepithelium and the trigeminal nerve (53), resulting in fatal encephalitis by day 
6-7 post infection (121).   
 Both innate and adaptive components of the immune system play a critical role in 
mediating protection from natural VEE infection.  A role for the type I interferon system is 
demonstrated by the observation that mice genetically deficient in the type I interferon 
receptor succumb to lethal VEE disease between 24-48 hpi (122, 383).  VEE-specific IgM 
and/or IgG antibodies appear to play an important role in clearance of VEE from the 
periphery (52) as well as the induction of protection following vaccination (123); however, 
antibody responses initiated during infection are not sufficient to prevent neuroinvasion and a 
lethal outcome following primary infection (123).  Infection with VEE, SIN, and SFV results 
in immunopathology in the CNS; although VEE, unlike the other alphaviruses, induces a 
lethal spongiform encephalopathy in animals devoid of functional lymphocytes, 
demonstrating the ability of VEE to directly damage neurons in the CNS (52). 
 
Protection from Mucosal Challenge and Mucosal Immune Induction 
 Mucosal immune induction and/or protection from mucosal challenge have been 
described in several VEE systems including attenuated virus mutants, as well as both 
replication-competent and replication-deficient viral vectors.  Here we review the evidence of 
mucosal immune induction, and discuss the putative inductive mechanisms under all three 
conditions. 
 
 Venezuelan equine encephalitis virus vectors.  In addition to attenuated VEE, two 
additional VEE vectors have been described.  The first, termed double promoter vectors, 
 46
contains a second cloned 26S subgenomic promoter expressing a foreign antigen, 
downstream of the authentic 26S promoter expressing the viral structural proteins (74).  
These replication-competent vectors express the foreign antigen in virus-infected cells and 
induce strong humoral and cell-mediated immune responses (74).  The other vaccine vectors 
are VRP, which are engineered such that the heterologous antigen is cloned in place of the 
viral structural genes.  These vectors express high levels of the heterologous transgene in 
infected cells; however, they fail to spread beyond the first infected cell as no new progeny 
virions are produced due to the lack of structural components (303).  VRP have proved to be 
effective inducers of protective immunity in several experimental models [reviewed in (77, 
214, 215, 297, 307, 312, 325)].  Here we describe the ability of VEE, VEE-based double 
promoter vectors, and VRP to induce protection from mucosal challenge and to induce 
mucosal immune responses, as well as discuss the putative inductive mechanisms in each 
scenario 
 
 Attenuated VEE mutants.  In nature, VEE is spread through mosquito bite, 
representing a subcutaneous challenge (377).  However, aerosol exposure of laboratory 
workers as well as threats of VEE as a bioterrorism agent warrant, the development of 
vaccines which are capable of protecting from a mucosal VEE exposure as well.  
Interestingly, nonmucosal delivery of attenuated mutants of VEE have been shown to induce 
protection from lethal aerosol challenge with virulent VEE in mice (51, 132-134, 286, 299), 
hamsters (299), and  monkeys (299, 308).  While attractive to speculate that peripheral 
delivery of attenuated VEE induced protection from mucosal challenge through the induction 
of a local mucosal immune response, this is not necessarily demonstrated by this observation.  
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However, VEE-specific IgG and/or IgA antibodies were in fact present in mucosal secretions 
following subcutaneous delivery of VEE mutants in mice (51, 132-134, 286) and monkeys 
(299), providing strong support for the notion that VEE stimulates an alternative pathway for 
mucosal immune induction which does not require delivery across a mucosal surface.  Hart et 
al. demonstrated that two attenuated mutants of VEE, the vaccine strain TC-83, as well as a 
virus harboring a mutation in the PE2 cleavage domain, V3526, both induced protection from 
aerosol challenge with virulent VEE, and likewise both induced VEE-specific IgA antibodies 
in bronchial lavage samples (133).  Interestingly, V3526 induced a stronger mucosal IgA 
response than TC-83, which correlated with stronger protection from mucosal challenge, 
suggesting that virus-induced mucosal IgA antibodies may mediate protection from virulent 
mucosal VEE challenge (133).   
 
 VEE-based double promoter vectors.  The examples cited above demonstrate that 
VEE induces local mucosal immune responses directed against itself following nonmucosal 
delivery, a response that likely mediates protection from a lethal mucosal challenge.  Double 
promoter vectors derived from VEE likewise induce protection from mucosal challenge and 
IgA antibody production at mucosal surfaces following nonmucosal delivery.  Davis et al. 
demonstrated that a VEE double promoter construct expressing the hemagglutinin (HA) gene 
from influenza virus not only protected mice from overt signs of clinical disease following a 
mucosal challenge with influenza virus, but also significantly reduced challenge virus 
replication in the URT, suggesting that local mucosal immune induction inhibited the earliest 
stages of challenge virus infection (74).  Additionally, Caley et al. demonstrated induction of 
matrix capsid (MA/CA)-specific IgA antibodies present in vaginal lavage fluids following 
 48
subcutaneous delivery of a double promoter VEE vector expressing the MA/CA gene from 
HIV-1.  Thus, VEE appears to be capable of inducing mucosal immune responses to the virus 
itself, as well as to antigens which are expressed from genetically modified virus vectors. 
 The mechanisms by which VEE and replicating VEE vectors induce mucosal 
immunity remains to be fully determined; however, Charles et al. (51) recently proposed a 
model to explain such an observation.  The central thesis of the natural pathway for mucosal 
immune induction suggests mucosal antigen delivery, as occurs following nasal or oral 
inoculation, is required to target antigen to the MALT, and to induce mucosal immunity.  
However, VEE induces mucosal immunity without the necessity of mucosal delivery.  
Charles et al. suggested that VEE induces mucosal immunity by delivering viral antigens to 
the MALT not across the mucosal barrier, but instead from the anatomical interior of the 
animal (51).  Consistent with this hypothesis, VEE efficiently replicates in the MALT tissues 
of the gut, providing a plausible mechanism by which viral antigens gain access to the 
mucosal immune system in the absence of mucosal delivery (51).  In further support of this 
notion, attenuated VEE mutants efficiently replicate in the PPs and mesenteric lymph node 
following subcutaneous vaccination, and not only protect animals from nasal challenge with 
virulent VEE, but also reduce challenge virus replication in the mucosal epithelium to below 
background levels (Richmond E. M., and Johnston, R. E., unpublished).  These observations 
are consistent with mucosal immune induction from the “inside out” as opposed to the 
natural “outside in” pathway.  Further experimentation will be required to validate such an 
hypothesis.   
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VEE replicon particles.  While studies with replicating VEE mutants and double 
promoter vectors have clearly demonstrated mucosal immune induction following 
nonmucosal delivery, the VRP system provides an opportunity to study mucosal immune 
induction with VEE under conditions in which the infection is limited to the first infected 
cells.  Protection from mucosal challenge with VRP has been demonstrated with influenza 
virus in mice (303) and chickens (329), Simian immunodeficiency virus in non-human 
primates (166), and Equine arteritis virus in horses (15).  Additionally, results from intranasal 
challenge of HA-VRP-immunized mice suggested that VRP reduced challenge virus 
replication in the URT to below the limits of detection (Richmond, E. M., Davis, N. L., 
Brown, K., West, A. C., and Johnston, R. E., unpublished).  These observations are 
consistent with a model of local mucosal immune induction; however, they are not definitive.  
Recently, mucosal immune responses have in fact been observed in animals immunized 
parenterally with VRP.  Antigen-specific IgG and IgA antibodies were present in gut 
mucosal secretions in two separate studies utilizing VRP expressing the major capsid protein 
from Norwalk virus (131, 212).  Likewise, analysis of immune responses in animals 
immunized in the footpad with VRP expressing influenza virus HA revealed production of 
HA-specific IgG and IgA antibodies both in the URT (358) and in vaginal secretions 
(Thompson, J. M., Richmond, E. M., Davis, N. L., and Johnston, R. E., unpublished) as well 
as antigen-specific IFN-γ-secreting cells in the URT (Thompson, J. M., Whitmore, A. C., 
Heise, M. T., and Johnston, R. E., unpublished).   
Replicon particles derived from SIN and SFV also have demonstrated induction of 
mucosal antibody and/or T cell responses, but only after a protocol involving mucosal 
delivery, not following nonmucosal delivery alone (19, 370).  Comparative immunogenicity 
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studies between SIN and VEE replicon particles have been performed recently.  Stronger 
antigen-specific CD8+ T cell responses were present in animals immunized with VEE 
replicon particles as compared to animals immunized with SIN replicon particles expressing 
the same antigen (283).  Interestingly, analysis of systemic immune induction with chimeric 
particles derived from VEE and SIN suggested that the increased immunogenicity phenotype 
was dependent upon the VEE RNA, regardless of whether the VEE RNA was enveloped in 
VEE capsid and glycoproteins or the SIN capsid and glycoproteins (283).   
Nonmucosal delivery of chimeric particles in which the RNA was derived from VEE, 
and the structural components derived from SIN resulted in antigen-specific IFN-γ-secreting 
cells at the local vaginal mucosal surface following heterologous vaginal boost (125), as well 
as strong protection in a mouse HIV challenge model (125).  Combined parenteral/mucosal 
delivery of VEE/SIN chimeras results in antigen-specific mucosal immunity in macaques as 
well (126).  Interestingly, Greer et al. recently demonstrated that parenteral delivery of 
chimeric particles expressing parainfluenza virus (PIV) antigens not only protected animals 
from clinical signs associated with mucosal challenge with PIV, but also reduced early 
challenge virus replication in the URT and LRT to levels below the limits of detection in 
both mice and hamsters (120), consistent with immune induction at the local mucosal level.  
While these examples warrant the further investigation of VEE/SIN chimeras, local mucosal 
immune induction following nonmucosal delivery has as yet only been observed with 
alphavirus replicon particles derived from VEE.   
Understanding the mechanism by which replication-defective VEE vectors promote 
mucosal immune induction represents an active area of inquiry.  Replication-competent VEE 
appears to access the MALT following nonmucosal delivery; it is possible that VRP-infected 
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DCs also target VEE antigens to the mucosal lymphoid tissues.  VRP promote the migration 
of infected DCs to the DLN.  It is possible that free VRP, or VRP-infected DCs, could 
migrate to the MALT and present antigen to the mucosal inductive sites in a manner similar 
to replication competent virus.  However, to date, there is no evidence of VRP-infected cells 
within mucosal lymphoid tissues following footpad inoculation (Thompson, J. M., 
Richmond, E. M., and Johnston, R. E., unpublished).   
 It is plausible that instead of targeting MALT following peripheral delivery, VRP set 
in motion the events required to activat mucosal immune responses in a non-mucosa-draining 
lymph node.  If this hypothesis were true, one would predict such a lymph node to exhibit 
markers of mucosal lymphoid tissues following VRP infection.  In fact, recent work supports 
such a notion (Thompson et al., in preparation, Chapter 3).  The DLN of VRP-immunized 
animals appears to serve as the earliest site of antigen-specific IgA antibody production, 
including production of polymeric forms of IgA.  Additionally, B cells present in the VRP 
DLN upregulate expression of the mucosal homing receptor, and MAdCAM-1 is expressed 
on the HEVs of the VRP-targeted DLN.  Moreover, analysis of cytokines present in the VRP 
DLN suggests the activation of a massive inflammatory response, with expression of several 
cytokines with documented roles in mucosal immune induction, including IL-6 and TNF-α.  
While further experimentation is required to validate such an hypothesis, all of these 
observations are consistent with a model in which the VRP-infected draining lymph node is 
converted into the functional equivalent of a mucosal inductive site.   
 
 Adjuvant effects.  Studies performed as early as the 1960s suggested that viral 
infection could dramatically affect the magnitude and duration of a concomitant immune 
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response to an unrelated antigen (263).  At the same time, a similar effect was demonstrated 
with an attenuated VEE in both mice (151) and guinea pigs (65).  This work demonstrated 
the adjuvant effect of replicating VEE on the generation of a humoral immune response to an 
antigen present in virus-infected animals.  Interestingly, the strongest adjuvant effect was 
observed when attenuated VEE was delivered 24 hours prior to antigen delivery (65).  In fact 
only a very modest increase in humoral immunity was observed when VEE was delivered 5 
minutes prior to antigen inoculation.  These observations suggest that VEE possess inherent 
immunostimulatory properties and strong adjuvant activity for the induction of humoral 
immunity. 
 Little, to no follow up work has been performed with replicating VEE adjuvants; 
however, we have recently demonstrated that the adjuvant effect of VEE is not dependent 
upon propagation and spread in vivo, as VRP likewise possess adjuvant activity (358).  
Further characterization of this effect demonstrated robust adjuvant activity for both systemic 
and mucosal antibody responses (358) as well as T cell responses in mice (Thompson et al, 
in preparation, Chapter 4).  The adjuvant effect was sensitive to ultraviolet (UV) light, 
suggesting that elements of VRP RNA replication play a critical role in immune induction 
(358).  Recently, replicon particles derived from SFV were also shown to possess adjuvant 
activity for systemic humoral immunity (142).  While the mechanistic explanation for the 
adjuvant effect appears to differ between the two systems in terms of sensitivity to UV, and 
dependence upon type I interferon signaling (discussed in Chapter 5), these observations 
suggest that alphavirus replicon particles possess intrinsic immunostimulatory properties 
independent of antigen expression and provide the basis for a novel vaccine technology.   
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DISSERTATION OBJECTIVES 
 
The purpose of the studies described here are the following: 
 
1) Identify the critical immunological and virological components responsible for VRP 
systemic and mucosal adjuvant activity, 
 
2) Define the mechanism(s) by which VRP promote mucosal immune induction 
following nonmucosal delivery, and  
 
3) Evaluate the efficacy of VRP adjuvants in protective vaccines 
 
 
 
 
 
 
 
 
 
 
 
 
 54
REFERENCES 
1. 2003. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, 
influenza vaccine live intranasal. Drugs R D 4:312-9. 
2. Agren, L. C., L. Ekman, B. Lowenadler, and N. Y. Lycke. 1997. Genetically 
engineered nontoxic vaccine adjuvant that combines B cell targeting with 
immunomodulation by cholera toxin A1 subunit. J Immunol 158:3936-3946. 
3. Akira, S., and K. Takeda. 2004. TOLL-LIKE RECEPTOR SIGNALLING. Nature 
Reviews Immunology 4:499-511. 
4. Alexander, L. N., J. F. Seward, T. A. Santibanez, M. A. Pallansch, O. M. Kew, D. 
R. Prevots, P. M. Strebel, J. Cono, M. Wharton, W. A. Orenstein, and R. W. 
Sutter. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the 
United States. Jama 292:1696-701. 
5. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition 
of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. 
Nature 413:732-738. 
6. Amara, R. R., F. Villinger, S. I. Staprans, J. D. Altman, D. C. Montefiori, N. L. 
Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G. Herndon, H. M. McClure, B. Moss, 
and H. L. Robinson. 2002. Different Patterns of Immune Responses but Similar 
Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by 
Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines. J. Virol. 
76:7625-7631. 
7. Andre, F. E. 1992. New developments in vaccinology. An Esp Pediatr 36 Suppl 
48:189. 
8. Andre, F. E. 2003. Vaccinology: past achievements, present roadblocks and future 
promises. Vaccine 21:593-595. 
9. Anjuere, F., C. Luci, M. Lebens, D. Rousseau, C. Hervouet, G. Milon, J. 
Holmgren, C. Ardavin, and C. Czerkinsky. 2004. In Vivo Adjuvant-Induced 
Mobilization and Maturation of Gut Dendritic Cells after Oral Administration of 
Cholera Toxin. J Immunol 173:5103-5111. 
10. Apodaca, G., L. A. Katz, and K. E. Mostov. 1994. Receptor-mediated transcytosis 
of IgA in MDCK cells is via apical recycling endosomes. J. Cell Biol. 125:67-86. 
11. Aronson, J. F., F. B. Grieder, N. L. Davis, P. C. Charles, T. Knott, K. Brown, 
and R. E. Johnston. 2000. A Single-Site Mutant and Revertants Arising in Vivo 
Define Early Steps in the Pathogenesis of Venezuelan Equine Encephalitis Virus. 
Virology 270:111-123. 
 55
12. Arulanandam, B. P., R. H. Raeder, J. G. Nedrud, D. J. Bucher, J. Le, and D. W. 
Metzger. 2001. IgA Immunodeficiency Leads to Inadequate Th Cell Priming and 
Increased Susceptibility to Influenza Virus Infection. J Immunol 166:226-231. 
13. Arvin, A. M. 1992. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 
166 Suppl 1:S35-41. 
14. Ashkar, A. A., and K. L. Rosenthal. 2002. Toll-like receptor 9, CpG DNA and 
innate immunity. Curr Mol Med 2:545-56. 
15. Balasuriya, U. B. R., H. W. Heidner, N. L. Davis, H. M. Wagner, P. J. Hullinger, 
J. F. Hedges, J. C. Williams, R. E. Johnston, W. David Wilson, I. K. Liu, and N. 
James MacLachlan. 2002. Alphavirus replicon particles expressing the two major 
envelope proteins of equine arteritis virus induce high level protection against 
challenge with virulent virus in vaccinated horses. Vaccine 20:1609-1617. 
16. Befus, D., and J. Bienenstock. 1984. Induction and expression of mucosal immune 
responses and inflammation to parasitic infections. Contemp Top Immunobiol 12:71-
108. 
17. Belyakov, I. M., S. A. Hammond, J. D. Ahlers, G. M. Glenn, and J. A. Berzofsky. 
2004. Transcutaneous immunization induces mucosal CTLs and protective immunity 
by migration of primed skin dendritic cells. J. Clin. Invest. 113:998-1007. 
18. Berge, T. O., I. S. Banks, and W. D. Tigertt. 1961. Attenuation of Venezuelan 
equine encephalomyelitis virus by in vitro cultivation in guinae-pig heart cells. Am. J. 
Epidemiol. 73:209-218. 
19. Berglund, P., M. N. Fleeton, C. Smerdou, and P. Liljestrom. 1999. Immunization 
with recombinant Semliki Forest virus induces protection against influenza challenge 
in mice. Vaccine 17:497-507. 
20. Berlin, C., E. L. Berg, M. J. Briskin, D. P. Andrew, P. J. Kilshaw, B. Holzmann, 
I. L. Weissman, A. Hamann, and E. C. Butcher. 1993. Alpha 4 beta 7 integrin 
mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 
74:185-95. 
21. Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 
Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate 
Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice. Virology 
276:93-103. 
22. Billiau, A., and P. Matthys. 2001. Modes of action of Freund's adjuvants in 
experimental models of autoimmune diseases. J Leukoc Biol 70:849-860. 
23. Bjerke, K., and P. Brandtzaeg. 1990. Terminally differentiated human intestinal B 
cells. J chain expression of IgA and IgG subclass-producing immunocytes in the 
 56
distal ileum compared with mesenteric and peripheral lymph nodes. Clin Exp 
Immunol 82:411-5. 
24. Bjerke, K., P. Brandtzaeg, and O. Fausa. 1988. T cell distribution is different in 
follicle-associated epithelium of human Peyer's patches and villous epithelium. Clin 
Exp Immunol 74:270-5. 
25. Blazevic, V., C. Mac Trubey, and G. M. Shearer. 2000. Comparison of in vitro 
immunostimulatory potential of live and inactivated influenza viruses. Human 
Immunology 61:845-849. 
26. Bodian, D. 1953. Experimental studies on passive immunization against 
poliomyelitis. III. Passive-active immunization and pathogenesis after virus feeding 
in chimpanzees. Am J Hyg 58:81-100. 
27. Boisgerault, F., P. Rueda, C. M. Sun, S. Hervas-Stubbs, M. Rojas, and C. 
Leclerc. 2005. Cross-Priming of T Cell Responses by Synthetic Microspheres 
Carrying a CD8+ T Cell Epitope Requires an Adjuvant Signal. The Journal of 
Immunology 174:3432-3439. 
28. Boismenu, R. 2000. Function of intestinal gammadelta T cells. Immunol Res 21:123-
7. 
29. Bonanni, P. 1999. Demographic impact of vaccination: a review. Vaccine 17:S120-
S125. 
30. Bouvet, J. P., N. Decroix, and P. Pamonsinlapatham. 2002. Stimulation of local 
antibody production: parenteral or mucosal vaccination? Trends in Immunology 
23:209-213. 
31. Bowman, E. P., N. A. Kuklin, K. R. Youngman, N. H. Lazarus, E. J. Kunkel, J. 
Pan, H. B. Greenberg, and E. C. Butcher. 2002. The Intestinal Chemokine 
Thymus-expressed Chemokine (CCL25) Attracts IgA Antibody-secreting Cells. J. 
Exp. Med. 195:269-275. 
32. Boyaka, P. N., M. Ohmura, K. Fujihashi, T. Koga, M. Yamamoto, M.-N. Kweon, 
Y. Takeda, R. J. Jackson, H. Kiyono, Y. Yuki, and J. R. McGhee. 2003. Chimeras 
of Labile Toxin One and Cholera Toxin Retain Mucosal Adjuvanticity and Direct Th 
Cell Subsets Via Their B Subunit. J Immunol 170:454-462. 
33. Boyaka, P. N., A. Tafaro, R. Fischer, K. Fujihashi, E. Jirillo, and J. R. McGhee. 
2003. Therapeutic manipulation of the immune system: enhancement of innate and 
adaptive mucosal immunity. Curr Pharm Des 9:1965-72. 
34. Brandtzaeg, P. 1997. Mucosal immunity in the female genital tract. J Reprod 
Immunol 36:23-50. 
 57
35. Brandtzaeg, P. 2003. Role of secretory antibodies in the defence against infections. 
Int J Med Microbiol 293:3-15. 
36. Brandtzaeg, P., I. N. Farstad, and G. Haraldsen. 1999. Regional specialization in 
the mucosal immune system: primed cells do not always home along the same track. 
Immunology Today 20:267-277. 
37. Brandtzaeg, P., and F.-E. Johansen. 2005. Mucosal B cells: phenotypic 
characteristics, transcriptional regulation, and homing properties. Immunological 
Reviews 206:32-63. 
38. Brandtzaeg, P., and F. E. Johansen. 2005. Mucosal B cells: phenotypic 
characteristics, transcriptional regulation, and homing properties. Immunol Rev. 
206:32-63. 
39. Brandtzaeg, P., L. M. Sollid, P. S. Thrane, D. Kvale, K. Bjerke, H. Scott, K. Kett, 
and T. O. Rognum. 1988. Lymphoepithelial interactions in the mucosal immune 
system. Gut 29:1116-30. 
40. Brave, A., K. Ljungberg, B. Wahren, and M. A. Liu. 2007. Vaccine delivery 
methods using viral vectors. Mol Pharm 4:18-32. 
41. Brewer, Conacher, Gaffney, Douglas, Bluethmann, and Alexander. 1998. Neither 
interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the 
adjuvant activity of Alum and Freund's adjuvant. Immunology 93:41-48. 
42. Brewer, J. M. 2006. (How) do aluminium adjuvants work? Immunology Letters 
102:10-15. 
43. Brewer, J. M., M. Conacher, C. A. Hunter, M. Mohrs, F. Brombacher, and J. 
Alexander. 1999. Aluminium Hydroxide Adjuvant Initiates Strong Antigen-Specific 
Th2 Responses in the Absence of IL-4- or IL-13-Mediated Signaling. J Immunol 
163:6448-6454. 
44. Brimnes, M. K., L. Bonifaz, R. M. Steinman, and T. M. Moran. 2003. Influenza 
Virus-induced Dendritic Cell Maturation Is Associated with the Induction of Strong T 
Cell Immunity to a Coadministered, Normally Nonimmunogenic Protein. The Journal 
of Experimental Medicine 198:133-144. 
45. Bromander, A. K., L. Ekman, M. Kopf, J. G. Nedrud, and N. Y. Lycke. 1996. IL-
6-deficient mice exhibit normal mucosal IgA responses to local immunizations and 
Helicobacter felis infection. J Immunol 156:4290-4297. 
46. Butcher, E. C. 1999. Lymphocyte Homing and Intestinal Immunity, p. 507-522. In P. 
L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee 
(ed.), Mucosal Immunology, 2nd ed. Academic Press, London. 
 58
47. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. 
Science 272:60-6. 
48. Callan, M. F. 2003. The evolution of antigen-specific CD8+ T cell responses after 
natural primary infection of humans with Epstein-Barr virus. Viral Immunol 16:3-16. 
49. Calmette, A., C. Guerin, and M. Breton. 1907. Contribution a l'edude de la 
tuberculose experimental du cobaya (infection et essais de vaccination par la voie 
digestive). Ann. Inst. Pasteur Paris 21:401-416. 
50. Campbell, J. J., J. Hedrick, A. Zlotnik, M. A. Siani, D. A. Thompson, and E. C. 
Butcher. 1998. Chemokines and the Arrest of Lymphocytes Rolling Under Flow 
Conditions. Science 279:381-384. 
51. Charles, P. C., K. W. Brown, N. L. Davis, M. K. Hart, and R. E. Johnston. 1997. 
Mucosal Immunity Induced by Parenteral Immunization with a Live Attenuated 
Venezuelan Equine Encephalitis Virus Vaccine Candidate. Virology 228:153-160. 
52. Charles, P. C., J. Trgovcich, N. L. Davis, and R. E. Johnston. 2001. 
Immunopathogenesis and Immune Modulation of Venezuelan Equine Encephalitis 
Virus-Induced Disease in the Mouse. Virology 284:190-202. 
53. Charles, P. C., E. Walters, F. Margolis, and R. E. Johnston. 1995. Mechanism of 
Neuroinvasion of Venezuelan Equine Encephalitis Virus in the Mouse. Virology 
208:662-671. 
54. Cherry, J. D., and P. Olin. 1999. The Science and Fiction of Pertussis Vaccines. 
Pediatrics 104:1381-1383. 
55. Cho, H. J., K. Takabayashi, P. M. Cheng, M. D. Nguyen, M. Corr, S. Tuck, and 
E. Raz. 2000. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte 
activity by a T-helper cell-independent mechanism. Nat Biotechnol 18:509-14. 
56. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. 
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) 
immunity. J Exp Med 186:1623-31. 
57. Clark, A., C. W. Potter, R. Jennings, J. P. Nicholl, A. F. Langrick, G. C. Schild, 
J. M. Wood, and D. A. Tyrrell. 1983. A comparison of live and inactivated 
influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond) 90:361-70. 
58. Clements, M. L., R. F. Betts, E. L. Tierney, and B. R. Murphy. 1986. Serum and 
nasal wash antibodies associated with resistance to experimental challenge with 
influenza A wild-type virus. J. Clin. Microbiol. 24:157-160. 
59. Coffin, S. E., S. L. Clark, N. A. Bos, J. O. Brubaker, and P. A. Offit. 1999. 
Migration of Antigen-Presenting B Cells from Peripheral to Mucosal Lymphoid 
 59
Tissues May Induce Intestinal Antigen-Specific IgA Following Parenteral 
Immunization. The Journal of Immunology 163:3064-3070. 
60. Coffin, S. E., M. Klinek, and P. A. Offit. 1995. Induction of virus-specific antibody 
production by lamina propria lymphocytes following intramuscular inoculation with 
rotavirus. J Infect.Dis. 172:874-878. 
61. Conley M.E., and D. L. Delacroix. Intravascular and mucosal immunoglobulin A: 
two separate but related systems of immune defense? Ann Intern Med. 1987 
Jun;106(6):892-9. 
62. Conrad, M. E., and S. M. Lemon. 1987. Prevention of endemic icteric viral 
hepatitis by administration of immune serum gamma globulin. J Infect Dis 156:56-
63. 
63. Coulson, B. S., K. Grimwood, I. L. Hudson, G. L. Barnes, and R. F. Bishop. 
1992. Role of coproantibody in clinical protection of children during reinfection with 
rotavirus. J. Clin. Microbiol. 30:1678-1684. 
64. Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza Virus: Immunity and 
Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, 
Attenuated Influenza Vaccines. Scandinavian Journal of Immunology 59:1-15. 
65. Craig, C. P., S. L. Reynolds, J. W. Airhart, and E. V. Staab. 1969. Alterations in 
immune responses by attenuated Venezuelan equine encephalitis vaccine. I. Adjuvant 
effect of VEE virus infection in guinea pigs. J Immunol 102:1220-7. 
66. Cui, Z., and M.-C. H. a. E. W. Leaf Huang. 2005. DNA Vaccine, p. 257-289, 
Advances in Genetics, vol. Volume 54. Academic Press. 
67. Czerkinsky, C., F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. 
P. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. B. 
Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. 
Immunol Rev 170:197-222. 
68. Danes, L., V. Rychterova, V. Kliment, and J. Hruskova. 1973. Penetration of 
Venezuelan equine encephalomyelitis virus into the brain of guinea pigs and rabbits 
after intranasal infection. Acta Virol 17:138-46. 
69. Dannenberg, A. M., Jr. 1991. Delayed-type hypersensitivity and cell-mediated 
immunity in the pathogenesis of tuberculosis. Immunol Today 12:228-33. 
70. Dannenberg, A. M., Jr. 1989. Immune mechanisms in the pathogenesis of 
pulmonary tuberculosis. Rev Infect Dis 11 Suppl 2:S369-78. 
71. Davies, J. R., and E. A. Grilli. 1989. Natural or vaccine-induced antibody as a 
predictor of immunity in the face of natural challenge with influenza viruses. 
Epidemiol Infect 102:325-33. 
 60
72. Davies, J. R., E. A. Grilli, and A. J. Smith. 1986. Infection with influenza A H1N1. 
2. The effect of past experience on natural challenge. J Hyg (Lond) 96:345-52. 
73. Davis, H. L. 2000. Use of CpG DNA for enhancing specific immune responses. Curr 
Top Microbiol Immunol 247:171-83. 
74. Davis, N. L., K. W. Brown, and R. E. Johnston. 1996. A viral vaccine vector that 
expresses foreign genes in lymph nodes and protects against mucosal challenge. J. 
Virol. 70:3781-3787. 
75. Davis, N. L., I. J. Caley, K. W. Brown, M. R. Betts, D. M. Irlbeck, K. M. 
McGrath, M. J. Connell, D. C. Montefiori, J. A. Frelinger, R. Swanstrom, P. R. 
Johnson, and R. E. Johnston. 2000. Vaccination of macaques against pathogenic 
simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon 
particles. J Virol 74:371-8. 
76. Davis, N. L., F. B. Grieder, J. F. Smith, G. F. Greenwald, M. L. Valenski, D. C. 
Sellon, P. C. Charles, and R. E. Johnston. 1994. A molecular genetic approach to 
the study of Venezuelan equine encephalitis virus pathogenesis. Arch Virol Suppl 
9:99-109. 
77. Davis, N. L., A. West, E. Reap, G. MacDonald, M. Collier, S. Dryga, M. 
Maughan, M. Connell, C. Walker, K. McGrath, C. Cecil, L. H. Ping, J. 
Frelinger, R. Olmsted, P. Keith, R. Swanstrom, C. Williamson, P. Johnson, D. 
Montefiori, and R. E. Johnston. 2002. Alphavirus replicon particles as candidate 
HIV vaccines. IUBMB Life 53:209-11. 
78. Davis, N. L., L. V. Willis, J. F. Smith, and R. E. Johnston. 1989. In vitro synthesis 
of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis 
of a viable deletion mutant. Virology 171:189-204. 
79. de la Monte S. M., F. Castro, N. J. Bonilla, A. G. de Urdaneta, and G. M. 
Hutchins. 1985. The systemic pathology of Venezuelan equine encephalitis virus 
infection in humans. Am. J. Trop. Med. Hyg. 34:194-202. 
80. Devin B. Lowe, M. H. S. R. C. K. 2006. DNA vaccines: Successes and limitations in 
cancer and infectious disease. Journal of Cellular Biochemistry 98:235-242. 
81. Dietrich, G., M. Griot-Wenk, I. C. Metcalfe, A. B. Lang, and J.-F. Viret. 2003. 
Experience with registered mucosal vaccines. Vaccine 21:678-683. 
82. Dietrich, G., S. Spreng, D. Favre, J. F. Viret, and C. A. Guzman. 2003. Live 
attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr Opin Mol Ther 
5:10-9. 
83. Doherty, P. C., D. J. Topham, R. A. Tripp, R. D. Cardin, J. W. Brooks, and P. G. 
Stevenson. 1997. Effector CD4+ and CD8+ T-cell mechanisms in the control of 
respiratory virus infections. Immunol Rev 159:105-17. 
 61
84. Dudek, T., and D. M. Knipe. 2006. Replication-defective viruses as vaccines and 
vaccine vectors. Virology 344:230-239. 
85. Egan, M. A., S. Y. Chong, M. Hagen, S. Megati, E. B. Schadeck, P. Piacente, B. 
J. Ma, D. C. Montefiori, B. F. Haynes, Z. R. Israel, J. H. Eldridge, and H. F. 
Staats. 2004. A comparative evaluation of nasal and parenteral vaccine adjuvants to 
elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in 
cynomolgus macaques. Vaccine 22:3774-3788. 
86. Ehrenkranz, N. J., and A. K. Ventura. 1974. Venezuelan Equine Encephalitis 
Virus Infection in Man. Annual Review of Medicine 25:9-14. 
87. Elson, C. O., Dertzbaugh, M.T. 1999. Mucosal Adjuvants, p. 817-838. In P. L. 
Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), 
Mucosal Immunology, 2nd ed. Academic Press, London. 
88. Elson, C. O., M. Tomasi, T.-T. Chang, and M. G. Jobling, Holmes, R. K. 1995. 
Immunogenicity and adjuvanticity of mutant cholera toxin (CT) molecules. FASEB J. 
9:A290. 
89. Enioutina, E. Y., D. Visic, Z. A. McGee, and R. A. Daynes. 1999. The induction of 
systemic and mucosal immune responses following the subcutaneous immunization 
of mature adult mice: characterization of the antibodies in mucosal secretions of 
animals immunized with antigen formulations containing a vitamin D3 adjuvant. 
Vaccine 17:3050-3064. 
90. Ennis, F. A., Q. Yi-Hua, and G. C. Schild. 1982. Antibody and cytotoxic T 
lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen 
Virol 58:273-81. 
91. Ermak, T. H., and R. L. Owen. 1986. Differential distribution of lymphocytes and 
accessory cells in mouse Peyer's patches. Anat Rec 215:144-52. 
92. Ermak, T. H., H. J. Steger, and J. Pappo. 1990. Phenotypically distinct 
subpopulations of T cells in domes and M-cell pockets of rabbit gut-associated 
lymphoid tissues. Immunology 71:530-7. 
93. Esser, M. T., R. D. Marchese, L. S. Kierstead, L. G. Tussey, F. Wang, N. 
Chirmule, and M. W. Washabaugh. 2003. Memory T cells and vaccines. Vaccine 
21:419-430. 
94. Faden, H., J. F. Modlin, M. L. Thoms, A. M. McBean, M. B. Ferdon, and P. L. 
Ogra. 1990. Comparative evaluation of immunization with live attenuated and 
enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and 
local immune responses. J Infect Dis 162:1291-7. 
95. Faveeuw, C., M. E. Di Mauro, A. A. Price, and A. Ager. 2000. Roles of {alpha}4 
integrins/VCAM-1 and LFA-1/ICAM-1 in the binding and transendothelial migration 
 62
of T lymphocytes and T lymphoblasts across high endothelial venules. Int. Immunol. 
12:241-251. 
96. Fearon, D. T. 1997. Seeking wisdom in innate immunity. Nature 388:323-4. 
97. Feng, N., M. C. Jaimes, N. H. Lazarus, D. Monak, C. Zhang, E. C. Butcher, and 
H. B. Greenberg. 2006. Redundant Role of Chemokines CCL25/TECK and 
CCL28/MEC in IgA+ Plasmablast Recruitment to the Intestinal Lamina Propria After 
Rotavirus Infection. J Immunol 176:5749-5759. 
98. Fenner, F., D. A. Henderson, L. Arita, S. Jezek, and I. D. Ladnyi. 1988. Smallpox 
and its Eradication.  Geneva:  World Health Organization. 
99. Fine, P. E., and L. C. Rodrigues. 1990. Modern vaccines. Mycobacterial diseases. 
Lancet 335:1016-20. 
100. Fletcher, H., and H. McShane. 2006. Tuberculosis vaccines: current status and 
future prospects. Expert Opinion on Emerging Drugs 11:207-215. 
101. Freund, J. 1956. The mode of action of immunologica adjuvants. Adv. Tuberc. Res. 
7:130-148. 
102. Frolova, E., I. Frolov, and S. Schlesinger. 1997. Packaging signals in alphaviruses. 
J. Virol. 71:248-258. 
103. Gardner, J. P., I. Frolov, S. Perri, Y. Ji, M. L. MacKichan, J. zur Megede, M. 
Chen, B. A. Belli, D. A. Driver, S. Sherrill, C. E. Greer, G. R. Otten, S. W. 
Barnett, M. A. Liu, T. W. Dubensky, and J. M. Polo. 2000. Infection of Human 
Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single Amino 
Acid Substitution in the E2 Glycoprotein. J. Virol. 74:11849-11857. 
104. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. 
Nemazee. 2006. Adjuvant-Enhanced Antibody Responses in the Absence of Toll-
Like Receptor Signaling. Science 314:1936-1938. 
105. Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara. 2001. 
Cutting Edge: Bacterial Flagellin Activates Basolaterally Expressed TLR5 to Induce 
Epithelial Proinflammatory Gene Expression. J Immunol 167:1882-1885. 
106. Ghendon, Y. 1990. The immune response to influenza vaccines. Acta Virol 34:295-
304. 
107. Gherardi, M. M., and M. Esteban. 2005. Recombinant poxviruses as mucosal 
vaccine vectors. J Gen Virol 86:2925-2936. 
108. Giudice, E. L., and J. D. Campbell. 2006. Needle-free vaccine delivery. Advanced 
Drug Delivery Reviews 58:68-89. 
 63
109. Glass, R. I., M. K. Bhan, P. Ray, R. Bahl, U. D. Parashar, H. Greenberg, C. 
Durga Rao, N. Bhandari, Y. Maldonado, R. L. Ward, D. I. Bernstein, and J. R. 
Gentsch. 2005. Development of Candidate Rotavirus Vaccines Derived from 
Neonatal Strains in India. J Infect Dis 192:S30-S35. 
110. Gleiser, C. A., W. S. Gochenour, Jr., T. O. Berge, and W. D. Tigertt. 1962. The 
comparative pathology of experimental Venezuelan equine encephalomyelitis 
infection in different animal hosts. J Infect Dis 110:80-97. 
111. Glenn, G. M., and R. T. Kenney. 2006. Mass vaccination: solutions in the skin. Curr 
Top Microbiol Immunol 304:247-68. 
112. Glenn, G. M., and R. T. Kenney. 2004. Transcutaneous Immunization, p. 401-412. 
In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, and M. F. Good (ed.), New 
Generation Vaccines, 3rd ed. Marcel Dekker, New York. 
113. Glenn, G. M., R. T. Kenney, L. R. Ellingsworth, S. A. Frech, S. A. Hammond, 
and J. P. Zoeteweij. 2003. Transcutaneous immunization and immunostimulant 
strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 
2:253-67. 
114. Glenn, G. M., R. T. Kenney, S. A. Hammond, and L. R. Ellingsworth. 2003. 
Transcutaneous immunization and immunostimulant strategies. Immunol Allergy 
Clin North Am 23:787-813. 
115. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. 
Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy 
using a patch. Nat Med. 6:1403-1406. 
116. Glenny, A. T., G. A. H. Buttle, and M. F. Stevens. 1931. Rate of disappearance of 
diphtheria toxoid injected into rabbits and guinae-pigs:  toxoid precipitated with alum. 
J. Pathol. 34:267-275. 
117. Glenny, A. T., C. G. Pope Hilda Waddington U. Wallace. 1926. Immunological 
notes. XVII-XXIV. The Journal of Pathology and Bacteriology 29:31-40. 
118. Gockel, C. M., S. Bao, and K. W. Beagley. 2000. Transcutaneous immunization 
induces mucosal and systemic immunity: a potent method for targeting immunity to 
the female reproductive tract. Molecular Immunology 37:537-544. 
119. Gorchakov, R., E. Frolova, and I. Frolov. 2005. Inhibition of Transcription and 
Translation in Sindbis Virus-Infected Cells. J. Virol. 79:9397-9409. 
120. Greer, C. E., F. Zhou, H. S. Legg, Z. Tang, S. Perri, B. A. Sloan, J. z. Megede, Y. 
Uematsu, M. Vajdy, and J. M. Polo. 2007. A chimeric alphavirus RNA replicon 
gene-based vaccine for human parainfluenza virus type 3 induces protective 
immunity against intranasal virus challenge. Vaccine 25:481-489. 
 64
121. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, 
and R. E. Johnston. 1995. Specific Restrictions in the Progression of Venezuelan 
Equine Encephalitis Virus-Induced Disease Resulting from Single Amino Acid 
Changes in the Glycoproteins. Virology 206:994-1006. 
122. Grieder, F. B., and S. N. Vogel. 1999. Role of Interferon and Interferon Regulatory 
Factors in Early Protection against Venezuelan Equine Encephalitis Virus Infection. 
Virology 257:106-118. 
123. Griffin, D. E. 2001. Alphaviruses, p. 917-962. In D. M. Knipe, B. N. Fields, and P. 
M. Howley (ed.), Fields Virology, 4th ed. Lippincott Williams & Wilkins, 
Philadelphia, PA. 
124. Gupta, R. K., A.-C. Chang, P. Griffin, R. Rivera, and G. R. Siber. 1996. In vivo 
distribution of radioactivity in mice after injection of biodegradable polymer 
microspheres containing 14C-labeled tetanus toxoid. Vaccine 14:1412-1416. 
125. Gupta, S., R. Janani, Q. Bin, P. Luciw, C. Greer, S. Perri, H. Legg, J. Donnelly, 
S. Barnett, D. O'Hagan, J. M. Polo, and M. Vajdy. 2005. Characterization of 
Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells 
following Protective Mucosal Immunization with Alphavirus Replicon Particles. J. 
Virol. 79:7135-7145. 
126. Gupta, S., F. Zhou, C. E. Greer, H. Legg, T. Tang, P. Luciw, J. zur Megede, S. 
W. Barnett, J. J. Donnelly, D. T. O'Hagan, J. M. Polo, and M. Vajdy. 2006. 
Antibody responses against HIV in rhesus macaques following combinations of 
mucosal and systemic immunizations with chimeric alphavirus-based replicon 
particles. AIDS Res Hum Retroviruses 22:993-7. 
127. Hadden, J. W. 1994. T-cell adjuvants. Int J Immunopharmacol 16:703-10. 
128. Haigwood, N. L., A. Watson, W. F. Sutton, J. McClure, A. Lewis, J. Ranchalis, 
B. Travis, G. Voss, N. L. Letvin, S. L. Hu, V. M. Hirsch, and P. R. Johnson. 
1996. Passive immune globulin therapy in the SIV/macaque model: early intervention 
can alter disease profile. Immunol Lett 51:107-14. 
129. Hajjar, A. M., D. S. O'Mahony, A. Ozinsky, D. M. Underhill, A. Aderem, S. J. 
Klebanoff, and C. B. Wilson. 2001. Cutting Edge: Functional Interactions Between 
Toll-Like Receptor (TLR) 2 and TLR1 or TLR6 in Response to Phenol-Soluble 
Modulin. J Immunol 166:15-19. 
130. Hamann, A., D. P. Andrew, D. Jablonski-Westrich, B. Holzmann, and E. C. 
Butcher. 1994. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in 
vivo. J Immunol 152:3282-3293. 
131. Harrington, P. R., B. Yount, R. E. Johnston, N. Davis, C. Moe, and R. S. Baric. 
2002. Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated 
 65
with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like 
Particles. The Journal of Virology 76:730-742. 
132. Hart, M. K., K. Caswell-Stephan, R. Bakken, R. Tammariello, W. Pratt, N. 
Davis, R. E. Johnston, J. Smith, and K. Steele. 2000. Improved mucosal protection 
against Venezuelan equine encephalitis virus is induced by the molecularly defined, 
live-attenuated V3526 vaccine candidate. Vaccine 18:3067-3075. 
133. Hart, M. K., C. Lind, R. Bakken, M. Robertson, R. Tammariello, and G. V. 
Ludwig. 2001. Onset and duration of protective immunity to IA/IB and IE strains of 
Venezuelan equine encephalitis virus in vaccinated mice. Vaccine 20:616-622. 
134. Hart, M. K., W. Pratt, F. Panelo, R. Tammariello, and M. Dertzbaugh. 1997. 
Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and 
protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine 
15:363-369. 
135. Hartmann, G., G. J. Weiner, and A. M. Krieg. 1999. CpG DNA: A potent signal 
for growth, activation, and maturation of human dendritic cells. PNAS 96:9305-9310. 
136. Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. 
Eng, S. Akira, D. M. Underhill, and A. Aderem. 2001. The innate immune 
response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-
103. 
137. Heeger, P. S., T. Forsthuber, C. Shive, E. Biekert, C. Genain, H. H. Hofstetter, 
A. Karulin, and P. V. Lehmann. 2000. Revisiting Tolerance Induced by 
Autoantigen in Incomplete Freund's Adjuvant. J Immunol 164:5771-5781. 
138. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. 
Lipford, H. Wagner, and S. Bauer. 2004. Species-Specific Recognition of Single-
Stranded RNA via Toll-like Receptor 7 and 8. Science 303:1526-1529. 
139. Helen, S. G., E. C. L. Sophie, F. G. Kate, E. D. Williamson, A. B. Katherine, and 
W. T. Richard. 2004. The Use of Live Attenuated Bacteria as a Delivery System for 
Heterologous Antigens. Journal of Drug Targeting 11:471-479. 
140. Hendrickson, B. A., D. A. Conner, D. J. Ladd, D. Kendall, J. E. Casanova, B. 
Corthesy, E. E. Max, M. R. Neutra, C. E. Seidman, and J. G. Seidman. 1995. 
Altered hepatic transport of immunoglobulin A in mice lacking the J chain. J. Exp. 
Med. 182:1905-1911. 
141. Herremans, T. M. P. T., J. H. J. Reimerink, A. M. Buisman, T. G. Kimman, and 
M. P. G. Koopmans. 1999. Induction of Mucosal Immunity by Inactivated 
Poliovirus Vaccine Is Dependent on Previous Mucosal Contact with Live Virus. J 
Immunol 162:5011-5018. 
 66
142. Hidmark, A. S., E. K. L. Nordstrom, P. Dosenovic, M. N. E. Forsell, P. 
Liljestrom, and G. B. Karlsson Hedestam. 2006. Humoral Responses against 
Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require 
Alpha/Beta Interferon Signaling. J. Virol. 80:7100-7110. 
143. Hieshima, K., Y. Kawasaki, H. Hanamoto, T. Nakayama, D. Nagakubo, A. 
Kanamaru, and O. Yoshie. 2004. CC Chemokine Ligands 25 and 28 Play Essential 
Roles in Intestinal Extravasation of IgA Antibody-Secreting Cells. J Immunol 
173:3668-3675. 
144. Hobson, D., R. L. Curry, A. S. Beare, and A. Ward-Gardner. 1972. The role of 
serum haemagglutination-inhibiting antibody in protection against challenge infection 
with influenza A2 and B viruses. J Hyg (Lond) 70:767-77. 
145. Hofer, T., G. Muehlinghaus, K. Moser, T. Yoshida, H. E. Mei, K. Hebel, A. 
Hauser, B. Hoyer, E. O. Luger, T. Dorner, R. A. Manz, F. Hiepe, and A. 
Radbruch. 2006. Adaptation of humoral memory. Immunological Reviews 211:295-
302. 
146. Hohlfeld, R., and A. G. Engel. 1994. The immunobiology of muscle. Immunol 
Today 15:269-74. 
147. Holmgren, J., J. Adamsson, F. Anjuere, J. Clemens, C. Czerkinsky, K. Eriksson, 
C.-F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, T. Lehner, M. 
Lindblad, E. Nygren, S. Raghavan, J. Sanchez, M. Stanford, J.-B. Sun, A.-M. 
Svennerholm, and S. Tengvall. 2005. Mucosal adjuvants and anti-infection and anti-
immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG 
DNA. Immunology Letters 97:181-188. 
148. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat Med 
11:S45-53. 
149. Holmgren, J., C. Czerkinsky, K. Eriksson, and A. Mharandi. 2003. Mucosal 
immunisation and adjuvants: a brief overview of recent advances and challenges. 
Vaccine 21:S89-S95. 
150. Holmgren, J., C. Czerkinsky, N. Lycke, and A. M. Svennerholm. 1992. Mucosal 
immunity: implications for vaccine development. Immunobiology 184:157-79. 
151. Howard, R. J., C. P. Craig, G. S. Trevino, S. F. Dougherty, and S. E. 
Mergenhagen. 1969. Enhanced humoral immunity in mice infected with attenuated 
Venezuelan equine encephalitis virus. J Immunol 103:699-707. 
152. Hutchings, C. L., S. C. Gilbert, A. V. S. Hill, and A. C. Moore. 2005. Novel 
Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of 
Humoral and Cell-Mediated Immunity. The Journal of Immunology 175:599-606. 
 67
153. Ioannou, X. P., S. M. Gomis, B. Karvonen, R. Hecker, L. A. Babiuk, and S. van 
Drunen Littel-van den Hurk. 2002. CpG-containing oligodeoxynucleotides, in 
combination with conventional adjuvants, enhance the magnitude and change the bias 
of the immune responses to a herpesvirus glycoprotein. Vaccine 21:127-137. 
154. Iwai, M., T. Nakayama, K. Matsuura, S. Hasegawa, S. Ando, M. Obara, Y. 
Nagai, H. Yoshida, and H. Horie. 2006. Assessment of efficacy of a live oral 
poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan. Acta Virol 
50:139-43. 
155. Jakob, T., and M. C. Udey. 1999. Epidermal Langerhans cells: from neurons to 
nature's adjuvants. Adv Dermatol 14:209-58; discussion 259. 
156. Jakob, T., P. S. Walker, A. M. Krieg, M. C. Udey, and J. C. Vogel. 1998. 
Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: 
A Role for Dendritic Cells in the Augmentation of Th1 Responses by 
Immunostimulatory DNA. J Immunol 161:3042-3049. 
157. Janeway, C. A., Jr. 1989. Approaching the asymptote? Evolution and revolution in 
immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1:1-13. 
158. Janeway, C. A., and R. Medzhitov. 2002. INNATE IMMUNE RECOGNITION. 
Annual Review of Immunology 20:197-216. 
159. Jenner, E. 1801. The Origin of the Vaccine Inoculation.  London:  Shury, 1-12. 
160. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, and 
serum antibody responses as indirect measures of intestinal immunity after oral 
cholera vaccination or natural disease. J. Clin. Microbiol. 24:203-209. 
161. Johansen, Braathen, and Brandtzaeg. 2000. Role of J Chain in Secretory 
Immunoglobulin Formation. Scandinavian Journal of Immunology 52:240-248. 
162. Johansen, F.-E., R. Braathen, and P. Brandtzaeg. 2001. The J Chain Is Essential 
for Polymeric Ig Receptor-Mediated Epithelial Transport of IgA. J Immunol 
167:5185-5192. 
163. Johansen, F.-E., M. Pekna, I. N. Norderhaug, B. Haneberg, M. A. Hietala, P. 
Krajci, C. Betsholtz, and P. Brandtzaeg. 1999. Absence of Epithelial 
Immunoglobulin A Transport, with Increased Mucosal Leakiness, in Polymeric 
Immunoglobulin Receptor/Secretory Component–deficient Mice. J. Exp. Med. 
190:915-922. 
164. John, T. J., and S. Reuben. 2000. Herd immunity and herd effect: new insights and 
definitions. European Journal of Epidemiology V16:601-606. 
165. Johnson, G. P., S. J. Goebel, and E. Paoletti. 1993. An Update on the Vaccinia 
Virus Genome. Virology 196:381-401. 
 68
166. Johnston, R. E., P. R. Johnson, M. J. Connell, D. C. Montefiori, A. West, M. L. 
Collier, C. Cecil, R. Swanstrom, J. A. Frelinger, and N. L. Davis. 2005. 
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine 
encephalitis virus replicon particle vectors followed by a mucosal challenge with 
SIVsmE660. Vaccine 23:4969-79. 
167. Kaetzel, C. S. 2005. The polymeric immunoglobulin receptor: bridging innate and 
adaptive immune responses at mucosal surfaces. Immunological Reviews 206:83-99. 
168. Karrer, U., M. Wagner, S. Sierro, A. Oxenius, H. Hengel, T. Dumrese, S. 
Freigang, U. H. Koszinowski, R. E. Phillips, and P. Klenerman. 2004. Expansion 
of Protective CD8+ T-Cell Responses Driven by Recombinant Cytomegaloviruses. J. 
Virol. 78:2255-2264. 
169. Kato, T., Owen, R.L. 1999. Structure and Function of Intestinal Mucosal 
Epithelium, p. 115-132. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. 
Bienstock, and J. McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, 
London. 
170. Kaul, D., and P. L. Ogra. 1998. Mucosal responses to parenteral and mucosal 
vaccines. Dev Biol Stand 95:141-6. 
171. Kauppi, M., J. Eskola, and H. Kayhty. 1995. Anti-capsular polysaccharide 
antibody concentrations in saliva after immunization with Haemophilus influenzae 
type b conjugate vaccines. Pediatr.Infect.Dis.J 14:286-294. 
172. Kawabata, S., C. J. Miller, T. Lehner, K. Fujihashi, M. Kubota, J. R. McGhee, 
K. Imaoka, T. Hiroi, and H. Kiyono. 1998. Induction of Th2 cytokine expression 
for p27-specific IgA B cell responses after targeted lymph node immunization with 
simian immunodeficiency virus antigens in rhesus macaques. J Infect.Dis. 177:26-33. 
173. Kawai, T., M. Seki, K. Hiromatsu, J. W. Eastcott, G. F. M. Watts, M. Sugai, D. 
J. Smith, S. A. Porcelli, and M. A. Taubman. 1999. Selective Diapedesis of Th1 
Cells Induced by Endothelial Cell RANTES. J Immunol 163:3269-3278. 
174. Kenney, R. T., and R. Edelman. 2004. Adjuvants for the Future. In M. M. Levine, J. 
B. Kaper, R. Rappuoli, M. A. Liu, and M. F. Good (ed.), New Generation Vaccines, 
3rd ed. Marcel Dekker, New York. 
175. Kew, O. M., P. F. Wright, V. I. Agol, F. Delpeyroux, H. Shimizu, N. Nathanson, 
and M. A. Pallansch. 2004. Circulating vaccine-derived polioviruses: current state of 
knowledge. Bull World Health Organ 82:16-23. 
176. Kindler, V., A.-P. Sappino, G. E. Grau, P.-F. Piguet, and P. Vassalli. 1989. The 
inducing role of tumor necrosis factor in the development of bactericidal granulomas 
during BCG infection. Cell 56:731-740. 
 69
177. Kleinau, S., L. Dencker, and L. Klareskog. 1995. Oil-induced arthritis in da rats: 
Tissue distribution of arthritogenic 14C-labelled hexadecane. International Journal of 
Immunopharmacology 17:393-397. 
178. Klimstra, W. B., E. M. Nangle, M. S. Smith, A. D. Yurochko, and K. D. Ryman. 
2003. DC-SIGN and L-SIGN Can Act as Attachment Receptors for Alphaviruses and 
Distinguish between Mosquito Cell- and Mammalian Cell-Derived Viruses. J. Virol. 
77:12022-12032. 
179. Koff, W. C., P. R. Johnson, D. I. Watkins, D. R. Burton, J. D. Lifson, K. J. 
Hasenkrug, A. B. McDermott, A. Schultz, T. J. Zamb, R. Boyle, and R. C. 
Desrosiers. 2006. HIV vaccine design: insights from live attenuated SIV vaccines. 
Nat Immunol 7:19-23. 
180. Konradsen, H. B., and J. Henrichsen. 1991. The need for revaccination 10 years 
after primary pneumococcal vaccination in splenectomized adults. Scand J Infect Dis 
23:397. 
181. Kraehenbuhl, J. P., and M. R. Neutra. 1992. Molecular and cellular basis of 
immune protection of mucosal surfaces. Physiol. Rev. 72:853-879. 
182. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu 
Rev Immunol 20:709-60. 
183. Krieg, A. M., and H. L. Davis. 2001. Enhancing vaccines with immune stimulatory 
CpG DNA. Curr Opin Mol Ther 3:15-24. 
184. Kubes, V., and F. Rios. 1939. The causitive agent of infectious equine 
encephalomyelitis in Venezuela. Science 90:20-21. 
185. Kuklin, N. A., L. Rott, N. Feng, M. E. Conner, N. Wagner, W. Muller, and H. B. 
Greenberg. 2001. Protective Intestinal Anti-Rotavirus B Cell Immunity Is Dependent 
on {{alpha}}4{{beta}}7 Integrin Expression But Does Not Require IgA Antibody 
Production. J Immunol 166:1894-1902. 
186. Kunkel, E. J., and E. C. Butcher. 2002. Chemokines and the Tissue-Specific 
Migration of Lymphocytes. Immunity 16:1-4. 
187. Kunkel, E. J., and E. C. Butcher. 2003. PLASMA-CELL HOMING. Nature 
Reviews Immunology 3:822-829. 
188. Kunkel, E. J., C. H. Kim, N. H. Lazarus, M. A. Vierra, D. Soler, E. P. Bowman, 
and E. C. Butcher. 2003. CCR10 expression is a common feature of circulating and 
mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111:1001-1010. 
189. Kutzler, M. A., and D. B. Weiner. 2004. Developing DNA vaccines that call to 
dendritic cells. J. Clin. Invest. 114:1241-1244. 
 70
190. Kuwata, T., T. Miura, and M. Hayami. 2001. Using SHIVs to develop an anti-
HIV-1 live-attenuated vaccine. Trends Microbiol 9:475-80. 
191. Lai, C. M., Y. K. Lai, and P. E. Rakoczy. 2002. Adenovirus and adeno-associated 
virus vectors. DNA Cell Biol 21:895-913. 
192. Lavelle, E. C. 2005. Generation of improved mucosal vaccines by induction of innate 
immunity. Cell Mol Life Sci 62:2750-70. 
193. Lavelle, E. C., A. Jarnicki, E. McNeela, M. E. Armstrong, S. C. Higgins, O. 
Leavy, and K. H. G. Mills. 2004. Effects of cholera toxin on innate and adaptive 
immunity and its application as an immunomodulatory agent. J Leukoc Biol 75:756-
763. 
194. Lazarus, N. H., E. J. Kunkel, B. Johnston, E. Wilson, K. R. Youngman, and E. 
C. Butcher. 2003. A Common Mucosal Chemokine (Mucosae-Associated Epithelial 
Chemokine/CCL28) Selectively Attracts IgA Plasmablasts. J Immunol 170:3799-
3805. 
195. Lebman, D. A., and R. L. Coffman. 1988. The effects of IL-4 and IL-5 on the IgA 
response by murine Peyer's patch B cell subpopulations. J Immunol 141:2050-2056. 
196. Leclerc, C. 2003. New approaches in vaccine development. Comparative 
Immunology, Microbiology and Infectious Diseases 26:329-341. 
197. Lee, J. S., B. K. Dyas, S. S. Nystrom, C. M. Lind, J. F. Smith, and R. G. Ulrich. 
2002. Immune protection against staphylococcal enterotoxin-induced toxic shock by 
vaccination with a Venezuelan equine encephalitis virus replicon. J Infect.Dis. 
185:1192-1196. 
198. Lee, J. S., A. G. Hadjipanayis, and M. D. Parker. 2005. Viral vectors for use in the 
development of biodefense vaccines. Advanced Drug Delivery Reviews 57:1293-
1314. 
199. Lee, J. S., P. Pushko, M. D. Parker, M. T. Dertzbaugh, L. A. Smith, and J. F. 
Smith. 2001. Candidate Vaccine against Botulinum Neurotoxin Serotype A Derived 
from a Venezuelan Equine Encephalitis Virus Vector System. Infection and 
Immunity 69:5709-5715. 
200. Lee, L. H., C. E. Frasch, L. A. Falk, D. L. Klein, and C. D. Deal. 2003. Correlates 
of immunity for pneumococcal conjugate vaccines. Vaccine 21:2190-2196. 
201. Lehner, T., L. A. Bergmeier, L. Tao, C. Panagiotidi, L. S. Klavinskis, L. Hussain, 
R. G. Ward, N. Meyers, S. E. Adams, and A. J. Gearing. 1994. Targeted lymph 
node immunization with simian immunodeficiency virus p27 antigen to elicit genital, 
rectal, and urinary immune responses in nonhuman primates. J Immunol 153:1858-
1868. 
 71
202. Lemaitre, B., E. Nicolas, L. Michaut, J.-M. Reichhart, and J. A. Hoffmann. 1996. 
The Dorsoventral Regulatory Gene Cassette spatzle/Toll/cactus Controls the Potent 
Antifungal Response in Drosophila Adults. Cell 86:973-983. 
203. Letvin, N. L. 2006. Progress and obstacles in the development of an AIDS vaccine. 
Nat Rev Immunol 6:930-939. 
204. Levine, M. M., and J. D. Campbell. 2004. Mucosal Immunization and Needle-Free 
Injection Devices, p. 393-399. In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, 
and M. F. Good (ed.), New Generation Vaccines, 3rd ed. Marcel Dekker, New York. 
205. Levine, M. M., and G. Dougan. 1998. Optimism over vaccines administered via 
mucosal surfaces. Lancet 351:1375-6. 
206. Levine, M. M., C. Ferreccio, S. Cryz, and E. Ortiz. 1990. Comparison of enteric-
coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised 
controlled field trial. Lancet 336:891-4. 
207. Levine, M. M., and R. Lagos. 2004. Vaccines and Vaccination in Historical 
Perspective, p. 1-10. In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, and M. F. 
Good (ed.), New Generation Vaccines, 3rd ed. Marcel Dekker, New York. 
208. Lilic, D. 2002. New perspectives on the immunology of chronic mucocutaneous 
candidiasis. Curr Opin Infect Dis 15:143-7. 
209. Lind, P. E. 1968. Cellular localization of 125I-labelled Salmonella adelaide flagellin 
following injection into the rat in the presence of Freund's complete adjuvant. Aust J 
Exp Biol Med Sci 46:189-208. 
210. Lindblad, E. B., M. J. Elhay, R. Silva, R. Appelberg, and P. Andersen. 1997. 
Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. 
Immun. 65:623-629. 
211. Liu, T., K. M. Khanna, X. Chen, D. J. Fink, and R. L. Hendricks. 2000. CD8+ T 
Cells Can Block Herpes Simplex Virus Type 1 (HSV-1) Reactivation from Latency in 
Sensory Neurons. J. Exp. Med. 191:1459-1466. 
212. LoBue, A. D., L. Lindesmith, B. Yount, P. R. Harrington, J. M. Thompson, R. E. 
Johnston, C. L. Moe, and R. S. Baric. 2006. Multivalent norovirus vaccines induce 
strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 
24:5220-5234. 
213. Ludwig, G. V., J. P. Kondig, and J. F. Smith. 1996. A putative receptor for 
Venezuelan equine encephalitis virus from mosquito cells. J. Virol. 70:5592-5599. 
214. Lundstrom, K. 2002. Alphavirus-based vaccines. Curr Opin Mol Ther 4:28-34. 
 72
215. Lundstrom, K. 2003. Alphavirus vectors for vaccine production and gene therapy. 
Expert Rev Vaccines 2:447-59. 
216. Lycke, N. 2005. Targeted vaccine adjuvants based on modified cholera toxin. Curr 
Mol Med 5:591-7. 
217. Lycke, N., L. Erlandsson, L. Ekman, K. Schon, and T. Leanderson. 1999. Lack of 
J Chain Inhibits the Transport of Gut IgA and Abrogates the Development of 
Intestinal Antitoxic Protection. J Immunol 163:913-919. 
218. MacDonald, G. H., and R. E. Johnston. 2000. Role of Dendritic Cell Targeting in 
Venezuelan Equine Encephalitis Virus Pathogenesis. The Journal of Virology 
74:914-922. 
219. Marine, W. M., T. D. Y. Chin, and C. R. Gravelle. 1962. LIMITATION OF 
FECAL AND PHAEYNGEAL POLIOVIEUS EXCRETION IN SALK-
VACCINATED CHILDREN: A FAMILY STUDY DURING A TYPE 1 
POLIOMYELITIS EPIDEMIC. Am. J. Epidemiol. 76:173-195. 
220. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. 
K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, Y. Lu, M. L. Robb, H. 
Katinger, and D. L. Birx. 1999. Protection of Macaques against pathogenic 
simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing 
antibodies. J Virol 73:4009-18. 
221. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. 
Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. 
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV 
chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-10. 
222. Mason, R. A., N. M. Tauraso, R. O. Spertzel, and R. K. Ginn. 1973. Yellow fever 
vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl 
Microbiol 25:539-44. 
223. Matson, D. O., M. L. O'Ryan, I. Herrera, L. K. Pickering, and M. K. Estes. 1993. 
Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J 
Infect Dis 167:577-83. 
224. Matsumoto, R., M. Matsumoto, S. Mita, Y. Hitoshi, M. Ando, S. Araki, N. 
Yamaguchi, A. Tominaga, and K. Takatsu. 1989. Interleukin-5 induces maturation 
but not class switching of surface IgA-positive B cells into IgA-secreting cells. 
Immunology 66:32-8. 
225. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular 
neutralization of influenza virus by immunoglobulin A anti-hemagglutinin 
monoclonal antibodies. J. Virol. 69:1339-1343. 
 73
226. Mbawuike, I. N., P. A. Piedra, T. R. Cate, and R. B. Couch. 1996. Cytotoxic T 
lymphocyte responses of infants after natural infection or immunization with live 
cold-recombinant or inactivated influenza A virus vaccine. J Med Virol 50:105-11. 
227. McComb, J. A. 1964. The Prophylactic Dose of Homologous Tetanus Antitoxin. N 
Engl J Med 270:175-8. 
228. McComb, J. A., and R. C. Dwyer. 1963. Passive-active immunization with tetanus 
immune globulin (human). N Engl J Med 268:857-862. 
229. McDermott, M. R., and J. Bienenstock. 1979. Evidence for a common mucosal 
immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and 
genital tissues. J Immunol 122:1892-8. 
230. McGhee, J. R., Czerkinsky, C., Mestecky, J. 1999. Mucosal Vaccines:  An 
Overview, p. 741-758. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. 
Bienenstock, and J. McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, 
London. 
231. McGhee, J. R., M. E. Lamm, and W. Strober. 1999. Mucosal Immune Responses: 
An Overview, p. 485-506. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. 
Bienstock, and J. McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, 
London. 
232. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and 
H. Kiyono. 1992. The mucosal immune system: from fundamental concepts to 
vaccine development. Vaccine 10:75-88. 
233. McGhee, J. R., J. Mestecky, C. O. Elson, and H. Kiyono. 1989. Regulation of IgA 
synthesis and immune response by T cells and interleukins. J Clin Immunol 9:175-99. 
234. McKenzie, B. S., J. L. Brady, and A. M. Lew. 2004. Mucosal immunity: 
overcoming the barrier for induction of proximal responses. Immunol Res 30:35-71. 
235. McKenzie, B. S., A. J. Corbett, S. Johnson, J. L. Brady, J. Pleasance, D. R. 
Kramer, J. S. Boyle, D. C. Jackson, R. A. Strugnell, and A. M. Lew. 2004. 
Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits 
local IgA responses. International Immunology 16:1613-1622. 
236. Mestecky, J. 1987. The common mucosal immune system and current strategies for 
induction of immune responses in external secretions. J Clin Immunol 7:265-76. 
237. Mestecky, J., C. Lue, and M. W. Russell. 1991. Selective transport of IgA. Cellular 
and molecular aspects. Gastroenterol Clin North Am 20:441-71. 
238. Mestecky, J., and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular and 
cellular interactions involved in IgA biosynthesis and immune response. Adv 
Immunol 40:153-245. 
 74
239. Mestecky, J., Moro, I., Underdown, B.J. 1999. Mucosal Immunoglobulins, p. 133-
152. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. 
McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, London. 
240. Mestecky, J., R. E. Schrohenloher, R. Kulhavy, G. P. Wright, and M. Tomana. 
1974. Site of J chain attachment to human polymeric IgA. Proc Natl Acad Sci U S A 
71:544-8. 
241. Miller, C. J., and F. X. Lu. 2003. Anti-HIV and -SIV immunity in the vagina. Int 
Rev Immunol 22:65-76. 
242. Miller, E. 1999. Overview of Recent Clinical Trials of Acellular Pertussis Vaccines. 
Biologicals 27:79-86. 
243. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T Lymphocytes Are 
Required for Protection of the Vaginal Mucosae and Sensory Ganglia of Immune 
Mice Against Reinfection with Herpes Simplex Virus Type 2. J Immunol 160:6093-
6100. 
244. Mlckova, P., D. Cechova, P. Chalupna, O. Novotna, and L. Prokesova. 2001. 
Enhanced systemic and mucosal antibody responses to a model protein antigen after 
intranasal and intratracheal immunisation using Bacillus firmus as an adjuvant. 
Immunology Letters 77:39-45. 
245. Mohle-Boetani, J. C., G. Ajello, E. Breneman, K. A. Deaver, C. Harvey, B. D. 
Plikaytis, M. M. Farley, D. S. Stephens, and J. D. Wenger. 1993. Carriage of 
Haemophilus influenzae type b in children after widespread vaccination with 
conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 12:589-93. 
246. Monath, T. P., C. H. Calisher, M. Davis, G. S. Bowen, and J. White. 1974. 
Experimental studies of rhesus monkeys infected with epizootic and enzootic 
subtypes of Venezuelan equine encephalitis virus. J Infect Dis 129:194-200. 
247. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 Cells: Different Patterns 
of Lymphokine Secretion Lead to Different Functional Properties. Annual Review of 
Immunology 7:145-173. 
248. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. 
Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, 
and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus 
SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a 
gp120 subunit vaccine. J. Virol. 70:1953-1960. 
249. Mostov, K. E. 1994. Transepithelial Transport of Immunoglobulins. Annual Review 
of Immunology 12:63-84. 
250. Mostove K., and K. C. S. 1999. Immunoglobulin Transport and the Polymerid 
Immunoglobulin Receptor, p. 181-212. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. 
 75
Strober, J. Bienstock, and J. McGhee (ed.), Mucosal Immunology, 2nd ed. Academic 
Press, London. 
251. Mowat, A. M. 2003. ANATOMICAL BASIS OF TOLERANCE AND IMMUNITY 
TO INTESTINAL ANTIGENS. Nature Reviews Immunology 3:331-341. 
252. Moyle, P. M., R. P. McGeary, J. T. Blanchfield, and I. Toth. 2004. Mucosal 
immunisation: adjuvants and delivery systems. Curr Drug Deliv 1:385-96. 
253. Murdin, A. D., L. Barreto, and S. A. Plotkin. 1996. Inactivated poliovirus vaccine:  
past and present experience. Vaccine 14:735-746. 
254. Murphy, T. V., P. M. Gargiullo, M. S. Massoudi, D. B. Nelson, A. O. Jumaan, C. 
A. Okoro, L. R. Zanardi, S. Setia, E. Fair, C. W. LeBaron, M. Wharton, J. R. 
Livingood, and T. The Rotavirus Intussusception Investigation. 2001. 
Intussusception among Infants Given an Oral Rotavirus Vaccine. N Engl J Med 
344:564-572. 
255. Murphy, T. V., P. M. Gargiullo, and M. Wharton. 2002. More on rotavirus 
vaccination and intussusception. N Engl J Med 346:211-2. 
256. Musey, L., Y. Ding, M. Elizaga, R. Ha, C. Celum, and M. J. McElrath. 2003. 
HIV-1 Vaccination Administered Intramuscularly Can Induce Both Systemic and 
Mucosal T Cell Immunity in HIV-1-Uninfected Individuals. The Journal of 
Immunology 171:1094-1101. 
257. Nagler-Anderson, C. 2000. Tolerance and immunity in the intestinal immune 
system. Crit Rev Immunol 20:103-20. 
258. Neutra, M. R., A. Frey, and J.-P. Kraehenbuhl. 1996. Epithelial M Cells: 
Gateways for Mucosal Infection and Immunization. Cell 86:345-348. 
259. Neutra, M. R., E. Pringault, and J.-P. Kraehenbuhl. 1996. ANTIGEN 
SAMPLING ACROSS EPITHELIAL BARRIERS AND INDUCTION OF 
MUCOSAL IMMUNE RESPONSES. Annual Review of Immunology 14:275-300. 
260. Nichol, K. L. 2001. Live attenuated influenza virus vaccines: new options for the 
prevention of influenza. Vaccine 19:4373-4377. 
261. Nicol, T., D. C. Quantock, and B. Vernon-Roberts. 1966. Stimulation of 
phagocytosis in relation to the mechanism of action of adjuvants. Nature 209:1142-3. 
262. Norderhaug IN, J. F., Schjerven H, Brandtzaeg P. . Regulation of the formation 
and external transport of secretory immunoglobulins. Crit Rev Immunol. 1999;19(5-
6):481-508. 
263. Notkins, A. L., S. E. Mergenhagen, A. A. Rizzo, C. Scheele, and T. A. 
Waldmann. 1966. ELEVATED gamma-GLOBULIN AND INCREASED 
 76
ANTIBODY PRODUCTION IN MICE INFECTED WITH LACTIC 
DEHYDROGENASE VIRUS. J. Exp. Med. 123:347-364. 
264. O'Hagan, D. T., and R. Rappuoli. 2004. Novel approaches to vaccine delivery. 
Pharm Res 21:1519-30. 
265. O'Ryan, M. L., D. O. Matson, M. K. Estes, and L. K. Pickering. 1994. Anti-
rotavirus G type-specific and isotype-specific antibodies in children with natural 
rotavirus infections. J Infect Dis 169:504-11. 
266. Oda, K., and H. Kitano. 2006. A comprehensive map of the toll-like receptor 
signaling network. Mol Syst Biol 2:2006 0015. 
267. Offit, P. A., S. L. Cunningham, and K. I. Dudzik. 1991. Memory and distribution 
of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus 
infection. J. Virol. 65:1318-1324. 
268. Offit, P. A., and K. I. Dudzik. 1989. Rotavirus-specific cytotoxic T lymphocytes 
appear at the intestinal mucosal surface after rotavirus infection. J. Virol. 63:3507-
3512. 
269. Offit, P. A., and Y. M. Svoboda. 1989. Rotavirus-specific cytotoxic T lymphocyte 
response of mice after oral inoculation with candidate rotavirus vaccine strains RRV 
or WC3. J Infect Dis 160:783-8. 
270. Ogra, P. L., and D. T. Karzon. 1969. Distribution of poliovirus antibody in serum, 
nasopharynx and alimentary tract following segmental immunization of lower 
alimentary tract with poliovaccine. J Immunol 102:1423-30. 
271. Ogra, P. L., D. Kerr-Grant, G. Umana, J. Dzierba, and D. Weintraub. 1971. 
Antibody response in serum and nasopharynx after naturally acquired and vaccine-
induced infection with rubella virus. N.Engl.J Med. 285:1333-1339. 
272. Organization. 2003 The World Health Report 2003, World Health Organization, 
Geneve. 
273. Organization, W. H. The Global Polio Eradication Initiative, World Health 
Organization, CDC, Unicer.  www.polioeradication.org/.  2-15-2005. 
274. Orme, I. M. 1993. The role of CD8+ T cells in immunity to tuberculosis infection. 
Trends Microbiol 1:77-8. 
275. Orme, I. M. 2005. Tuberculosis vaccines: current progress. Drugs 65:2437-44. 
276. Owen, R. L., and T. H. Ermak. 1990. Structural specializations for antigen uptake 
and processing in the digestive tract. Springer Semin Immunopathol 12:139-52. 
 77
277. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 
infection: what we know, what we don't know, what we should know. Nat Med 
10:806-10. 
278. Paredes, A. M., D. Ferreira, M. Horton, A. Saad, H. Tsuruta, R. Johnston, W. 
Klimstra, K. Ryman, R. Hernandez, W. Chiu, and D. T. Brown. 2004. 
Conformational changes in Sindbis virions resulting from exposure to low pH and 
interactions with cells suggest that cell penetration may occur at the cell surface in the 
absence of membrane fusion. Virology 324:373-386. 
279. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune 
response with improved vaccine adjuvants. Nat Med 11:S63-8. 
280. Pasteur, L. 1880. De l'attenuation du virus du cholera des poules. C. R. Acad. Sci. 
Paris 91:673-680. 
281. Pasteur, L., and C.-E. Chamberland. 1881. Sur la vaccination charbonneuse. C. R. 
Acad. Sci. Paris 92:1378-1383. 
282. Perkus, M. E., A. Piccini, B. R. Lipinskas, and E. Paoletti. 1985. Recombinant 
vaccinia virus: immunization against multiple pathogens. Science 229:981-4. 
283. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. 
Tang, Q. Bin, T. W. Dubensky, Jr., M. Vajdy, G. R. Otten, and J. M. Polo. 2003. 
An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine 
Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector. 
The Journal of Virology 77:10394-10403. 
284. Peter, G., and M. G. Myers. 2002. Intussusception, Rotavirus, and Oral Vaccines: 
Summary of a Workshop. Pediatrics 110:e67-. 
285. Peters, C., X. Peng, D. Douven, Z. K. Pan, and Y. Paterson. 2003. The Induction 
of HIV Gag-Specific CD8+ T Cells in the Spleen and Gut-Associated Lymphoid 
Tissue by Parenteral or Mucosal Immunization with Recombinant Listeria 
monocytogenes HIV Gag. The Journal of Immunology 170:5176-5187. 
286. Phillpotts, R. J. 1999. Immunity to airborne challenge with Venezuelan equine 
encephalitis virus develops rapidly after immunisation with the attenuated vaccine 
strain TC-83. Vaccine 17:2429-2435. 
287. Phumiamorn, S., H. Sato, T. Kamiyama, M. Kurokawa, and K. Shiraki. 2003. 
Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a 
novel adjuvant activity of Oka varicella vaccine. Journal of General Virology 84:287-
291. 
288. Plotkin, S. A. 2001. Immunologic correlates of protection induced by vaccination. 
Pediatr Infect Dis J 20:63-75. 
 78
289. Plotkin, S. A. 2000. Rabies. Clin Infect Dis 30:4-12. 
290. Plotkin, S. A. 2002. Vaccines in the 21st century. Hybrid Hybridomics 21:135-45. 
291. Plotkin, S. A. 2005. Vaccines: past, present and future. Nat Med 11:S5-11. 
292. Plotkin, S. A., and N. Bouveret-Le Cam. 1995. A new typhoid vaccine composed of 
the Vi capsular polysaccharide. Arch Intern Med 155:2293-9. 
293. Plotkin, S. A., and M. Cadoz. 1997. The acellular pertussis vaccine trials: an 
interpretation. Pediatr Infect Dis J 16:508-17; discussion 517-9. 
294. Plotkin, S. L., and S. A. Plotkin. 2004. A short history of vaccination, p. 1-15. In S. 
A. Plotkin and W. A. Orenstein (ed.), Vaccines, 4th ed. W.B. Saunders, Philadelphia. 
295. Plotkina, S. A. 1999. Vaccination against the major infectious diseases. Comptes 
Rendus de l'Academie des Sciences - Series III - Sciences de la Vie 322:943-951. 
296. Pollock, K. G. J., M. Conacher, X.-Q. Wei, J. Alexander, and J. M. Brewer. 
2003. Interleukin-18 plays a role in both the alum-induced T helper 2 response and 
the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 
108:137-143. 
297. Polo, J. M., J. P. Gardner, Y. Ji, B. A. Belli, D. A. Driver, S. Sherrill, S. Perri, M. 
A. Liu, and T. W. Dubensky, Jr. 2000. Alphavirus DNA and particle replicons for 
vaccines and gene therapy. Dev Biol (Basel) 104:181-5. 
298. Poltorak, A., X. He, I. Smirnova, M.-Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. 
Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. 
Layton, and B. Beutler. 1998. Defective LPS Signaling in C3H/HeJ and 
C57BL/10ScCr Mice: Mutations in Tlr4 Gene. Science 282:2085-2088. 
299. Pratt, W. D., N. L. Davis, R. E. Johnston, and J. F. Smith. 2003. Genetically 
engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in 
animal models. Vaccine 21:3854-3862. 
300. Pruitt, K. M., B. Rahemtulla, F. FRahemtulla, and M. W. Russell. 1999. Innate 
Humoral Factors. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. 
Bienenstock, and J. McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, 
London. 
301. Pulendran, B., and R. Ahmed. 2006. Translating Innate Immunity into 
Immunological Memory: Implications for Vaccine Development. Cell 124:849-863. 
302. Pushko, P., M. Bray, G. V. Ludwig, M. Parker, A. Schmaljohn, A. Sanchez, P. B. 
Jahrling, and J. F. Smith. 2000. Recombinant RNA replicons derived from 
attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from 
Ebola hemorrhagic fever virus. Vaccine 19:142-153. 
 79
303. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. 
Smith. 1997. Replicon-Helper Systems from Attenuated Venezuelan Equine 
Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization 
against Heterologous Pathogens in Vivo. Virology 239:389-401. 
304. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, 
R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates 
multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent 
immunity. J. Exp. Med. 203:413-424. 
305. Quiroga, J. A., S. Llorente, I. Castillo, E. Rodriguez-Inigo, M. Pardo, and V. 
Carreno. 2006. Cellular Immune Responses Associated with Occult Hepatitis C 
Virus Infection of the Liver. J. Virol. 80:10972-10979. 
306. Ramon, G. 1924. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur 
38:1-7. 
307. Rayner, J. O., S. A. Dryga, and K. I. Kamrud. 2002. Alphavirus vectors and 
vaccination. Rev Med Virol 12:279-96. 
308. Reed, D. S., C. M. Lind, M. G. Lackemeyer, L. J. Sullivan, W. D. Pratt, and M. 
D. Parker. 2005. Genetically engineered, live, attenuated vaccines protect nonhuman 
primates against aerosol challenge with a virulent IE strain of Venezuelan equine 
encephalitis virus. Vaccine 23:3139-3147. 
309. Reed, D. S., C. M. Lind, L. J. Sullivan, W. D. Pratt, and M. D. Parker. 2004. 
Aerosol infection of cynomolgus macaques with enzootic strains of venezuelan 
equine encephalitis viruses. J Infect Dis 189:1013-7. 
310. Renegar, K. B., and P. A. Small, Jr. 1991. Immunoglobulin A mediation of murine 
nasal anti-influenza virus immunity. J. Virol. 65:2146-2148. 
311. Rhian Phillips, A. A. 2002. Activation of pertussis toxin-sensitive CXCL12 (SDF-1) 
receptors mediates transendothelial migration of T lymphocytes across lymph node 
high endothelial cells. European Journal of Immunology 32:837-847. 
312. Riezebos-Brilman, A., A. d. Mare, L. Bungener, A. Huckriede, J. Wilschut, and 
T. Daemen. 2006. Recombinant alphaviruses as vectors for anti-tumour and anti-
microbial immunotherapy. Journal of Clinical Virology 35:233-243. 
313. Robinson, H. L., L. A. Hunt, and R. G. Webster. 1993. Protection against a lethal 
influenza virus challenge by immunization with a haemagglutinin-expressing plasmid 
DNA. Vaccine 11:957-60. 
314. Rodrigues, E. G., F. Zavala, D. Eichinger, J. M. Wilson, and M. Tsuji. 1997. 
Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-
mediated protective immunity against malaria. J Immunol 158:1268-1274. 
 80
315. Rothman, A. L., Y. Yamada, J. Jameson, and e. al. 1998. Assessment of human 
CD4+ and CD8+ T lymphocyte responses in experimental viral vaccine studies, p. 95-
104. In S. A. Plotkin, F. Brown, and F. Horaud (ed.), Preclinical and clinical 
development of new vaccines, Basel:  Karger. 
316. Rudzik, R., R. L. Clancy, D. Y. Perey, R. P. Day, and J. Bienenstock. 1975. 
Repopulation with IgA-containing cells of bronchial and intestinal lamina propria 
after transfer of homologous Peyer's patch and bronchial lymphocytes. J Immunol 
114:1599-604. 
317. Ruprecht, R. M. 1999. Live attenuated AIDS viruses as vaccines: promise or peril? 
Immunol Rev 170:135-49. 
318. Russell, M. W., T. A. Brown, J. L. Claflin, K. Schroer, and J. Mestecky. 1983. 
Immunoglobulin A-mediated hepatobiliary transport constitutes a natural pathway for 
disposing of bacterial antigens. Infect. Immun. 42:1041-1048. 
319. Russell, M. W., M. Kilian, and M. M. Lamm. 1999. Biological Activities of IgA, p. 
225-240. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. 
McGhee (ed.), Mucosal Immunology, 2nd ed. Academic Press, London. 
320. Sanderson, I. R., and W. A. Walker. 1999. Mucosal Barrier:  An Overview, p. 5-18. 
In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienstock, and J. McGhee 
(ed.), Mucosal Immunology, 2nd ed. Academic Press, London. 
321. Sanmartin-Barberi, C., H. Groot, and E. Osorno-Mesa. 1954. Human epidemic in 
Colombia caused by the Venezuelan equine encephalomyelitis virus. Am J Trop Med 
Hyg 3:283-93. 
322. Sato, A., and A. Iwasaki. 2005. Intestinal epithelial barrier and mucosal immunity. 
Cellular and Molecular Life Sciences (CMLS) V62:1333-1338. 
323. Schindler, C., A. Fooks, J. Stephenson, and U. G. Liebert. 1994. Replication-
incompetent adenoviruses as vectors for protective immunization against measles 
virus infection. Behring Inst Mitt:109-15. 
324. Schlesinger, S. 2000. Alphavirus expression vectors. Adv Virus Res 55:565-77. 
325. Schlesinger, S., and T. W. Dubensky. 1999. Alphavirus vectors for gene expression 
and vaccines. Current Opinion in Biotechnology 10:434-439. 
326. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. 
Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. 
A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 
1999. Control of viremia in simian immunodeficiency virus infection by CD8+ 
lymphocytes. Science 283:857-60. 
 81
327. Schmitz, J. E., M. J. Kuroda, S. Santra, M. A. Simon, M. A. Lifton, W. Lin, R. 
Khunkhun, M. Piatak, J. D. Lifson, G. Grosschupff, R. S. Gelman, P. Racz, K. 
Tenner-Racz, K. A. Mansfield, N. L. Letvin, D. C. Montefiori, and K. A. 
Reimann. 2003. Effect of humoral immune responses on controlling viremia during 
primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 
77:2165-73. 
328. Schnare, M., G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 
2001. Toll-like receptors control activation of adaptive immune responses. Nat 
Immunol 2:947-50. 
329. Schultz-Cherry, S., J. K. Dybing, N. L. Davis, C. Williamson, D. L. Suarez, R. 
Johnston, and M. L. Perdue. 2000. Influenza Virus (A/HK/156/97) Hemagglutinin 
Expressed by an Alphavirus Replicon System Protects Chickens against Lethal 
Infection with Hong Kong-Origin H5N1 Viruses. Virology 278:55-59. 
330. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. 
Peptidoglycan- and Lipoteichoic Acid-induced Cell Activation Is Mediated by Toll-
like Receptor 2. J. Biol. Chem. 274:17406-17409. 
331. Selby, W. S., G. Janossy, M. Bofill, and D. P. Jewell. 1983. Lymphocyte 
subpopulations in the human small intestine. The findings in normal mucosa and in 
the mucosa of patients with adult coeliac disease. Clin Exp Immunol 52:219-28. 
332. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. 
Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. 
S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, 
L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. 
Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, 
P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. 
Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. 
R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. 
Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-
incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus 
immunity. Nature 415:331-5. 
333. Siegrist, C.-A. 1997. Potential advantages and risks of nucleic acid vaccines for 
infant immunization. Vaccine 15:798-800. 
334. Siegrist, C. A., and P. H. Lambert. 1998. Maternal immunity and infant responses 
to immunization: factors influencing infant responses. Dev Biol Stand 95:133-9. 
335. Singh, M., and D. T. O'Hagan. 2002. Recent advances in vaccine adjuvants. Pharm 
Res 19:715-28. 
336. Sonoda, E., R. Matsumoto, Y. Hitoshi, T. Ishii, M. Sugimoto, S. Araki, A. 
Tominaga, N. Yamaguchi, and K. Takatsu. 1989. Transforming growth factor beta 
 82
induces IgA production and acts additively with interleukin 5 for IgA production. J. 
Exp. Med. 170:1415-1420. 
337. Souza, A. P., L. Haut, A. Reyes-Sandoval, and A. R. Pinto. 2005. Recombinant 
viruses as vaccines against viral diseases. Braz J Med Biol Res 38:509-22. 
338. Stapleton, J. T. 1992. Passive immunization against hepatitis A. Vaccine 10 Suppl 
1:S45-7. 
339. Stern, B. I. 1927. Should we be vaccinated?  A Survey of the Controversey in its 
Historical and Scientific Aspects.  New York:  Harper, 1-576. 
340. Stills, H. F., Jr. 2005. Adjuvants and antibody production: dispelling the myths 
associated with Freund's complete and other adjuvants. Ilar J 46:280-93. 
341. Stittelaar, K. J., L. S. Wyatt, R. L. de Swart, H. W. Vos, J. Groen, G. van 
Amerongen, R. S. van Binnendijk, S. Rozenblatt, B. Moss, and A. D. M. E. 
Osterhaus. 2000. Protective Immunity in Macaques Vaccinated with a Modified 
Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively 
Acquired Antibodies. J. Virol. 74:4236-4243. 
342. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, 
replication, and evolution. Microbiol.Rev. 58:491-562. 
343. Streatfield, S. J. 2006. Mucosal immunization using recombinant plant-based oral 
vaccines. Methods 38:150-157. 
344. Streatfield, S. J., and J. A. Howard. 2003. Plant production systems for vaccines. 
Expert Rev Vaccines 2:763-75. 
345. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. 
Development of a preventive vaccine for Ebola virus infection in primates. Nature 
408:605-9. 
346. Sutter, G., and B. Moss. 1992. Nonreplicating Vaccinia Vector Efficiently Expresses 
Recombinant Genes. PNAS 89:10847-10851. 
347. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A 
recombinant vector derived from the host range-restricted and highly attenuated 
MVA strain of vaccinia virus stimulates protective immunity in mice to influenza 
virus. Vaccine 12:1032-40. 
348. Sutter, R. W., S. L. Cochi, and J. L. Melnick. 1999. Live attenuated poliovirus 
vaccine, p. 364-408. In S. A. Plotkin and W. A. Orenstein (ed.), Vaccines. Saunders, 
Philadelphia. 
 83
349. Sztein, M. B. 2004. Recent Advances in Immunology that impact Vaccine 
Development, p. 159-178. In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, and 
M. F. Good (ed.), New Generation Vaccines, 3rd ed. Marcel Dekker, New York. 
350. Taguchi, T., J. R. McGhee, R. L. Coffman, K. W. Beagley, J. H. Eldridge, K. 
Takatsu, and H. Kiyono. 1990. Analysis of Th1 and Th2 cells in murine gut-
associated tissues. Frequencies of CD4+ and CD8+ T cells that secrete IFN-gamma 
and IL-5. J Immunol 145:68-77. 
351. Takahashi, H. 2003. Antigen presentation in vaccine development. Comparative 
Immunology, Microbiology and Infectious Diseases 26:309-328. 
352. Takeda, K., and S. Akira. 2004. TLR signaling pathways. Seminars in Immunology 
16:3-9. 
353. Takeshita, F., C. A. Leifer, I. Gursel, K. J. Ishii, S. Takeshita, M. Gursel, and D. 
M. Klinman. 2001. Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-
Induced Activation of Human Cells. J Immunol 167:3555-3558. 
354. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, 
S. W. Davis, J. van der Hoeven, B. Meignier, M. Riviere, and et al. 1992. 
NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-32. 
355. Taylor, J., J. Tartaglia, M. Riviere, C. Duret, B. Languet, G. Chappuis, and E. 
Paoletti. 1994. Applications of canarypox (ALVAC) vectors in human and veterinary 
vaccination. Dev Biol Stand 82:131-5. 
356. Taylor, J., R. Weinberg, B. Languet, P. Desmettre, and E. Paoletti. 1988. 
Recombinant fowlpox virus inducing protective immunity in non-avian species. 
Vaccine 6:497-503. 
357. Theiler, M., and H. H. Smith. 1937. The use of yellow fever virus by in vitro 
cultivation for human immunization. J. Exp. Med. 65:787-800. 
358. Thompson, J. M., A. C. Whitmore, J. L. Konopka, M. L. Collier, E. M. B. 
Richmond, N. L. Davis, H. F. Staats, and R. E. Johnston. 2006. Mucosal and 
systemic adjuvant activity of alphavirus replicon particles. PNAS 103:3722-3727. 
359. Thompson, M. J. 2002. Immunizations for international travel. Prim Care 29:787-
814. 
360. Tindberg, Y., M. Blennow, and M. Granstrom. 1999. A ten year follow-up after 
immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J 
18:361-5. 
361. Tomasi, T. B., Jr., E. M. Tan, A. Solomon, and R. A. Prendergast. 1965. 
CHARACTERISTICS OF AN IMMUNE SYSTEM COMMON TO CERTAIN 
EXTERNAL SECRETIONS. J. Exp. Med. 121:101-124. 
 84
362. Ulanova, M., A. Tarkowski, M. Hahn-Zoric, and L. A. Hanson. 2001. The 
Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory 
Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism. Infect. 
Immun. 69:1151-1159. 
363. Ulmer, J. B., R. R. Deck, C. M. DeWitt, A. Friedman, J. J. Donnelly, and M. A. 
Liu. 1994. Protective immunity by intramuscular injection of low doses of influenza 
virus DNA vaccines. Vaccine 12:1541-4. 
364. Ulmer, J. B., and G. R. Otten. 2000. Priming of CTL responses by DNA vaccines: 
direct transfection of antigen presenting cells versus cross-priming. Dev Biol (Basel) 
104:9-14. 
365. Ulmer, J. B., B. Wahren, and M. A. Liu. 2006. DNA vaccines: recent technological 
and clinical advances. Discov Med 6:109-12. 
366. Underdown, B. J., Plotkin, S.A. 1999. The Induction of Mucosal Protection by 
Parenteral Immunization, p. 719-728. In P. L. Ogra, Mestecky, J., Lamm, M.E., 
Strober, W., Bienenstock, J., McGhee, J.R. (ed.), Mucosal Immunology, 2nd. 
Academic Press, London. 
367. Underhill, D. M., A. Ozinsky, A. M. Hajjar, A. Stevens, C. B. Wilson, M. 
Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage 
phagosomes and discriminates between pathogens. Nature 401:811-5. 
368. Uwiera, R. R. E., V. Gerdts, R. A. Pontarollo, L. A. Babiuk, D. M. Middleton, 
and P. J. Griebel. 2001. Plasmid DNA Induces Increased Lymphocyte Trafficking: 
A Specific Role for CpG Motifs. Cellular Immunology 214:155-164. 
369. Vaerman, J. P., A. Langendries, and C. Vander Maelen. 1995. Homogenous IgA 
monomers, dimers, trimers and tetramers from the same IgA myeloma serum. 
Immunol Invest 24:631-41. 
370. Vajdy, M., J. Gardner, J. Neidleman, L. Cuadra, C. Greer, S. Perri, D. O'Hagan, 
and J. M. Polo. 2001. Human immunodeficiency virus type 1 Gag-specific vaginal 
immunity and protection after local immunizations with sindbis virus-based replicon 
particles. J.Infect.Dis. 184:1613-1616. 
371. Vajdy, M., M. H. Kosco-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. 
Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 
181:41-53. 
372. Venkatesan, M. M., and R. T. Ranallo. 2006. Live-attenuated Shigella vaccines. 
Expert Review of Vaccines 5:669-686. 
373. Wang, R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, 
T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, M. Sedegah, C. de 
 85
Taisne, J. A. Norman, and S. L. Hoffman. 1998. Induction of antigen-specific 
cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476-80. 
374. Wanstrup, J., and H. E. Christensen. 1965. Granulomatous Lesions in Mice 
Produced by Freund's Adjuvant; Morphogenesis and Phasic Development. Acta 
Pathol Microbiol Scand 63:340-54. 
375. Warr, G. W., and K. James. 1975. Effect of Corynebacterium parvum on the class 
and subclass of antibody produced in the response of different strains of mice to 
sheep erythrocytes. Immunology 28:431-42. 
376. Weaver, S. C., and A. D. T. Barrett. 2004. TRANSMISSION CYCLES, HOST 
RANGE, EVOLUTION AND EMERGENCE OF ARBOVIRAL DISEASE. Nature 
Reviews Microbiology 2:789-801. 
377. Weaver, S. C., C. Ferro, R. Barrera, J. Boshell, and J.-C. Navarro. 2004. 
VENEZUELAN EQUINE ENCEPHALITIS. Annual Review of Entomology 49:141-
174. 
378. Weaver, S. C., R. Salas, R. Rico-Hesse, G. V. Ludwig, M. S. Oberste, J. Boshell, 
and R. B. Tesh. 1996. Re-emergence of epidemic Venezuelan equine 
encephalomyelitis in South America. The Lancet 348:436-440. 
379. Weller, T. H. 1949. Cultivation of poliomyelitis virus in cultures of human foreskin 
and embryonic tissues. Proc. Soc. Exp. Biol. Med. 72:153-155. 
380. Weltzin, R., S. A. Hsu, E. S. Mittler, K. Georgakopoulos, and T. P. Monath. 
1994. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus 
protects against upper and lower respiratory tract infections in mice. Antimicrob. 
Agents Chemother. 38:2785-2791. 
381. Weltzin, R., V. Traina-Dorge, K. Soike, J. Y. Zhang, P. Mack, G. Soman, G. 
Drabik, and T. P. Monath. 1996. Intranasal monoclonal IgA antibody to respiratory 
syncytial virus protects rhesus monkeys against upper and lower respiratory tract 
infection. J Infect Dis 174:256-61. 
382. Werling, D., and T. W. Jungi. 2003. TOLL-like receptors linking innate and 
adaptive immune response. Veterinary Immunology and Immunopathology 91:1-12. 
383. White, L. J., J. g. Wang, N. L. Davis, and R. E. Johnston. 2001. Role of 
Alpha/Beta Interferon in Venezuelan Equine Encephalitis Virus Pathogenesis: Effect 
of an Attenuating Mutation in the 5' Untranslated Region. The Journal of Virology 
75:3706-3718. 
384. Williams, W. W., M. A. Hickson, M. A. Kane, A. P. Kendal, J. S. Spika, and A. 
R. Hinman. 1988. Immunization policies and vaccine coverage among adults. The 
risk for missed opportunities. Ann Intern Med 108:616-25. 
 86
385. Winther, B., D. J. Innes, Jr., S. E. Mills, N. Mygind, D. Zito, and F. G. Hayden. 
1987. Lymphocyte subsets in normal airway mucosa of the human nose. Arch 
Otolaryngol Head Neck Surg 113:59-62. 
386. Woodard, L. F. 1989. Adjuvant activity of water-insoluble surfactants. Lab Anim 
Sci 39:222-5. 
387. Yamamoto, M., K. Takeda, and S. Akira. 2004. TIR domain-containing adaptors 
define the specificity of TLR signaling. Molecular Immunology 40:861-868. 
388. Yasuko Asahi-Ozaki, T. Y. Y. I. Y. S. S.-i. T. T. K. T. S. 2004. Secretory IgA 
antibodies provide cross-protection against infection with different strains of 
influenza B virus. Journal of Medical Virology 74:328-335. 
389. Yewdell, J. W., and S. M. M. Haeryfar. 2005. UNDERSTANDING 
PRESENTATION OF VIRAL ANTIGENS TO CD8+ T CELLS IN VIVO: The Key 
to Rational Vaccine Design. Annual Review of Immunology 23:651-682. 
390. Yip, H. C., A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. 
Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. 1999. 
Adjuvant-Guided Type-1 and Type-2 Immunity: Infectious/Noninfectious Dichotomy 
Defines the Class of Response. J Immunol 162:3942-3949. 
391. Yu, J., F. Cassels, T. Scharton-Kersten, S. A. Hammond, A. Hartman, E. Angov, 
B. Corthesy, C. Alving, and G. Glenn. 2002. Transcutaneous Immunization Using 
Colonization Factor and Heat-Labile Enterotoxin Induces Correlates of Protective 
Immunity for Enterotoxigenic Escherichia coli. Infect. Immun. 70:1056-1068. 
392. Zangwill, K. M., R. W. Stout, G. M. Carlone, L. Pais, H. Harekeh, S. Mitchell, 
W. H. Wolfe, V. Blackwood, B. D. Plikaytis, and J. D. Wenger. 1994. Duration of 
antibody response after meningococcal polysaccharide vaccination in US Air Force 
personnel. J Infect Dis 169:847-52. 
 
 
CHAPTER TWO 
 
MUCOSAL AND SYSTEMIC ADJUVANT ACTIVITY OF ALPHAVIRUS 
REPLICON PARTICLES 
 
 
Joseph M. Thompson1, 2, Alan C. Whitmore2, Jennifer L. Konopka1, 2, Martha L. 
Collier1, 2, Erin M. B. Richmond1, Nancy L. Davis1, 2, Herman F. Staats3, 4, 
and Robert E. Johnston1, 2 
 
1Department of Microbiology and Immunology, and 2Carolina Vaccine Institute, University 
of North Carolina, Chapel Hill, NC 27599; and 3Department of Pathology, and 4Human 
Vaccine Institute, Duke University Medical Center, Durham, NC 27710 
 
 
First published in Proceedings of the National Academy of Sciences 2006 Mar 
7;103(10):3722-7. Epub 2006 Feb 27. 
 
Copyright 2006 Proceedings of the National Academy of Sciences USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88
ABSTRACT 
Vaccination represents the most effective control measure in the fight against 
infectious diseases. Local mucosal immune responses are critical for protection from, and 
resolution of, infection by numerous mucosal pathogens. Antigen processing across mucosal 
surfaces is the natural route by which mucosal immunity is generated, as peripheral antigen 
delivery typically fails to induce mucosal immune responses. However, we demonstrate in 
this article that mucosal immune responses are evident at multiple mucosal surfaces after 
parenteral delivery of Venezuelan equine encephalitis virus replicon particles (VRP). 
Moreover, coinoculation of null VRP (not expressing any transgene) with inactivated 
influenza virions, or ovalbumin, resulted in a significant increase in antigen-specific systemic 
IgG and fecal IgA antibodies, compared with antigen alone. Pretreatment of VRP with UV 
light largely abrogated this adjuvant effect. These results demonstrate that alphavirus replicon 
particles possess intrinsic systemic and mucosal adjuvant activity and suggest that VRP RNA 
replication is the trigger for this activity. We feel that these observations and the continued 
experimentation they stimulate will ultimately define the specific components of an 
alternative pathway for the induction of mucosal immunity, and if the activity is evident in 
humans, will enable new possibilities for safe and inexpensive subunit and inactivated 
vaccines. 
 
INTRODUCTION 
The control of a number of important infectious diseases by immunization is arguably 
one of the most significant accomplishments of the 20th century (2). However, other 
infectious diseases remain intractable, causing devastating morbidity and mortality in human 
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populations, especially in resource-poor countries. Control of these diseases will depend on 
an expanded array of affordable and effective vaccine technologies, such as propagative and 
nonpropagative expression vectors based on viral and bacterial genomes. One such 
technology uses replicon particles based on the alphavirus Venezuelan equine encephalitis 
virus (VEE). VEE replicon particles (VRP) are potent inducers of antigen-specific immune 
responses and/or protection after pathogen or toxin challenge in various animal species 
including mice (31, 45), rabbits (17), cats (9), chickens (47), horses (3), guinea pigs (44), and 
nonhuman primates (25). Currently, VRP expressing the gag gene from HIV clade C are in 
phase-I clinical trials in the United States and Africa.  
VEE virions contain a positive sense RNA genome of 11.5 kb. The four viral 
nonstructural proteins, which constitute the enzymatic activity required for RNA replication, 
are encoded in the 5' two-thirds of the genome, whereas the viral structural proteins (capsid, 
E1, and E2) are expressed from a 26S subgenomic mRNA and encoded in the 3' one-third of 
the genome (27, 49). VRP are propagation-defective viral particles carrying a modified VEE 
genome. The VRP system takes advantage of the high-level expression of 26S mRNA by 
replacing the viral structural genes with a cloned antigen gene (45). Progeny virions are not 
produced in VRP-infected cells, as the viral structural genes are absent from the replicon 
RNA; however, the replicon RNA and the mRNA encoding the antigen are expressed at high 
levels after infection (20, 45). To facilitate assembly of VRP, the replicon RNA is 
coelectroporated into permissive cells with two defective helper RNAs that lack the viral 
packaging signal and provide the structural genes in trans (20, 45).  
VRP display a number of attractive features as vaccine delivery vehicles, including 
high-level antigen expression in infected cells (45), efficient in vivo targeting of mouse (34), 
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and primate (A. West and R.E.J., unpublished work) dendritic cells (DCs), efficient ex vivo 
infection of human DCs (40), and safety, as the vectors are incapable of synthesizing new 
virion particles in infected cells (20, 45). One of the most intriguing properties of VRP is their 
ability to induce significant protective immunity in mucosal challenge models, even when the 
immunization is at a nonmucosal site (3, 22, 25, 45, 47).  
The natural pathway of mucosal immune induction involves the direct delivery of 
immunogen to a mucosal surface and local processing of antigen in specialized aggregates of 
lymphoid tissue, termed mucosal inductive sites (35, 55). Stimulated lymphocytes then 
migrate to the corresponding mucosal surface where antigen-specific IgA and IgG are locally 
produced, and specific T cells reside to protect that mucosal surface from pathogen attack 
(10, 30). We show in this article that, unlike many vaccine vector systems that rely on 
mucosal delivery to access the natural inductive pathway, VRP are capable of inducing 
mucosal immune responses after nonmucosal delivery. Moreover, we demonstrate that this 
property is experimentally separable from VRP-driven immunogen production, as soluble or 
particulate immunogens can be simply mixed with VRP expressing an irrelevant transgene, or 
no transgene at all, to induce a mucosal response. Therefore, VRP exploit an alternative 
pathway for mucosal immune induction that is distinct from the natural pathway and suggest 
important applications of VRP as mucosal and systemic adjuvants in protein subunit or whole 
inactivated prophylactic vaccines and in immunomodulatory therapies for chronic diseases. 
 
MATERIALS AND METHODS 
VEE Replicon Constructs. The construction and packaging of VRP have been described 
(15, 45). Briefly, monolayers of baby hamster kidney (BHK) 21 cells (American Type 
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Culture Collection, passages 55-65) were coelectroporated with three RNAs transcribed in 
vitro: one replicon RNA, and two defective helper RNAs that lack the viral-specific 
packaging signal and drive the expression of the viral structural genes. The replicon 
constructs used in this study were (i) replicons expressing GFP (GFP-VRP), (ii) replicons 
expressing the HA gene from mouse-adapted influenza virus A/PR/8/34 (HA-VRP), and (iii) 
replicons that lack a functional transgene downstream of the 26S promoter (null VRP). Null 
VRP contain the viral nonstructural genes, 14 nt of VEE sequence downstream of the 26 
mRNA transcription start site, an inserted 43-nt-long multiple cloning site, and the 118-nt 3' 
UTR. All VRP were quantitated by infection of BHK cells followed by detection of infected 
cells by using either immunofluoresence (GFP-VRP), immunocytochemistry with antisera 
against HA for HA-VRP, or sera collected from animals immunized with null VRP for null 
VRP. Titers are expressed as IU. All replicon particles used in this study were packaged in 
the wild-type (V3000) envelope (45).  
Animals and Immunizations. Seven- to 8-week-old female BALB/c mice (Charles River 
Laboratories) were immunized with a 10-µl volume containing various VRP and/or soluble 
antigens either in the rear footpad by using a Hamilton syringe and a 30-gauge needle or 
intranasally by using a micropipette. Grade V chicken egg albumin (OVA) was purchased 
from Sigma, CT was purchased from List Biological Laboratories (Campbell, CA), and CpG 
DNA (ODN 1826) was purchased from Invivogen (Montreal). Formalin-I-Flu (Charles River 
Laboratories) was dialyzed against PBS in a Slidalyzer cassette (Pierce) according to the 
manufacturer’s guidelines before immunization. Diluent consisted of endotoxin-free, filter-
sterilized PBS, except for the experiment described in Fig. 1, in which 110 mM Ca2+, 50 mM 
 92
Mg2+, and 0.1% (vol/vol) donor calf serum were included. All animals were primed and then 
boosted 4 weeks later, either in the footpad or intranasally.  
Inactivation of VRP by UV Treatment. Null VRP preparations were diluted to a 
concentration of 106 units/ml, and 0.2-ml aliquots were placed in individual wells in a 48-well 
tissue culture plate. The plates were exposed to a UV lamp (Sun-Kraft, Chicago) at a distance 
of 5 cm for 20 min. This procedure ablated infectivity of two related alphaviruses (R. 
Shabman and M. Heise, personal communication). The effect of UV treatment was assessed 
by immunocytochemistry after infection of BHK cells. No VRP-infected cells were 
detectable in vitro after infection of baby hamster kidney cells with undiluted UV-VRP (data 
not shown).  
Sample Collection. Animals were bled either from the tail vein or after cardiac puncture, and 
sera were analyzed by ELISA (see below). Preparation of fecal extracts was modified from 
Bradney et al. (7). Briefly, ≈100-150 mg (5-8 pellets) of fecal material was freshly isolated 
from individual animals and placed into fecal extract buffer [PBS containing10% (vol/vol) 
normal goat serum and 0.1% (vol/vol) Kathon CG/ICP (Supeleco)] and vortexed for 10-20 
min until pellets were completely disrupted. Samples were then centrifuged at 12,000 × g for 
20 min and supernatants were transferred to new tubes and stored at -20°C. Although 
sampling variability may have been introduced by not directly weighing each sample, this 
variability was small relative to differences in immune responses between experimental 
groups and is considered in the statistical analysis comparing inoculation groups. Vaginal 
lavage was performed by washing the exterior vaginal opening with 0.07 ml of PBS 8–10 
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times. Wash fluid was stored at -20°C and centrifuged at 12,000 x g for 10 min before 
analysis.  
Lymphoid Organ Cultures. Lymphoid cultures, originally developed by Cebra and 
colleagues (33), were modified from Coffin et al. (12). Briefly, spleen and nasal tissue (tissue 
remaining after removal of nasal-associated-lymphoid tissue) were dissected from 
immunized animals and placed into Eppendorf tubes containing 1 ml of wash buffer (Hanks’ 
balanced salt solution containing 100 units/ml penicillin, 100 µg/ml streptomycin, 110 mM 
Ca2+, 50 mM Mg2+, and 15 mM Hepes) and washed three times by aspiration and 
resuspension. Nasal tissue from each individual animal was placed in a well of a 48-well 
tissue culture plate containing 300 µl of media [RPMI medium 1640 (GIBCO) containing 15 
mM Hepes, 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml 
gentamicin, 2 mM L-glutamine (GIBCO), and 0.25 µg/ml amphotericin B]. Plates were 
incubated at 37°C for 7 days to allow antibody secretion from B cells localized in the given 
tissue. After incubation, supernatants were collected, clarified, and analyzed for the presence 
of antigen-specific antibodies by ELISA (see below). 
ELISA. ELISAs for influenza- and OVA-specific antibodies were performed according to 
standard ELISA methods (45). Briefly, antigen solutions (either 250 ng/ml of influenza virus 
in carbonate buffer, or 1 mg/ml of OVA in PBS) were used to coat 96-well plates (Costar) 
overnight at 4°C. Antigen was removed, and blocking solution [PBS containing 5% milk for 
flu, or 1× Sigmablock (Sigma) for OVA] was added for 2 h for flu or overnight for OVA at 
room temperature. Blocking solution was removed, and plates were incubated at room 
temperature for 2 h (flu) or overnight (OVA) with 2-fold serial dilutions of samples. Plates 
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were washed and incubated for 1 h with horseradish peroxidase-conjugated secondary goat 
anti-mouse γ or α chain-specific antibodies (Southern Biotechnology Associates or Sigma). 
Plates were washed, and O-phenylenediamine dihydrochloride substrate was added for 30 
min and then stopped with the addition of 0.1 M NaF. Antibody endpoint titers are reported 
as the reciprocal of the highest dilution that resulted in an OD450 0.2. In lymphoid culture 
supernatants, endpoint titers for flu-specific IgA are reported as the reciprocal of the highest 
dilution that results in an OD450 reading at least 2 SDs greater than values obtained from 
mock-vaccinated animals. Data are presented as the geometric mean ± SEM.  
ASC ELISPOT.  To evaluate the presence of OVA-specific ASCs, single-cell suspensions 
were prepared from both spleen and the nasal epithelium. Whole spleens were disrupted 
between frosted glass slides, and red blood cells were lysed either under hypoosmotic 
conditions or after addition of ammonium chloride buffer. Cells were washed and placed on a 
Lympholyte-M density gradient (Accurate Scientific, Westbury, NY). Banded cells were 
harvested, washed, and counted. For preparation of nasal lymphocytes, nasal tissue from the 
tip of the nose to just anterior of the eye sockets was harvested from immunized animals, and 
the upper palate, including the nasal-associated lymphoid tissue, was carefully removed. 
Nasal tissue was physically disrupted and incubated at 37°C for 2 h in a 50-ml Erlenmeyer 
flask in complete R-10 media [RPMI medium 1640 containing 10% (vol/vol) FBS, 2 mM L-
glutamine, 50 µg/ml gentamicin, 100 units/ml penicillin, 100 µg/ml streptomycin, and 15 
mM Hepes] containing 2.5 mg/ml Collagenase A (Roche Applied Science), 17 µg/ml DNase 
I (Roche Applied Science), and glass beads. After digestion, cells were filtered through a 40-
µm cell strainer (BD Falcon), washed, resuspended in 44% Percoll (Amersham Pharmacia), 
and layered on Lympholyte-M as described for spleen cells above. Banded cells were 
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harvested, washed, and counted. Cells were pooled from two animals, and typical yields were 
≈2.5 × 105 to 1 × 106 cells per animal. ASC ELISPOT analysis was modified from previous 
reports (14, 53). Briefly, 96-well nitrocellulose membrane plates (Millipore) were incubated 
with 1 mg/ml OVA in PBS overnight at 4°C. Plates were then washed and blocked for 2 h 
with complete R-10 (10% serum). Two-fold dilutions of single-cell suspensions were then 
added to plates in duplicate in R-10 and incubated overnight. Plates were washed, and bound 
spots were detected by the addition of horseradiush peroxidase-conjugated secondary goat 
anti-mouse γ or α chain-specific antibodies (Southern Biotechnology Associates), followed 
by addition of 3-amino-9-ethylcarazole (Sigma), and enumerated with a computerized 
ELISPOT plate reader (Immunospot). Data are presented as the number of antigen-specific 
ASCs per 106 cells plated.  
Statistical Analysis. Antibody titers and ASC numbers were evaluated for statistically 
significant differences by either the ANOVA or Mann–Whitney tests (INSTAT; GraphPad, San 
Diego). P 0.05 was considered significant.  
RESULTS 
VRP Induce Mucosal Immune Responses. Previous reports have documented the ability of 
peripherally inoculated VRP to induce significant protection from virulent mucosal challenge 
with influenza virus in mice and chickens (45, 47), simian immunodeficiency virus in 
macaques (25), and equine arteritis virus in horses (3). Also, results obtained with intranasal 
influenza virus challenge of hemagglutinin (HA)-VRP-immunized mice showed significantly 
decreased influenza virus replication in the nasal epithelium, as determined by influenza-
specific plaque assay and in situ hybridization. (N.L.D., K. Brown, E.M.B.R., A. West, and 
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R.E.J., unpublished work). Although VRP induced protection of the mucosal tissue, it was 
not directly determined whether local mucosal immune responses contributed to the observed 
protection. Typically, mucosal immunity is induced only when antigens are processed and 
presented across mucosal surfaces (36); however, VRP induced protection in these mucosal 
challenge models after immunization by a nonmucosal route.  
We wanted to determine whether nonmucosal VRP delivery resulted in the induction 
of locally produced, mucosal immunity. Groups of female BALB/c mice were immunized in 
the rear footpad at weeks 0 and 4 with diluent, 105 infectious units (IU) of HA-VRP or 10 µg 
of formalin-inactivated influenza virus (I-Flu), as a non-VRP-vectored influenza antigen. 
Another group of animals was immunized in the rear footpad with 10 µg of I-Flu mixed with 
105 IU of GFP-VRP, as an irrelevant VRP control. At various times after the second 
inoculation (days 3, 7, 10, 14, 18, 21, and 28), groups of three animals were killed, and the 
nasal mucosa were harvested for analysis in a lymphoid culture assay originally developed by 
Cebra and colleagues (33). Detection of flu-specific antibody in supernatant fluids from ex 
vivo nasal epithelium organ cultures was used as a measure of mucosal immune induction. 
Significant antibody production was not observed in supernatants from nasal epithelium until 
day 7 postboost and was detectable from day 7 to day 28 postboost. In comparing nasal 
antibody production across the range of time points, we found that VRP-containing inocula 
induced a statistically significant increase in flu-specific IgA antibodies in organ cultures 
from the nasal epithelium, compared with cultures from animals inoculated with I-Flu alone 
(HA-VRP compared with I-Flu, P < 0.001; GFP-VRP + I-Flu compared with I-Flu, P < 
0.001, data not shown). Shown in Fig. 1 is the day-21 time point. All three antigen delivery 
methods were capable of stimulating local flu-specific IgG antibody production in nasal 
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mucosa as detected in the ex vivo supernatants, although VRP-induced responses were 
significantly increased compared with responses induced by delivery of I-Flu alone (Fig. 1A). 
HA-VRP and the delivery of I-Flu mixed with GFP-VRP, but not delivery of I-Flu alone, 
induced flu-specific, mucosal IgA antibodies (Fig. 1B). Also, VRP induced a statistically 
significant increase in flu-specific IgG and IgA antibodies present in nasal washes of 
immunized animals compared with inoculation of I-Flu alone (data not shown). These results 
indicate that (i) VRP are capable of inducing local, antigen-specific antibody production in 
mucosal tissues after nonmucosal delivery, (ii) mucosal immune induction is a property of 
VRP, as antigen alone fails to induce significant mucosal IgA responses, and (iii) VRP are 
capable of inducing mucosal immunity either when the immunogen is expressed by the VRP, 
or when the immunogen is simply mixed with an irrelevant VRP that appears to serve as an 
adjuvant. 
The mucosal response observed in the nasal epithelium did not result from an 
inordinately high systemic response in the VRP-containing groups. The experimental system 
was designed such that the systemic IgG response induced in I-Flu-immunized animals, as 
measured by flu-specific IgG antibodies in ex vivo spleen cultures, was statistically equivalent 
to the systemic responses induced by VRP-containing inocula (Fig. 1C). Therefore, any 
differences in the mucosal responses could not simply be attributed to higher immune 
responses in general. However, HA-VRP and I-Flu mixed with GFP-VRP induced 
significantly greater levels of flu-specific, systemic IgA antibodies than I-Flu alone, as 
measured in spleen culture supernatant fluids (Fig. 1D). Preliminary results with analogous 
vectors based on Girdwood virus and A.R.86 virus, alphaviruses in the Sindbis group, also 
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suggest induction of mucosal immune responses (J.M.T., A.C.W., and M. Heise, unpublished 
work).   
VRP Possess Systemic and Mucosal Adjuvant Activity. The results reported in Fig. 1 
strongly suggest that VRP themselves, independent of the expressed gene, are capable of 
serving as both a systemic and mucosal adjuvant after nonmucosal delivery. To confirm this 
hypothesis, groups of eight animals were immunized in the rear footpad with 106 IU of VRP 
not expressing any transgene (null VRP) mixed with either 0.1 or 1.0 µg of I-Flu at weeks 0 
and 4. Although null VRP do not express an inserted gene behind the 26S promoter, a short 
175-nt noncoding mRNA is predicted from the sequence. Animals were bled 2 weeks 
postboost, and flu-specific serum IgG antibodies were analyzed by ELISA. As shown in Fig. 
2, the presence of null VRP in the inoculum increased the flu-specific systemic antibody 
response by up to 44-fold (1.0 µg dose of I-Flu). To assess mucosal antibody responses, fecal 
extracts were prepared and analyzed for the presence of flu-specific mucosal antibodies by 
ELISA (Fig. 2 B and C). Antibodies present in fecal extracts are almost exclusively locally 
produced, with minimal contribution from serum-derived antibodies (38). Flu-specific fecal 
IgA antibodies were barely detectable after immunization with I-Flu alone; however, the 
inclusion of null VRP as an adjuvant augmented those responses by 60 fold (1.0-µg dose of 
I-Flu, IgA). These data confirm that VRP possess systemic and mucosal adjuvant activity for 
a particulate antigen.  
To further characterize the adjuvant properties of VRP, the following experiments 
used null VRP and a soluble test antigen, ovalbumin (OVA), rather than a particulate antigen 
(I-Flu). Groups of six female BALB/c mice were immunized at weeks 0 and 4 with 10 µg of 
OVA, either alone or coinoculated with 106 IU of null VRP, by both parenteral (footpad) and 
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mucosal (intranasal) delivery. As shown in Supplemental Fig. 2-1, both footpad and nasal 
delivery of OVA alone resulted in detectable OVA-specific serum IgG titers 3 weeks 
postboost. The coinoculation of null VRP with OVA increased OVA-specific serum IgG 
responses by 60- and 1,400-fold after footpad and nasal delivery, respectively. To assess 
mucosal antibody responses, fecal extracts were prepared from vaccinated animals before the 
booster inoculation and at weeks 1, 2, and 3 postboost, and analyzed for the presence of 
OVA-specific mucosal IgG and IgA antibodies by ELISA. Delivery of OVA alone failed to 
consistently induce detectable levels of OVA-specific fecal antibodies over background after 
either footpad or nasal immunization 3 weeks postboost. However, the inclusion of null VRP 
in the inoculum resulted in an 20- to 60-fold increase in OVA-specific fecal IgG and IgA 
antibody titers (Supplemental Fig. 2-1 B and C), regardless of the route of immunization. 
Taken together, the observations using I-Flu and OVA confirm the systemic and mucosal 
adjuvant activity of VRP after either mucosal or nonmucosal delivery of soluble or 
particulate immunogens. 
VRP RNA Replication Is a Trigger for Adjuvant Activity/Immune Induction. The 
critical VRP-specific parameters that mediate adjuvant activity are currently undefined. 
Numerous molecular sensors are capable of recognizing viral products in virus-infected cells 
(48), including members of the toll-like receptor family (1, 23), and a number of IFN-
inducible proteins (46, 54). We hypothesize that one or more of these pathways might be 
involved in recognizing RNA products produced after VRP infection and might play a critical 
role in VRP adjuvant activity. To test the hypothesis that VRP RNA replication is necessary 
for adjuvant activity, we treated null VRP with UV light before inoculation. UV treatment 
causes the formation of uridine dimers in the replicon RNA, which blocks both RNA 
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replication and translation of the input RNA, and allows evaluation of replication-defective 
VRP as molecular adjuvants.  
Groups of six BALB/c mice were inoculated in the rear footpad at weeks 0 and 4 with 
10 µg of OVA alone or 10 µg of OVA mixed with (i) 1.0 µg of cholera toxin (CT), a known 
systemic and mucosal adjuvant used here as a positive control (52), (ii) 104 IU of null VRP, 
(iii) 104 IU of null VRP treated with UV light (UV-VRP), or (iv) 106 IU of null VRP. At 1 
week postboost, serum was harvested from immunized animals and analyzed for the presence 
of OVA-specific IgG antibodies by ELISA. OVA-specific serum IgG titers were increased by 
64- and 114-fold after the codelivery of OVA plus 104 or 106 IU of VRP, respectively 
(Supplemental Table 2-1). In contrast, codelivery of OVA and 104 IU of UV-VRP failed to 
induce a statistically significant increase in OVA-specific serum IgG antibodies (P > 0.05). 
These results suggest that viral RNA replication was required for the immune stimulation 
observed with null VRP. Importantly, the adjuvant effect of VRP was comparable to 
responses induced by 1.0 µg of the control adjuvant, CT, under these conditions.  
To quantitate the number of OVA-specific IgG- and IgA-secreting cells in spleen and 
nasal epithelium of the same animals, single-cell suspensions were prepared and analyzed in 
an antibody-secreting cell (ASC) enzyme-linked immunospot assay (ELISPOT). Increased 
levels of IgG (Fig. 3A) and IgA (Fig. 3B) ASCs were present in spleen and nasal epithelium 
in the OVA-plus-VRP inoculated animals, compared with the OVA-alone group, again 
demonstrating a clear systemic and mucosal VRP adjuvant activity leading to the local 
production of antigen-specific antibodies in both systemic and mucosal tissues. UV treatment 
of VRP before inoculation largely abrogated this effect, indicating the importance of VRP 
RNA function and also suggesting that contaminants potentially present in the VRP 
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preparations (such as LPS) were not responsible for the observed adjuvant activity. Again, 
VRP adjuvant activity as measured by ASC ELISPOT was comparable with that of CT. 
These results demonstrate that null VRP can act as a true mucosal adjuvant, and VRP RNA 
replication is likely the molecular trigger for the adjuvant activity.  
VRP Adjuvant Activity as Compared with Adjuvant Activity of CpG DNA. We sought 
to determine how the VRP adjuvant compared with another known adjuvant, CpG DNA. 
Unmethylated CpG motifs found in bacterial genomes are recognized by the innate immune 
system through interactions with TLR9 and increase immunity to coimmunized antigens in 
numerous experimental systems [reviewed in ref. (28)]. To further characterize the relative 
strength of VRP adjuvant activity, groups of eight BALB/c mice were inoculated in the rear 
footpad at weeks 0 and 4 with 10 µg of OVA alone, 10 µg of OVA mixed with 105 IU of null 
VRP, or 10 µg of OVA mixed with 1.0 µg of CpG DNA. Two weeks after the second 
inoculation, sera, fecal extracts, and vaginal lavage samples were prepared from individual 
animals and analyzed for the presence of OVA-specific antibodies by ELISA. Also at 2 
weeks postboost, single-cell suspensions were prepared from spleen and nasal epithelium and 
analyzed for OVA-specific ASCs by ASC ELISPOT. As shown in Fig. 4, both VRP and CpG 
augmented OVA-specific spleen IgG ASCs compared with OVA alone (P < 0.001 and P < 
0.05, respectively). Although VRP adjuvanted systemic OVA responses to a greater extent 
than CpG, as measured by spleen ASC, measurement of OVA-specific serum IgG titers 
suggested that the CpG and VRP systemic adjuvant effects were comparable (Supplemental 
Table 2-2). However, VRP induced a significant adjuvant effect on mucosal IgA responses in 
fecal extracts and vaginal washes and in IgA ASCs in the nasal epithelium (Fig. 4 and 
Supplemental Table 2-2). By each of these assays, VRP-adjuvanted OVA responses in 
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mucosal tissues were superior to OVA plus CpG. These data suggest that the systemic 
adjuvant activity of VRP is at least as strong as that of CpG and that VRP possess 
significantly stronger mucosal adjuvant activity. 
DISCUSSION 
Alphavirus replicon vectors expressing pathogen-derived immunogens have been 
used extensively as vaccine delivery vehicles and have proven effective at inducing 
significant protection from challenge with a number of important pathogens in experimental 
and natural hosts. However, the mechanisms that govern immune induction after vector 
delivery remain largely unexplored.  
We demonstrate in this article that VRP possess inherent immunostimulatory 
properties that are independent of protein production. Either irrelevant or null VRP, simply 
codelivered with soluble OVA protein or inactivated influenza virions, dramatically 
augmented antigen-specific antibody production in both the systemic and mucosal 
compartments, compared with inoculation of antigen alone. In work not presented here, VRP 
systemic and mucosal adjuvant activity also has been demonstrated with Norwalk virus-like 
particles (A. LoBue, J.M.T., R. Baric, and R.E.J., unpublished work), cowpox B5R protein 
(N. Thornburg, J.M.T., and R.E.J., unpublished work), and simian immunodeficiency virus 
gp120 (A. West, J.M.T., and R.E.J., unpublished work), suggesting that the VRP adjuvant 
functions without respect to the antigen. In the present study we have measured only short-
term immunity with VRP adjuvants. However, VRP used as expression vectors elicited 
responses that endured throughout the lifetime of the animal. If we assume that the 
immunological parameters that govern VRP as expression vectors are the same as those that 
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govern immune induction with VRP as adjuvants, then it is likely that adjuvant-induced 
immunity will be equally long-lived.  
We demonstrate the adjuvant property of alphavirus replicon particles for both 
systemic and mucosal immunity, even when administered by a nonmucosal route. A number 
of recent reports have identified other viral (5, 8, 24, 43) and bacterial (39) particles that 
possess various types of adjuvant activity when codelivered with antigen. We speculate that 
such activity is also likely to play an important role in immune induction under conditions in 
which such particles (including VRP) are engineered as vectors to express a given 
immunogen. Although those other reports document the ability of microbial particles to serve 
as adjuvants, no other system has demonstrated mucosal immune induction after nonmucosal 
delivery, as is observed with VRP. It will be of interest to determine whether other viruses 
are capable of augmenting mucosal antibody responses after nonmucosal delivery, or if this 
property is unique to VEE.  
The natural pathway of mucosal immune induction relies on antigen processing and 
presentation at mucosal surfaces and results in the local production of IgA antibodies at those 
surfaces (29, 36). VRP were capable of immune induction via the natural pathway, as nasal 
delivery resulted in the induction of mucosal immunity. However, VRP were also capable of 
exploiting an alternative pathway that resulted in mucosal immunity after nonmucosal 
inoculation. Although there have been a limited number of examples where induction of 
mucosal immunity occurred after inoculation at a parenteral site [reviewed in refs. (6) and 
(50)] there is little consistency among the several examples, and none of them is analogous to 
the null VRP adjuvant activity described here (11, 13, 16, 18, 19, 21, 26, 37, 41, 42). 
Likewise, induction of mucosal immunity has been demonstrated with alphavirus expression 
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vectors, but only after immunization (4, 51) or boost (22) at a mucosal surface, and in none of 
these instances was the potential for mucosal adjuvant activity examined.  
The mechanism by which VRP trigger mucosal immunity after nonmucosal delivery 
is undefined at present. One potential explanation is that either free VRP, or cells infected by 
VRP in the skin (34) or lymph node migrate to a traditional mucosal inductive site, such as 
Peyer’s patches or mesenteric lymph node, and induce local antibody production (6). 
However, experiments using GFP-VRP have failed to consistently demonstrate VRP-infected 
cells in such tissues (E.M.B.R., J.M.T., and R.E.J., unpublished work). We favor the 
hypothesis that the lymph node draining the site of VRP inoculation develops at least some 
functions characteristic of a mucosal inductive site. In support of this idea, preliminary 
experiments demonstrate the production of antigen-specific, multimeric IgA in the draining 
lymph node (DLN) in response to inoculation of VRP (J.M.T. and R.E.J., unpublished work). 
It needs to be determined whether additional characteristics of a true mucosal inductive site 
are present in the DLN of VRP-inoculated mice. We feel that detailed examination of this 
alternative pathway for the induction of mucosal immunity in the VRP experimental system 
will contribute to a greater understanding of alphavirus-induced immunity, in particular, and 
mucosal immunity in general.  
The molecular basis for the adjuvant activity likely resides in the ability of the VRP 
genome to replicate, given the sensitivity of adjuvant activity to UV inactivation. We suggest 
that an element present during virus replication is recognized in infected host cells and that 
this recognition initiates a cascade of events that ultimately leads to the induction of 
immunity to codelivered antigens. The most prominent candidates include viral RNA and/or 
replicative intermediates and their interactions with components of the innate immune 
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system. A variety of cellular sentinel molecules exist, such as TLR3 (1), TLR7 (23), RIG-I, 
MDA-5 (54), protein kinase R, and RNaseL (46), which are capable of recognizing viral 
replicative molecules. In fact, a recent report (32) implicates RNaseL in immune induction to 
a tolerant melanoma antigen in an alphavirus replicon system.  
Both transgene-expressing particles and particles lacking a transgene possess adjuvant 
activity, suggesting that adjuvant activity neither depends on, nor is inhibited by, the presence 
of a particular transgene protein. The VRP constructs lacking a transgene are predicted to 
express a short, noncoding RNA. It is unlikely that this truncated subgenomic RNA, or the 
presence or activity of the 26S promoter itself, is responsible for the observed adjuvant 
activity. Another formal possibility is that translation of the replicase proteins is responsible 
for the activity.  
One potential trivial explanation for the adjuvant effect is that it is mediated by a 
contaminant present in VRP preparations (such as LPS). However, two observations strongly 
suggest that a contaminant is not the predominant mechanism of immune activation: (i) no 
adjuvant activity was observed after codelivery of identically treated media from a mock 
VRP preparation (data not shown), and (ii) UV treatment of VRP ablated adjuvant activity.  
We have compared VRP adjuvant activity to that of CT and CpG DNA. Results from 
such comparisons suggest that systemic responses induced by VRP are at least equivalent to 
that of both CT and CpG DNA. Moreover, after nonmucosal delivery VRP mucosal adjuvant 
activity appears to be comparable to that of CT and superior to CpG DNA. A number of 
important questions regarding VRP adjuvant activity remain to be answered, such as how 
VRP-induced systemic and mucosal immune responses compare with those of other 
peripherally delivered adjuvants, such as alum, and mucosally delivered CT and whether 
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VRP act as a systemic and mucosal T cell adjuvant. These additional comparisons will allow 
more accurate evaluations of the relative efficiency of VRP-induced immune stimulation.  
In summary, we have demonstrated two activities of alphavirus-derived viral vectors: 
(i) induction of local mucosal immune responses after inoculation at a remote, nonmucosal 
site and (ii) systemic and mucosal adjuvant activity with codelivered soluble and particulate 
immunogens. We feel that these observations and the continued experimentation they 
stimulate will advance a search for adjuvant activity among other viruses and viral vectors, 
will ultimately define the specific components of an alternative pathway for the induction of 
mucosal immunity, and if the activity is evident in humans, will enable new possibilities for 
safe and inexpensive subunit and inactivated vaccines.  
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Figure 2-1 
 
 
 
 
 
 
 
Fig. 2-1. VRP induce mucosal immune responses. Groups of animals were immunized in 
the rear footpad with diluent, 10 µg of I-Flu (solid bars), 105 IU of HA-VRP (open bars), or 
10 µg of I-Flu plus 105 IU of GFP-VRP (hatched bars) at weeks 0 and 4. Three weeks after 
the second inoculation, lymphoid organ cultures were established from the nasal epithelium 
(A and B) and spleen (C and D). Culture supernatants were evaluated for flu-specific IgG (A 
and C) and IgA antibodies (B and D) by ELISA. Data are presented as the geometric mean ± 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with I-Flu alone, as determined by 
ANOVA. 
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Figure 2-2 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2-2. VRP adjuvant activity for particulate antigens. Groups of eight animals were 
immunized in the rear footpad with 0.1 or 1.0 µg of I-Flu in the presence (hatched bars) or 
absence (solid bars) of 106 IU of null VRP at weeks 0 and 4. Two weeks after the second 
inoculation, flu-specific IgG antibodies were measured in sera (A) and fecal extracts (B), and 
flu-specific IgA antibodies were measured in fecal extracts (C) by ELISA. Data are presented 
as the geometric mean ± SEM. *, P < 0.02; **, P < 0.005; ***, P < 0.0003 compared with I-Flu 
alone, as determined by Mann–Whitney. 
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Figure 2-3 
 
 
 
 
 
 
Fig. 2-3. Systemic and mucosal adjuvant activity of UV-treated VRP. Groups of six 
animals were immunized in the rear footpad with 10 µg of OVA alone or coinoculated with 
1.0 µg of CT, 104 IU of null VRP, 104 IU of UV-VRP, or 106 IU of null VRP at weeks 0 and 
4. One week after the second inoculation, splenocytes (open bars) and nasal lymphocytes 
(solid bars) were isolated from immunized animals and analyzed for the presence of OVA-
specific IgG-secreting cells (A) and IgA-secreting cells (B) by ELISPOT. Data are presented 
as the geometric mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with OVA 
alone, as determined by ANOVA. 
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Figure 2-4 
 
 
 
 
 
 
 
 
 
Fig. 2-4. Systemic and mucosal adjuvant activity of VRP compared with CpG DNA. 
Groups of eight animals were immunized in the rear footpad with 10 µg of OVA alone (solid 
bars) or coinoculated with 105 IU of null VRP (hatched bars) or 1.0 µg of CpG DNA (open 
bars) at weeks 0 and 4. Two weeks after the second inoculation, splenocytes were isolated 
and analyzed for the presence of OVA-specific IgG ASCs, and nasal lymphocytes were 
isolated and analyzed for the presence of OVA-specific IgA ASCs by ELISPOT. Data are 
presented as the geometric mean ± SEM. *, P < 0.001 compared with OVA alone; , P < 0.01 
compared with CpG; , P < 0.05 compared with CpG. 
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Supplemental Figure 2-1 
 
 
 
 
 
 
 
Supplemental Fig. 2-1.  VRP adjuvant activity for soluble antigens. Groups of six 
animals were immunized in the rear footpad or intranasally with 10 µg of OVA in the 
presence (hatched bars) or absence (solid bars) of 106 IU of null VRP at weeks 0 and 4. 
Three weeks after the second inoculation, OVA-specific IgG antibodies were measured in 
sera (A) and fecal extracts (B), and OVA-specific IgA antibodies were measured in fecal 
extracts (C) by ELISA. Data are presented as the geometric mean ± SEM. *, P < 0.003 
compared with OVA alone, as determined by Mann-Whitney. 
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Supplemental Table 2-1.   
 
 
 
Systemic adjuvant activity of UV-treated VRP. Groups of six animals were immunized in 
the rear footpad with 10 µg of OVA alone or coinoculated with 1.0 µg of CT, 104 IU of null 
VRP, 104 IU of UV-VRP, or 106 IU of null VRP at weeks 0 and 4. One week after the second 
inoculation, sera were analyzed for OVA-specific IgG antibodies by ELISA. Data are 
presented as the geometric mean +/- SEM. *, P < 0.05; **, P < 0.001 compared with OVA 
alone, as determined by ANOVA. 
 
 
 
 
 
 
Supplemental Table 2-2.   
 
 
 
Systemic and mucosal adjuvant activity of VRP compared with CpG DNA. Groups of 
eight animals were immunized in the rear footpad with 10 µg of OVA alone or coinoculated 
with 105 IU of null VRP or 1.0 µg of CpG DNA at weeks 0 and 4. Two weeks after the 
second inoculation, sera, fecal extracts, and vaginal wash samples were prepared and 
analyzed for OVA-specific antibodies by ELISA. Data are presented as the geometric mean 
+/- SEM. 
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ABSTRACT 
  The strongest mucosal immune responses are induced following mucosal antigen 
delivery and antigen processing in the lymphoid tissues of the mucosal immune system.  
Much is known regarding the immunological parameters which regulate immune induction 
via this pathway.  Recently, a number of experimental systems have been identified in which 
mucosal immune responses are induced following nonmucosal antigen delivery.  One such 
system, footpad delivery of Venezuelan equine encephalitis virus replicon particles (VRP) 
led to the production of IgA antibodies directed against both expressed and co-delivered 
antigens at multiple mucosal surfaces in mice.  In contrast to the mucosal delivery pathway, 
little is known regarding the lymphoid structures and immunological components which are 
responsible for mucosal immune induction following nonmucosal delivery.  Here we have 
utilized peripheral VRP delivery to probe the inner workings of this alternative pathway for 
mucosal immune induction.  Following nonmucosal VRP delivery, IgA antibodies, and 
polymeric or mucosal forms of IgA antibodies, were first detected in the peripheral draining 
lymph node (DLN), prior to IgA detection at the mucosal surfaces.  Further analysis of the 
DLN revealed upregulated expression of the α4β7 integrin on DLN B cells, expression of 
MAdCAM-1, the ligand for the α4β7 integrin, and production of IL-6 and CC chemokines, all 
characteristics of mucosal lymphoid tissues.  Taken together, these results implicate the 
peripheral DLN as an integral component of an alternative pathway for mucosal immune 
induction.  An understanding of the critical immunological and viral components of this 
pathway may significantly improve both our knowledge of viral-induced immunity and the 
efficacy of viral-based vaccines.   
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INTRODUCTION 
The mammalian immune system has evolved two minimally overlapping arms: the 
systemic immune system which relies upon lymphoid cells and structures in the skin, spleen, 
bone marrow and peripheral lymph nodes for immune induction; and the mucosal immune 
system with its coupled mucosa-associated lymphoid tissue (MALT) responsible for immune 
activation at the mucosal level (8, 10, 23, 30). This distinctive segregation allows focused 
immune induction in the compartment in which the relevant antigen predominates.  As the 
vast majority of harmful pathogens rely on penetration of a mucosal barrier as an integral 
step in the initiation of infection, innate and adaptive immune mechanisms which uphold the 
integrity of the mucosal surface are paramount for mediating protection from invading 
microbes (48).  To date, vaccination has proven to be one of the most effective strategies of 
prophylactic immunomodulation against mucosal pathogens; however, mucosal infections 
with agents such as human immunodeficiency and highly virulent influenza viruses still pose 
a significant threat to human health.  Therefore, the development of vaccine regimens 
capable of stimulating protective mucosal immunity would represent a powerful opportunity 
to intercede in the disease course of many infectious organisms (57).   
It is well established in the literature that the strongest mucosal immune responses are 
induced following mucosal antigen delivery and antigen processing in the lymphoid tissues 
of the mucosal immune system (6, 48, 57).  This natural pathway of mucosal immune 
induction following mucosal antigen delivery in the presence of immunomodulatory agents, 
such as the enterotoxins from various gram negative bacteria, has been studied extensively 
(1, 12, 48, 57, 65). Following nasal or oral delivery, antigens are captured by specialized 
epithelial cells termed M cells, or microfold cells of the follicle associated epithelium (FAE) 
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(25, 35).  The FAE envelopes the lymphoid cell component of the mucosal inductive sites 
such as the Peyer’s patches (PPs) in the gut.   PPs contain dendritic cells (DCs), 
macrophages, B lymphocytes, T lymphocytes, and endothelial cells which all work in concert 
to chaperone luminal antigens from harmful organisms into an immunostimulatory 
environment, culminating in the activation of antigen-specific B cells and T cells which 
mediate protection of the mucosal surface (38, 39, 56).  
A cascade of events is initiated following lymphocyte activation in mucosal inductive 
tissues in the presence of appropriate inflammatory signals (49).  As a consequence of B cell 
activation in mucosa-draining-lymphoid tissues, activated B cells migrate from the PPs 
through the mesenteric lymph node and ultimately enter systemic circulation via the thoracic 
duct.  These B cells differentiate along an activation pathway as a result of priming signals 
received in the mucosal lymphoid tissues, and upregulate a group of surface molecules which 
direct their migration back to the mucosal surface from which they were originally activated 
(7, 8).  One of the most important mediators of mucosal homing is the α4β7 integrin, also 
termed the mucosal homing receptor (9).  This heterodimeric integrin pair is upregulated on 
mucosally-activated B and T cells and binds to its ligand, mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1), which is expressed on the high endothelial venules (HEVs) of 
mucosal lymphoid tissues (2, 9).  MAdCAM-1 expression is a discriminating characteristic 
of mucosal lymphoid tissues and is abundant on the HEVs of PPs and MLN.  In contrast, 
very little MAdCAM-1 is detectable in systemic lymphoid structures such as the spleen and 
peripheral lymph nodes.  Instead, the HEVs of systemic lymphoid tissue express the 
peripheral lymph node addressin (PNAd), which binds to CD62L and mediates migration of 
lymphocytes throughout the systemic lymphoid tissues (7).  Additionally, chemokine 
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receptors CCR9 and CCR10 mediate lymphocyte migration into the mucosal compartment 
following migration towards mucosal chemokines TECK and MEC respectively (29, 40, 41). 
Following integrin/chemokine-mediated migration back to the mucosa lamina 
propria, mucosally-activated B cells undergo further differentiation and activation in the 
mucosal environment directed by numerous cytokines and growth factors (31).  The mucosal 
inflammatory milieu promotes the activation of antigen-specific B cells and orchestrates 
antibody isotype class switch towards the IgG and IgA isotypes (47).  IgA is the most 
prominent antibody isotype present at mucosal surfaces (52).  In fact, in humans more IgA is 
produced in the intestinal tract each day than all other isotypes in the body combined (15).  
Mucosal IgA antibodies exist as dimeric or polymeric forms by inclusion of the joining 
chain, or J chain protein during antibody secretion from mucosally-activated B cells (32).  J 
chain-containing IgA molecules are transported onto mucosal surfaces following a specific 
interaction with the poly immunoglobulin receptor (pIgR) expressed on the basolateral 
surface of mucosal epithelial cells (32).  Following transport through mucosal epithelial cells, 
dimeric/polymeric IgA is released into/onto the mucosal surface and retains a portion of the 
pIgR.  This complex is subsequently termed secretory IgA (33).   
As mentioned above, mucosal antigen delivery is the most efficient method of 
inducing local mucosal antibody responses; however, a growing body of evidence supports 
the existence of an additional pathway capable of stimulating mucosal antibody synthesis 
following nonmucosal antigen delivery [reviewed in (5, 71)].  The examples are varied and a 
common unifying mechanism responsible for mucosal immune induction under all 
circumstances is not readily evident upon initial review.  Peripheral, or nonmucosal delivery 
of a diverse class of viruses or viral vaccine vectors including rotavirus (13, 14), canarypox 
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vectors (55), Venezuelan equine encephalitis virus (11) and replicon particles (28, 45, 70), 
and Rubella virus (58) potentate either mucosal antibody or T cell activation.  Likewise, 
nonmucosal delivery of bacterial antigens/vectors derived from Listeria monocytogenes (59) 
and Haemophilus influenzae type  b (36) promote mucosal immunity, suggesting that both 
viral and bacterial particles are capable of stimulating this pathway. 
While traditional nonmucosal delivery methods are clearly capable of stimulating 
mucosal immunity, several specialized nonmucosal delivery approaches have been developed 
which likewise promote mucosal immune induction.  One example is parenteral targeting of 
mucosal lymphoid tissues using anti-MAdCAM-1 antibodies, which dramatically augment 
mucosal antibody responses (50).  In an alternative strategy, antigens are delivered through 
the skin in the presence of known mucosal adjuvants in a technique termed transcutaneous 
immunization (26).  This technique results in significantly increased mucosal antibody 
responses both in mice and in humans (27, 72).  Interestingly, an approach termed targeted 
lymph node immunization, which relies on direct antigen inoculation into a peripheral lymph 
node, also stimulates mucosal immunity in non-human primates (37, 42).   
At this point it is unclear whether mucosal immune induction following either 
traditional nonmucosal delivery or following one of the specialized approaches outlined 
above of is in fact due to an intrinsic signal provided by the viral/bacterial particle itself or 
instead is due to the induction of a specific cellular factor or group of factors following.  A 
number of candidate immunomodulatory factors have been identified including various 
forms of vitamin D3 (22) as well as a group of specific cytokines and chemokines (19) which 
potentially provide a mechanistic explanation for mucosal immune induction following 
nonmucosal antigen delivery. 
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The identification of the components of a peripheral mucosal immune induction 
pathway will provide valuable insights into the regulatory networks involved in mucosal 
immune induction, as well as the potential to significantly improve mucosal vaccines.  We 
have recently demonstrated the ability of modified viruses derived from the alphavirus, 
Venezuelan equine encephalitis virus (VEE), to promote IgG and IgA antibody synthesis at 
multiple mucosal surfaces (28, 45, 70).  The particles utilized in these studies, termed VEE 
replicon particles (VRP), express only the viral non-structural, or replicase components 
responsible for replication of the genomic RNA (60).  VRP efficiently infect dendritic cells 
(DCs) following footpad inoculation in mice and replicate the viral genome to high levels 
(46).  However, VRP fail to propagate beyond the first infected cell, as progeny virions are 
not produced following infection (24).  In this study, we have utilized nonmucosal delivery 
of VRP as a model system to dissect the individual components of the peripheral mucosal 
immune induction pathway.  Here we demonstrate several markers of mucosal lymphoid 
tissues including antigen-specific multimeric IgA antibodies, increased levels of mucosal 
cytokines such as IL-6 and TNF-α, a population of B cells with upregulated mucosal homing 
receptor expression, and expression of MAdCAM-1 on the HEVs of the DLN of VRP-
inoculated animals.  These observations are consistent with a model in which, following 
nonmucosal VRP delivery, the DLN is converted into the functional equivalent of a mucosal 
inductive site and serves as a component of an alternative pathway for mucosal immune 
induction.  These studies provide a framework for the identification of the critical 
components of the alternative pathway for mucosal immune induction and the potential to 
improve mucosal vaccination strategies.   
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MATERIALS AND METHODS 
VEE replicon constructs.  The construction and packaging of VRP was performed as 
previously described (16, 60).  Briefly, confluent monolayers of BHK-21 cells were co-
electroporated with three separate in-vitro-transcribed RNAs, the replicon RNA, and two 
defective helper RNAs which drive the expression of the viral structural genes in trans.  Only 
the replicon RNA is packaged into VRP as the helper RNAs lack the viral packaging signal.  
In this study, three different replicon constructs were utilized:  1) replicons expressing GFP 
(GFP-VRP); 2) replicons expressing the HA gene from influenza virus (HA-VRP); and 3) 
replicons which lack a functional transgene downstream of the 26S promoter (null VRP) 
(70).  Null VRP contain the viral nonstructural genes, a  14 nt stretch  of VEE sequence 
downstream of the 26S mRNA transcription start site, a heterologous 43-nt long cassette 
containing multiple restriction sites for cloning into the replicon backbone, and the 118-nt 3' 
UTR. HA-VRP and null VRP were quantitated by immunocytochemistry of infected BHK 
cells with anti-sera against HA (60) and null VRP (70), respectively.  GFP-VRP were 
quantitated by immunofluoresence of infected BHK cells.  All replicon particles utilized in 
this study were packaged in the wild-type (V3000) envelope.   
Animals and immunizations.  Seven-to-10-week-old female BALB/c mice were immunized 
in a 0.01 ml volume in the rear footpad/s as previously described (70).  Briefly, animals were 
immunized at week 0 and week 4 with antigen alone or antigen co-inoculated with either 
VRP or CpG DNA as an adjuvant.   Chicken egg albumin (OVA) was purchased from 
Sigma; inactivated influenza virus (I-Flu) was purchased from Charles River Laboratories 
and was dialyzed against PBS in a Slidalyzer cassette (Pierce) according to manufacturer’s 
guidelines prior to use.  CpG DNA (ODN 1826) was purchased from Invivogen.  Diluent 
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consisted of low endotoxin, filter-sterilized PBS, except for the lymphoid organ culture 
experiments (see below), in which 110 mM Ca2+, 50 mM Mg2+, and 0.1% (vol/vol) donor 
calf serum were included. 
Lymphoid Organ Cultures.  Lymphoid cultures were prepared as previously described (45, 
70).  Briefly, spleen, nasal tissue, and draining popliteal lymph nodes were harvested from 
immunized animals and placed in Eppendorf tubes containing 1 ml of wash buffer (Hanks’ 
balanced salt solution containing 100 units/ml penicillin, 100 µg/ml streptomycin, 110 mM 
Ca2+, 50 mM Mg2+, and 15 mM Hepes) and washed three times by aspiration and 
resuspension.  Spleen and nasal tissue were placed in individual wells of a 48-well tissue 
culture plate in 0.3 mls of media [RPMI medium 1640 (GIBCO) containing 15 mM Hepes, 
10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml gentamicin, 2 mM L-
glutamine (GIBCO), and 0.25 µg/ml amphotericin B], and DLNs were placed in individual 
wells in a 96-well tissue culture plate in 0.1 mls of media.  Plates were incubated at 37ºC for 
7 days to allow antibody secretion from tissue-resident B cells into the supernatant.  
Following incubation, supernatants were collected, clarified by centrifugation at 4ºC, and 
analyzed for the presence of antigen-specific antibodies by ELISA and/or large molecular 
weight IgA antibodies by western blot. A limited set of tissue samples from an additional 
timepoint (day 21 post-boost) was previously published in Thompson et al (70) (figure 1) as 
evidence of VRP-induced mucosal immune induction.   
Preparation of DLN extracts.  Draining popliteal lymph nodes were dissected from 
immunized animals, and each lymph node was placed in a 1.5 ml tube (Kontes) with 0.1 mls 
of PBS containing protease inhibitors (PIs) [complete mini protease inhibitor cocktail tablet 
(Roche)].  DLNs were physically homogenized with a plastic pestle (Kontes) with the aid of 
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a hand-held motor and were frozen at -20ºC.  Following thaw, debris was pelleted by 
centrifugation at 4ºC, and supernatants were analyzed for IgA antibodies by ELISA, or for 
cytokine production by Beadlyte multiplex LUMINEX custom analysis performed by 
Millipore/Upstate (see below).  Extracts were compared from individual lymph nodes across 
the various immunization groups.  As a control, lymph node extracts were prepared from 
individual Peyer’s patches (PPs) exactly as described for the popliteal lymph nodes 
(homogenized in 0.1 mls of PBS).   
Sera, Fecal Extracts, and Vaginal Washes.  All sample collection was performed as 
previously described (70).  Blood was harvested from either the tail vein, following cardiac 
puncture, or from the submandimular plexus from individual animals, and sera were 
collected following centrifugation in microtainer serum separator tubes (Becton Dickinson).  
For fecal extracts, fresh fecal pellets (5-8, ≈ 100-150 mg) were isolated from individual 
animals and placed in a 1.5 ml Eppendorf tube containing 1 ml of fecal extract buffer [PBS 
containing10% (vol/vol) normal goat serum and 0.1% (vol/vol) Kathon CG/ICP (Supeleco)].  
Samples were vortexed for at least 10 mins until all pellets were disrupted into a homogenous 
mixture.  Samples clarified by centrifugation at 4ºC, and supernatants were transferred to 
fresh tubes and stored at -20 ºC prior to analysis by ELISA assay (see below).  Vaginal 
washes were performed by lavage of the exterior vaginal opening with 0.07 mls of PBS 8-10 
times.  Lavage samples were stored at -20 ºC and clarified at 4ºC prior to ELISA analysis 
(see below).   
Flow Cytometric Analysis.  DLNs were harvested from immunized animals, and the overall 
mass of the lymph nodes was determined by weighing individual lymph nodes on an 
analytical balance (Mettler).  Each lymph node was next disrupted with a razor blade and a 
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hemostat, and single cell suspensions were created by agitating each lymph node in complete 
RPMI media [RPMI medium 1640 containing 10% (vol/vol) FBS, 2 mM L-glutamine, 50 
µg/ml gentamicin, 100 units/ml penicillin, 100 µg/ml streptomycin, and 15 mM Hepes] 
containing 2.5 mg/ml Collagenase A (Roche Applied Science), 17 µg/ml DNase I (Roche 
Applied Science) for 30 minutes at 37ºC.  Single cell suspensions were then stained with 
antibodies directed against CD3, CD19, CD45 (B220), CD11c, CD11b (all purchased from 
ebioscience) as well as α4β7 integrin (LPAM-1, clone DATK32) purchased from BD 
Pharmingen and examined on a Becton Dickinson Facscaliber Flow cytometer.  Stained cells 
were analyzed using Cellquest software. 
Enzyme Linked Immunosorbant Assay (ELISA). ELISAs for influenza- and OVA-
specific antibodies were performed on serum, fecal extracts, vaginal washes, and lymphoid 
culture supernatants as previously described (70).   Briefly, antigen solutions (either 250 
ng/ml of influenza virus in carbonate buffer, or 1 mg/ml of OVA in PBS) were incubated in 
96-well plates (NUNC Immulon 4) overnight at 4°C to allow antigens to bind to the plate. 
Excess antigen was removed, and blocking solution [PBS containing 5% milk for flu, or 1× 
Sigmablock (Sigma) for OVA] was added for 2 h for flu or overnight for OVA at room 
temperature. Following removal of blocking solution, plates were incubated at room 
temperature for 2 h (flu) or overnight (OVA) with serial dilutions of individual samples 
diluted in the appropriate blocking buffer. Plates were washed with a multi-channel plate 
washer (NUNC) and incubated for 1 h with horseradish peroxidase-conjugated secondary 
goat anti-mouse γ or α chain-specific antibodies (Southern Biotechnology Associates or 
Sigma). Finally, plates were again washed, O-phenylenediamine dihydrochloride substrate 
was added for 30 min, and the reaction was stopped with the addition of 0.1 M NaF. 
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Antibody endpoint titers are reported as the reciprocal of the highest dilution that resulted in 
an OD450 ≥ 0.2. In lymphoid culture supernatants, endpoint titers for flu-specific IgA are 
reported as the reciprocal of the highest dilution that results in an OD450 reading at least 2 
SDs greater than values obtained from mock-vaccinated animals (figure 1). Data are 
presented as the geometric mean ± standard error of the mean (SEM). 
Analysis of Polymeric IgA.  Lymph node (popliteal and PP) extracts were assayed for the 
presence of polymeric IgA antibodies by non-reducing western blot analysis.  Proteins were 
separated in Laemmli buffer in the absence of reducing agent (no β-ME) by 6% SDS-PAGE 
and transferred to polyvinlyidene difluoride membrane (Bio-Rad) in transfer buffer (48mM 
Tris, 39mM Glycine, 10% Methanol) at 12V for 1 hour.  Membranes were subsequently 
blocked in PBS with 5% dry milk, 0.1% Tween-20 (Sigma) at room temperature overnight.  
Blocked membranes were next washed in PBS with 1% dry milk, 0.1% Tween-20 and 
incubated with a goat anti-IgA antibody (Sigma and/or Southern Biotechnology Associates) 
at room temperature for 2 hours.  Membranes were again washed and then incubated with a 
rabbit anti-goat horseradish peroxidase (HRP)-conjugated secondary antibody (Sigma) at 
room temperature for 1 hour.  Membranes were washed again, and HRP-conjugated 
antibodies were detected via chemiluminesence with ECL detection reagents (Amersham 
Pharmacia).  For analysis of influenza-specific, polymeric IgA, lymphoid culture 
supernatants or lymph node extracts were mixed with either influenza virus or an irrelevant 
virus (Girdwood virus) for 2 hours at 4ºC, and virus-antibody complexes were centrifuged at 
100,000 x g for 1 hour through a sucrose cushion.  Pelleted virus-antibody complexes were 
resuspended in non-reducing sample buffer and analyzed by IgA western blotting as 
described above.   
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Statistical Analysis. Antibody titers and cytokine values were evaluated for statistically 
significant differences by either the ANOVA or Mann-Whitney test (GraphPad INSTAT). A P 
value of ≤0.05 was considered significant. 
Immunofluoresent staining of DLNs.  To examine the addressin profile present in the DLN 
of immunized animals, DLNs were harvested, snap frozen in liquid nitrogen and sectioned.  
Frozen sections were stained with antibodies against PNAd and MAdCAM-1 as previously 
described (67, 73) and analyzed by confocal microscopy (Zeiss LSM510; Oberkochen, 
Germany). 
Cytokine/Chemokine analysis  PBS homogenates of lymph nodes (see above) were 
analyzed for the presence of IL-1β, TNF-α, IL-5, IL-6, IFN-γ, RANTES, GM-CSF, MIP-1 β, 
TGF-β1, TGF-β2, and TGF-β3 on a Luminex machine.  Samples were analyzed by the 
Upstate/Millipore Custom Multiplex cytokine analysis service.  DLN samples were diluted 
1:10 in PBS plus PIs (see above) and were analyzed by Upstate.  At least 4 individual lymph 
nodes for each inoculaum and timepoint were analyzed.  For statistical purposes, any analyte 
with a value below the assay limit of detection (LOD) was assigned a value of the LOD 
minus 1 pg/ml.   
 
 
RESULTS 
 
The DLN is an early site of IgA production following VRP infection.  In this study we 
have utilized nonmucosal delivery of VRP to probe the cellular components and molecular 
basis of an alternative pathway for mucosal immune induction.  IgA antibodies are the most 
prominent antibodies present at mucosal surfaces in both small rodents and humans, and 
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represent a critical component of the mucosal immune system (52).  Therefore, the kinetics 
and anatomical localization of IgA production following VRP delivery were determined. 
Groups of female BALB/c mice were immunized in a rear footpad at week 0 and 
week 4 with diluent, 1x105 infectious units (IU) of HA-VRP, or 10 µg of formalin-
inactivated-influenza virus (I-Flu) which serves as a non-VRP-vectored antigen control.  In 
order to evaluate the ability of VRP to induce mucosal immunity to a co-delivered antigen, 
an additional group of animals received 10 µg of I-Flu mixed with 1x105 IU of VRP 
expressing green fluorescent protein (GFP) as an adjuvant (GFP-VRP).  Groups of 3 animals 
were sacrificed on days 3, 7, 14, and 28 post-boost, and lymphoid organ cultures (45, 70) 
were established from the spleen, as a characteristic systemic lymphoid tissue, the nasal 
epithelium, as a characteristic mucosal surface, as well as the draining popliteal lymph node, 
as a candidate component of an alternative mucosal immune induction pathway.  Organ 
culture supernatants were evaluated for the presence of influenza (flu)-specific IgG and IgA 
antibodies by ELISA.  In general, the appearance of flu-specific IgG and IgA antibodies in a 
given tissue were similar in terms of kinetics of induction (Fig 3-1).  The dose of I-Flu 
utilized in this study (10 µg) was chosen so as to induce an antigen-specific systemic IgG 
response similar to that of HA-VRP, allowing assessment of the role of VRP in IgA 
production under conditions of equivalent overall immune stimulation.  Following delivery 
of I-Flu alone, flu-specific IgG (Fig. 3-1A) and IgA (Fig 3-1B) antibodies were detectable in 
spleen organ culture supernatants, however, flu-specific IgA antibodies were significantly 
increased following either delivery of HA-VRP or when GFP-VRP were co-administered 
with I-Flu.    Likewise, significantly increased flu-specific IgG (Fig. 3-1C) and IgA (Fig. 3-
1D) antibodies also were detected in the nasal epithelium of animals immunized with VRP-
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containing inocula.  Flu-specific IgG (Fig. 3-1E) and IgA (Fig. 3-1F) antibodies also were 
detected in the supernatants from the DLN following delivery of antigen alone.  These values 
were again significantly increased in animals immunized with VRP as expression vectors and 
as adjuvants.  Taken together, these results further validate the use of VRP as both expression 
vectors and adjuvants for the induction of pathogen-specific immunity 
Additionally, in this study we sought to determine the anatomical location in which 
IgA antibodies were first produced in VRP-immunized animals.  Flu-specific IgA antibody 
responses peaked in the DLN at day 3 post-boost (Fig. 3-1F), a time at which  such 
antibodies were essentially undetectable at the mucosal surface (Fig 3-1D).  These results 
suggest that VRP-induced IgA production occurs in the DLN prior to production at mucosal 
surfaces and provides a foundation for the further study of VRP-stimulated IgA synthesis in 
the DLN in the context of mucosal immune induction. 
The data presented in figure 3-1 suggested that IgA antibodies were produced in the 
DLN following VRP delivery, and that such production was dependent upon signals 
provided by the VRP and/or VRP infection, as equivalent levels of antigen-specific IgA 
antibodies were not produced in the DLN following delivery of antigen alone.  However, the 
issue of whether DLN IgA antibodies are produced in vivo in the absence of ex vivo culture 
was not addressed in the previous study.  Therefore, groups of female BALB/c mice were 
immunized in a rear footpad at week 0 and week 4 with 1 µg I-Flu alone, or 1 µg I-Flu alone 
co-delivered with 1x105 IU of null VRP.  Null VRP genomes express the viral nonstructural 
genes which drive RNA replication.  However, they do not encode a heterologous transgene 
downstream of the subgenomic promoter, but nevertheless provide a strong adjuvant signal 
(70).  To evaluate the kinetics of IgA synthesis following VRP delivery in the absence of ex 
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vivo culture, DLNs were harvested at day 1, 3, 7, and 14 post-boost, and homogenized in 0.1 
mls of PBS.  Supernatants were evaluated for the presence of flu-specific IgA antibodies by 
ELISA.  Fecal extracts also were prepared from immunized animals as a measure of mucosal 
immune induction (28, 70).  As demonstrated in figure 3-2, antigen-specific IgA antibodies 
were in fact produced in the DLN in vivo; and were detectable in DLN homogenates (Fig 3-
2A).  IgA antibody levels peaked at day 3 post-boost, similar to the kinetics of IgA 
production in the DLN in the lymphoid culture system, and likewise decreased over the 
timecourse.  Conversely, antigen-specific IgA antibodies peaked in fecal extracts at day 7 
post-boost, a time after peak production in the DLN (Fig 3-2B).   
The contribution of components of the conventional pathway for the mucosal immune 
induction also were evaluated in the VRP system.  As a first step, we harvested a single PP 
from each of six individual animals and prepared PBS homogenates as described for DLNs.  
PP homogenates were evaluated for the presence of flu-specific antibodies by ELISA; 
however, the mean values produced in PP homogenates at all four timepoints tested were 
below the limits of detection of the ELISA assay, and were not statistically distinct from the 
assay background (Fig 3-2C).  Taken together, these results suggest that antigen-specific IgA 
antibodies are produced in vivo in the DLN prior to production at mucosal surfaces following 
stimulation of the alternative pathway by VRP. 
VRP stimulate high molecular weight IgA antibody production in the DLN.    IgA-
producing B cells in the mucosal lamina propria secrete large amounts of dimeric or 
polymeric forms of IgA, a defining characteristic of IgA antibodies produced at mucosal 
surfaces (52).  IgA dimer/polymer formation is mediated by the inclusion of the J chain 
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protein during antibody secretion.  Thus, mucosal IgA antibodies are high molecular weight 
antibodies as a result of J chain incorporation (32). 
 While delivery of VRP-containing inocula clearly increased the levels of antigen-
specific-IgA antibodies produced in the DLN, antigen-specific IgA antibodies also were 
produced at detectable levels following delivery of I-Flu alone.  Based on the idea that 
mucosal IgA antibodies are polymeric, the molecular size of the IgA species produced in the 
DLN was determined following delivery of both VRP and non-VRP inocula.  Monomeric 
IgA antibodies run at a molecular weight of approximately 150 kilodaltons (kDa) (2 heavy 
chains of 50 kDa, and 2 light chains of 25 kDa), while polymeric IgA molecules have a 
molecular weight of 300 kDa or higher (32).  Supernatants from day 3 DLN cultures were 
analyzed by SDS-PAGE under non-reducing conditions for the presence of IgA antibodies.  
As shown in Figure 3-3A, the IgA antibodies in the DLN following delivery of I-Flu alone 
were predominantly monomeric, with a molecular weight of approximately 160 kDa.  
Interestingly, the delivery of both HA-VRP and I-Flu in the presence of a VRP adjuvant 
resulted in the production of monomeric forms of DLN IgA as well as large molecular 
weight (greater than 250 kDa) forms not present at substantial levels following delivery of 
antigen alone.  IgA antibodies were not produced in the contralateral popliteal lymph node.    
To determine whether VRP-induced high molecular weight IgA antibodies were 
specific for the influenza antigen, day 3 DLN supernatants were incubated with influenza 
virus, or an irrelevant virus (Girdwood virus) to allow the formation of virus-antibody 
complexes.  The complexes were pelleted through a sucrose cushion by ultracentrifugation.  
This procedure utilized co-sedimentation of influenza virions as a means to affinity purify 
virus-specific antibodies from non-flu-specific antibodies prior to western blot analysis.  As 
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shown in figure 3-3B, the flu-specific IgA antibodies present in the DLN following delivery 
of I-Flu were predominantly monomeric.  Immunization with either HA-VRP or I-Flu plus 
GFP-VRP resulted in the production of both a monomeric species of flu-specific IgA, as well 
as two high molecular weight forms not present at appreciable levels following delivery of I-
flu alone.  Taken together, these results suggest that VRP provide a signal which promotes 
the production of high molecular weight IgA molecules in the DLN. 
While production of polymeric forms of IgA in the DLN was clearly dependent upon 
the presence of the VRP, the question of whether such antibodies are produced in the DLN in 
vivo was not evaluated in the preceding study.  To evaluate the presence of polymeric IgA 
antibodies in the DLN in vivo, groups of female BALB/c mice were immunized at week 0 
and week 4 with 10 µg OVA alone, or OVA mixed with either 1x105 IU of null VRP or 1 µg 
of CpG DNA.  At day 3 post-boost, DLNs were harvested, and homogenates in PBS were 
prepared.  Homogenates were evaluated for the presence of IgA antibodies by non-reducing 
western blot analysis as described above.  As shown if figure 3-3C, IgA antibodies were not 
detectable in the DLN following delivery of OVA alone or following co-delivery of OVA 
with CpG DNA.  In contrast, both monomeric and dimeric forms of IgA were produced in 
the VRP DLN, suggesting that high molecular weight IgA antibodies are in fact produced in 
the DLN in vivo.   
Antigen stimulation is required for DLN polymeric IgA production.  To determine 
whether the production of polymeric IgA antibodies in the DLN was dependent upon 
exogenous antigen stimulation, or if antigens naturally present in the DLN have the capacity 
to promote IgA production during a concomitant VRP infection an additional experiment was 
performed.  Groups of female BALB/c mice were immunized at week 0 and week 4 with 10 
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µg OVA alone, 10 µg of OVA mixed 1x105 IU of null VRP, PBS, or 1x105 IU of null VRP 
alone and DLN homogenates in PBS were prepared at day 3 post-boost and analyzed for the 
presence of IgA by western blot under non-reducing conditions.  As shown in figure 3-4, 
VRP induced the production of both monomeric and polymeric forms of IgA following co-
delivery with antigen.  In contrast, only a monomeric species was present following delivery 
of the same VRP in the absence of exogenous antigen, suggesting that antigenic stimulation, 
in addition to VRP infection is required to promote polymeric IgA synthesis in the DLN. 
Characterization of DLN cells following VRP delivery.  The fact that the DLN appeared to 
serve as the earliest site of IgA production, and high molecular weight antigen-specific IgA 
was synthesized there following VRP delivery, led us to further characterize the general 
characteristics of the DLN under these conditions.  The overall mass of the DLN, as a general 
marker of inflammation as well as the global cellularity of the DLN were determined.  
Groups of animals were immunized with 1 µg of I-Flu alone, 1 µg of I-Flu mixed with 1x105 
IU null VRP, or 1x105 IU null VRP alone, and DLNs were harvested at days 0, 1, and 3 post-
boost.  DLNs were carefully weighed on an analytical balance to determine overall mass, and 
single cell suspensions were created by collagenase digestion.  Total cell counts were 
performed by trypan blue exclusion, and cells were analyzed by flow cytometry for the 
presence of B cells, T cells, and dendritic cells (DCs) following staining with antibodies 
directed against the appropriate cell surface markers (CD19, CD3, and CDllc respectively).  
As shown in figure 3-5A, VRP delivery in the presence or absence of co-delivered antigen 
resulted in a 2-4 fold increase in the overall mass of the DLN depending upon the timepoint 
examined.  Moreover, the total cellularity of the VRP DLN was increased by 4-6 fold (Fig 3-
5B).  The increase in cellularity most likely represents a significant proportion of the 
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increased mass of the lymph node.  This is of interest as Soderberg et al. recently 
demonstrated that viral signals increase arterial blood feed to inflamed lymph nodes, which 
also would result in a lymph node with increased mass (68).   VRP induced a proportional 3-
10 fold increase in B cells, T cells, and CD11c positive, CD11b negative DCs in the DLN at 
days 1 and 3 post-boost (Fig 3-5C-3-5E). Conversely, VRP infection led to an approximately 
20-40 fold increase in the number of CD11c positive, CD11b positive DCs in the DLN at 
days 1 and 3 post-boost, both in the presence and absence of exogenous antigen (Fig 3-5F).  
These results suggest that VRP delivery results in a significant increase of numerous cell 
types to the inflamed DLN independent of exogenous antigen delivery, as well as a 
preferential recruitment of a CD11b positive DC subset to the DLN. 
VRP induce the expression of the mucosal homing receptor on DLN B cells.  Analysis of 
the kinetics of IgA synthesis following VRP delivery suggested that the DLN serves as one 
of the earliest sites of IgA production following VRP immunization, and that a significant 
portion of DLN IgA displayed characteristics typical of mucosal IgA antibodies.  
Additionally, VRP induced a significant increase in the number of B cells present within the 
DLN concomitant with IgA production.  Here we sought to further characterize the 
phenotype of DLN B cells for markers characteristic of mucosal B cells.  A number of 
investigators have demonstrated that the α4β7 integrin, also known as the mucosal homing 
receptor, plays a significant role in licensing lymphocyte migration into the mucosal 
compartment, especially in the gut (9). This heterodimeric integrin binds to mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1) expressed on the high endothelial venules 
of mucosal lymphoid structures such as Peyer’s patches and the mesenteric lymph node, and 
retains α4β7 positive cells at the mucosal surface (4).   Therefore, we wanted to determine 
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whether B cells present in the DLN following nonmucosal VRP delivery expressed the α4β7 
integrin.   
  Groups of female BALB/c mice were immunized in a rear footpad at week 0 and 
week 4 with 10 µg OVA alone or co-inoculated with 1x105 IU null VRP, and DLNs were 
harvested at day 1 and day 3 post-boost.  Single cell suspensions were generated by 
collagenase digestion, and DLN B cells were analyzed for expression of CD19, B220, and 
the α4β7 integrin by flow cytometry.  Additionally, single cell suspensions prepared from the 
MLN were also analyzed as a representative mucosal lymphoid tissue.  As shown in figure 3-
6A, the α4β7 integrin was in fact expressed to similar levels on B cells isolated from the 
mesenteric lymph node at both day 1 and day 3, regardless of the immunizing inoculum.  
Analysis of DLN B cells revealed two populations of B cells according to B220 expression 
levels; a B220 high, CD19 high population, and a B220 low, CD19 high population.  
Expression levels of the α4β7 integrin were analyzed on both populations at day 1 and day 3 
post-boost.  As shown in figure 3-6B, a small B220 low population of B cells was present in 
the DLN of animals inoculated with OVA alone at day 1 post-boost.  Increased α4β7 integrin 
expression was observed in a subset of these B220 low B cells (see inset).  Delivery of OVA 
in the presence of VRP resulted in a significantly increased population of B220 low B cells 
with upregulated α4β7 integrin expression at day 1 post-boost.  The α4β7 integrin levels were 
comparable to those of MLN B cells.  Interestingly, while a B220 high population was still 
present in the DLN following delivery of OVA in the presence and absence of VRP at day 3 
post-boost, this population of cells no longer expressed increased levels of the α4β7 integrin.  
Increased α4β7 integrin expression was detected on a subset of B220 high B cells at day 3 
following delivery of OVA alone.  
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 To determine the proportion of B220 low DLN B cells with upregulated α4β7 integrin 
expression, as well as to evaluate the role of exogenous antigen delivery in the activation of 
mucosal homing receptor, an additional experiment was performed.  Groups of mice were 
immunized at week 0 and week 4 with 1 µg of I-Flu alone, 1 µg of I-Flu plus 1x105 IU null 
VRP, or 1x105 IU null VRP alon, and α4β7 integrin expression was evaluated on DLN B cells 
at days 0 (prior to boost), 1, and 3 post-boost.  As shown in figure 3-6C, α4β7 integrin 
expression was induced only in the B220 low population at day 1 post-boost and was again 
undetectable at day 3.  Moreover, VRP induced an upregulation of the α4β7 integrin either 
when co-inoculated with a viral antigen or when delivered in the absence of any exogenous 
antigen, suggesting that the signals which drive increased mucosal homing receptor 
expression are provided exclusively by the VRP.   Taken together, these results suggest that 
peripheral inoculation of VRP results in a mucosal homing profile of DLN B cells that is 
similar to the homing profile of B cells isolated from mucosal lymphoid tissues (MLN). 
VRP induce MAdCAM-1 expression on the HEVs of the DLN.  MAdCAM-1 expression 
is characteristic of mucosal lymphoid tissues, and this marker also was present in the DLN of 
mice immunized with VRP.  Female BALB/c mice were immunized in both rear footpads 
with 1 µg of I-Flu alone, 1 µg of I-Flu plus 1x105 IU null VRP, or 1 µg of I-Flu plus 1 µg of 
CpG DNA at weeks 0 and 4.  DLNs were harvested from immunized animals at day 1, day 2, 
and day 3 post-boost, snap frozen in liquid nitrogen, sectioned, and analyzed for expression 
of MAdCAM-1 and peripheral lymph node addressin (PNAd) by confocal microscopy (67, 
73)  PNAd is expressed on the HEV of systemic and mucosal lymphoid tissues and binds to 
CD62L, or L-selectin (2, 9).  Sections derived from MLN served as a mucosal lymphoid 
tissue positive control.  As expected, expression of both PNAd (green) and MAdCAM-1 
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(red) were readily detectable on the HEV of the MLN, including double positive cells 
(yellow, figure 3-7A).  PNAd staining was abundant in the DLN following delivery of I-Flu 
alone at all timepoints examined, consistent with a systemic lymphoid tissue phenotype.  
Interestingly, MAdCAM-1 expression was detected in the DLN following delivery of I-Flu 
in the presence of VRP beginning at day 2 post-boost, with increased expression at day 3 
post-boost.  Analysis of MAdCAM-1 staining suggested that endothelial cells lining the HEV 
upregulated MAdCAM-1, similar to expression in mucosal lymphoid tissues, such as the 
MLN (figure 3-7C).  Both “1st type” staining, in which a single cell inside the vessel is 
detected (these cells could be endothelial cells), as well as “2nd type,” in which MAdCAM-1 
is clearly expressed by the endothelial cells is appearant in the VRP DLN (figure 3-7C).  
Positive staining was also detected in the DLN following delivery of I-Flu plus CpG DNA at 
day 3, however to a lesser extent.  These results suggest that stimulation of an alternative 
mucosal inductive pathway by VRP results in an HEV profile in the DLN which is distinct 
from traditional systemic lymphoid tissues, but instead more accurately resembles the profile 
of mucosal lymph nodes.   
VRP drive mucosal cytokine/chemokine production in the DLN.   Mucosal antigen 
delivery in the presence of a number of important cytokines and chemokines significantly 
augments mucosal antibody and T cell responses (reviewed in (51).  As VRP induced a 
mucosal phenotype in the DLN in terms of IgA antibody production, homing receptor 
expression, and addressin profile, the cytokine/chemokine profile in the DLN following VRP 
infection was analyzed for mucosally-relevant lymphokines.  Groups of female BALB/c mice 
were immunized in the rear footpads at week 0 and week 4 with 10 µg of OVA alone, 10 µg 
of OVA co-inoculated with 1x105 IU null VRP, or 10 µg of OVA plus 1 µg of CpG DNA 
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and DLNs were harvested at 6 hrs, 12 hrs, and 24 hrs post-boost. DLN homogenates in PBS 
were prepared as described above.  Homogenates were analyzed for expression of IL-1β, IL-
5, IL-6, TNF-α, IFN-γ, MIP-1β, RANTES, TBF-β1, 2, and 3 in a LUMINEX assay by 
UPSTATE/Millipore (figure 3-8).  In general, VRP-induced cytokine/chemokine production 
peaked at 6 hrs post-boost and decreased over the timecourse.  However, subtle differences 
existed between the kinetics of expression of the individual proteins.  The inclusion of VRP 
in the inoculum significantly increased expression of IL-1β (11 fold), IL-5 (3.5 fold), IL-6 
(16.5 fold), TNF-α (7 fold), IFN-γ (5 fold), MIP-1β (27 fold), and RANTES (6.5 fold) at the 
6 hr and/or 12 hr timepoints compared to delivery of antigen alone.  Although significant 
levels of all 3 subtypes of TGF-β were present in the DLN at 6 hrs, VRP infection did not 
induce a statistically significant increase in these proteins, and responses were quite variable 
(data not shown).  This analysis suggests that VRP significantly augment the production of 
numerous mucosally-relevant cytokines and chemokines in the DLN compared with 
immunization with antigen alone. 
 
DISCUSSION 
Of the infectious agents causing morbidity and mortality in humans, the 
overwhelming majority, including HIV, initiate infection at a mucosal surface.  While the 
correlates of protection differ with individual diseases, it is logical that induction of immune 
responses active at the site of virus challenge would represent a substantial obstacle to 
infection (44, 66), and that the induction of mucosal immune responses by vaccination has 
the potential to dramatically curtail the spread of mucosal pathogens.  Therefore, an 
understanding of the basic parameters which regulate mucosal immune induction in the 
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numerous existing experimental systems represents a meaningful accomplishment, and may 
considerably promote the efficacy of mucosal vaccines. 
 An extensive body of work supports the notion that the strongest mucosal immune 
responses are present following mucosal antigen delivery and antigen processing in the 
specialized mucosal lymphoid tissues lining the various mucosal surfaces (57).  The strongest 
support for this comes from studies of mucosal antibody and T cell activation which have 
revealed the components and the immune inductive requirements of the natural pathway of 
mucosal immune induction.  It has been suggested that mucosal delivery of foreign antigens  
in the presence of bacterial enterotoxins such as cholera toxin and labile toxin (20, 61) is 
required for the stimulation of the natural pathway of mucosal immune induction.  However, 
it has become increasingly clear that nonmucosal antigen delivery also can result in mucosal 
immune induction under specific conditions.  The molecular mechanisms which regulate 
peripherally-induced mucosal immunity are poorly understood at present.  The examples are 
varied and suggest either a consistent unifying mechanism is responsible for such induction 
under all circumstances, or conversely, that numerous diverse signals have the capacity to 
drive mucosal immunity following nonmucosal delivery.   
It is possible that mucosal immune induction following nonmucosal delivery is 
merely a result of stimulating components of the natural pathway, such as has been proposed 
by McKenzie et al., following peripheral delivery of anti-MAdCAM-1 antibodies (50).  
Conversely, mucosal immune induction following nonmucosal delivery may be a result of 
stimulation of an alternative pathway for mucosal immune induction; a pathway with 
components distinct from those of the natural pathway.  A third possibility is that specific 
vaccine signals promote the generation of a “mucosal-like” site outside of the mucosal 
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compartment.  We hypothesize that this is the mechanism by which VRP promote mucosal 
immune induction following nonmucosal delivery, as several characteristics of mucosal 
lymphoid tissues are observed in the DLN of VRP-immunized mice.   
 We feel that the combined examples of mucosal immune induction following 
nonmucosal delivery in the literature support the notion that other immunizations, other than 
VRP also stimulate an alternative pathway (5, 11, 14, 17, 19, 22, 27, 28, 36, 37, 42, 45, 55, 
58, 59, 71).  In order to test the “conversion” hypothesis in the VRP system, we first sought 
to determine the anatomical location in which IgA antibodies are produced following VRP 
delivery.  Such analysis revealed that antigen-specific IgA antibodies were first detected in 
the popliteal lymph node draining the site of VRP infection, prior to antibody production at 
mucosal surfaces. Moreover, further characterization of DLN IgA antibodies revealed the 
presence of polymeric forms present in the DLN.  Such antibodies are typically absent from 
systemic lymphoid tissues, and instead found at mucosal lymphoid sites.  These results are 
supportive of a model in which the DLN serves as the primary inductive tissue for the 
activation of mucosal immune responses following footpad VRP delivery.   
 The peripheral draining lymph node has been implicated in three other models of 
mucosal immune activation following nonmucosal delivery.  Enioutina et al. demonstrated 
the presence of IgA antibodies at multiple mucosal surfaces following co-delivery of antigen 
in the presence o the active form of vitamin D3 (22).  Interestingly, IgA-producing cells were 
also present in the DLN following vitamin D delivery; however, the presence of polymeric 
IgA was not evaluated in that study.  Following intramuscular rotavirus delivery, cells 
isolated from the draining lymph node induced gut IgA and IgG responses following 
adoptive transfer into naïve recipients (13).  An additional approach, further implicates a 
 145
peripheral lymph node as a component of the alternative pathway.  In targeted lymph node 
immunizations, antigens are inoculated directly into the lymph node itself, promoting antigen 
acquisition and processing by lymph node resident cells.  This inoculation regimen induces 
IgA antibody synthesis in the local inoculated lymph node as well as in mucosal secretions in 
the absence of antigen processing in other peripheral lymphoid structures (42).  The precise 
mechanism underlying mucosal immune induction in this system remains elusive.  However, 
Lehner et al. demonstrated antigen-specific IgA antibody production in the targeted lymph 
node and proposed that the affected lymph node in fact serves as an inductive site for the 
generation of cells with protective properties at the local mucosal surface (43).  These 
examples, together with the data presented here in the VRP system, are consistent with a 
model in which the DLN serves as an integral component of an alternative pathway for 
mucosal immune induction. 
The role of the DLN in mucosal immune induction in the VRP system may derive 
from the cell populations induced in or recruited to the DLN.  The DLN contains numerous 
cell types and a significant increase in B cells, T cells, and DCs occurs in the VRP-infected 
DLN.   It was of interest that VRP infection resulted in a significant increase in the number 
of B cells present in the DLN, as IgG and IgA antibodies were also present in the DLN.  
Further characterization revealed a population of B cells which express the α4β7 integrin in 
the DLN.  This observation is significant as α4β7 integrin expression is thought to be 
restricted to cells activated at a mucosal surface, and represents a characteristic marker of 
mucosal lymphocytes (9).  These results potentially implicate the mucosal homing receptor 
in the alternative pathway for mucosal immune induction and suggest that components of the 
alternative pathway, α4β7-MAdCAM-1 interactions, overlap with the natural pathway.   It is 
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important to consider the commonalities between the natural and alternative pathways within 
the VRP experimental system, as well as the commonalities in the alternative pathway 
amongst the various examples of peripherally-induced mucosal immunity. 
It is attractive to speculate that VRP infection provides a specific signal leading to 
increased mucosal homing receptor expression on DLN B cells, and as a result, such cells 
eventually migrate to the mucosal surface where they continue to secrete antigen-specific 
IgG and IgA antibodies.  It will be important to determine definitively the relationship 
between the α4β7 positive DLN B cells and the B cells secreting antigen-specific antibodies at 
the mucosal surface some days later.  The exact viral signal responsible for α4β7 integrin 
upregulation remains undefined to date; however, data presented here suggest that the signal 
is antigen-independent, as increased α4β7 integrin expression was observed following 
delivery of both antigen plus null VRP and null VRP alone.   
  The observation that DLN B cells harbor a mucosal homing phenotype provides a 
potential mechanistic explanation for the inclusion of the DLN in the alternative pathway for 
mucosal immune induction.  However, whether α4β7 integrin positive B cells are generated in 
the DLN or are recruited to the DLN from another site remains to be determined.  The ligand 
for the α4β7 integrin, MAdCAM-1, also is expressed in the DLN at day 3 post-boost, 
consistent with a model in which the DLN serves as the functional equivalent of a mucosal 
inductive site, and a potential mechanism by which α4β7 integrin positive cells are recruited 
to the VRP DLN.  However, α4β7 integrin expression was detected at day 1 post-boost, a time 
which MAdCAM-1 expression was not detected.  Instead, MAdCAM-1 expression kinetics 
correlated with the kinetics of IgA antibody production in the DLN, suggesting that the 
 147
involvement of MAdCAM-1 may not be in the recruitment of IgA-producing cells to the 
DLN but rather in the retention of such cells in the DLN 
An additional marker of mucosal lymphoid tissues, polymeric IgA antibodies, was 
also detected in the DLN of VRP-immunized animals.  The production of polymeric IgA in 
the DLN again suggests that VRP provide a qualitatively distinct signal driving the 
production of large molecular weight forms of IgA than that provided by antigen alone.  
Whether the viral signal driving polymeric IgA production is the same as the signal for α4β7 
integrin upregulation remains to be fully determined; however, we speculate that such signals 
are distinct, as α4β7 integrin upregulation occurred following VRP delivery in the absence of 
antigen but high molecular weight IgA antibodies were not detected following delivery of 
VRP alone.  Polymeric IgA was produced following delivery of HA-VRP, suggesting that 
specific B cell activation or antigenic stimulation in some fashion is a prerequisite.  It will be 
interesting to determine whether delivery of BCR cross-linking agents in the presence of null 
VRP rescue high molecular weight IgA production. 
 The α4β7 integrin and high molecular weight IgA phenotype in the DLN potentially 
implicate DLN B cells as components of the alternative pathway in the VRP system.  
However, whether DLN B cells are programmed by soluble mediators present in the DLN 
alone or require additional signals provided by other DLN-resident cells is unclear.   As 
presented here, VRP infection resulted in a significant increase in DLN B cells, T cells, and 
DCs.  All cell populations increased in proportion to the total cell increase in the DLN with 
the exception of CDllb+ DCs, which were increased by up to 40 fold.   
A large body of evidence supports the notion that mucosal DCs are qualitatively 
distinct from systemic DCs in terms of their ability to prime mucosally-relevant B cell and T 
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cell responses (18, 34, 54, 69), reviewed in (63).  For example, von Andrian and colleagues 
recently demonstrated that mucosal DCs co-cultured in vitro with CD8 T cells significantly 
increased α4β7 integrin expression on antigen-specific T cells compared to systemic DCs, 
promoting homing to the mucosal surface (53).  Likewise, Sato et al demonstrated the ability 
of mucosal DCs to promote increased IgA synthesis in vitro compared to systemic DCs (62).  
In fact, this ability was mapped to mucosal DC production of IL-6, as mucosal DCs cultured 
in the presence of an anti-IL-6 antibody failed to stimulate IgA production.  VRP infection 
resulted in the production of strong IL-6 responses in the DLN; however, whether DCs, and 
in particular CDllb+ DCs were fully responsible for DLN IL-6 production has not been 
determined.   
Interestingly, the mucosal DCs responsible for driving IgA production in the 
experimental system described by Sato et al. were CDllb+, the same population of DCs that 
were dramatically increased in the DLN of VRP-immunized mice.  Indeed, preliminary 
experiments suggest that the CDllb+ DC population represents the major target of VRP 
infection (data not shown); however, whether these cells represent a migratory population 
originating in the skin or elsewhere, or represent a lymph node-resident population remains 
to be determined.   It is attractive to speculate that VRP not only rely upon the DLN as a 
component of the alternative mucosal immune induction pathway, but that VRP infection 
promotes a “mucosal DC-like” phenotype in DLN CD11b positive DCs, potentially through 
IL-6 production.   It will be interesting to determine if VRP-infected DCs possess the 
capacity to drive both increased α4β7 integrin expression as well as IgA production following 
in vitro lymphocyte co-culture.   
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VRP delivery significantly increased the levels of numerous cytokines and 
chemokines in the DLN, in addition to IL-6, which potentially play a role in the alternative 
mucosal immune induction pathway.  It will be interesting to determine the exact role of such 
cytokine production in directly modulating the DLN mucosal environment.  For example, 
Sikorski et al. demonstrated the ability of both Il-1 and TNF-α to upregulate MAdCAM-1 
expression (64).  Additionally, expression of RANTES and MIP-1β, both of which were 
highly upregulated in the DLN by VRP, correlated with lymph node IgA production in the 
DLN in the targeted lymph node immunization model (43).  The question of which cell type 
is responsible for the DLN proinflammatory response has yet to be determined as many of 
the observed cytokines and chemokines examined in the present study can be secreted by 
numerous cell types which are present in the VRP DLN including endothelial cells, DCs, and 
infiltrating T lymphocytes.  Irrespective of the cell type(s) responsible for the lymph node 
inflammatory environment, we propose that the VRP-induced DLN cytokine milieu is critical 
role for both the mucosal phenotype of the DLN, as well as the VRP-induced mucosal 
immune response.   
The data presented here suggest that the DLN of VRP-inoculated animals develops 
numerous characteristics of a mucosal lymphoid tissue including antigen-specific polymeric 
IgA production, mucosal homing receptor expression, and MAdCAM-1 expression.  
However, it is possible that components of the natural pathway of mucosal immune induction 
also play a role following nonmucosal VRP delivery.  VRP specifically target DCs following 
footpad delivery (46) and it is possible that VRP-infected DCs migrate beyond the DLN to 
PPs and/or MLN following footpad delivery.  These VRP-infected DCs may initiate mucosal 
immune induction following migration to known mucosal inductive tissues as has been 
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proposed following both transcutaneous immunization (3) and antigen delivery in the 
presence of vitamin D3 (21).  However, a series of experiments have failed to experimentally 
support such an hypothesis.  Analysis of PP, MLN, and nasal-associated lymphoid tissue 
following peripheral delivery of GFP-VRP has failed to reproducibly detect VRP-infected 
cells in these tissues (Thompson, Richmond, and Johnston, unpublished).  Additionally, 
antigen-specific antibodies were not detected in PP homogenates from VRP-immunized 
animals under conditions where antigen-specific polymeric IgA was readily detectable in the 
DLN.  Thus, we feel it is unlikely that infection of mucosal lymphoid tissues represents the 
predominant mechanism of immune induction in the VRP system 
In summary, nonmucosal delivery of alphavirus replicon particles has been employed  
as a model system to dissect the organization of an alternative pathway for mucosal immune 
induction.  The draining peripheral lymph node appears to be the central component of this 
pathway, as the VRP-infected DLN produced polymeric forms of IgA, increased mucosal 
cytokines, a population of B cells harboring a mucosal homing phenotype, and ‘mucosal-
like’ HEVs.  Identification of the essential viral and immunological factors which regulate 
mucosal immune induction following nonmucosal VRP delivery may shed new light on an 
alternative pathway for mucosal immune induction.  Moreover, such insights may allow for 
robust stimulation of this alternative pathway, resulting in vaccines with protective efficacy 
against mucosal pathogens and consequent reduced morbidity/mortality associated with such 
infections.   
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Figure 3-1 
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Figure 3-1.  The DLN is an early site of IgA production following VRP infection. 
Groups of BALB/c mice were immunized in the rear footpad with 1x105 IU of HA-VRP, 10 
µg of I-Flu alone, or 10 µg of I-Flu plus 1x105 GFP-VRP at weeks 0 and 4.  At the indicated 
timepoints, lymphoid organ cultures were established from the spleen (A and B), nasal 
epithelium (C and D), and DLN (E and F) and evaluated for the presence of flu specific IgG 
(A, C, E) and IgA antibodies (B, D, F) by ELISA.  Values represent Mean+/- SEM. 
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Figure 3-2 
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Figure 3-2.  VRP induce IgA antibody production in the DLN in vivo.   
Groups of BALB/c mice were immunized in the rear footpad with 1 µg of I-Flu alone, or I-
Flu plus of I-Flu plus 1x105  null VRP at weeks 0 and 4.  At the indicated timepoints, flu-
specific IgA antibodies were evaluated in DLN homogenates (A),  fecal extracts (B), and PP  
homogenates (C) by ELISA.  Values represent Mean+/- SEM. 
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Figure 3-3 
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Figure 3-3.  VRP induce the production of large molecular weight IgA antibodies in the  
DLN.  Groups of BALB/c mice were immunized in the rear footpad with 1x105 IU of HA- 
VRP, 10 µg of I-Flu alone, or 10 µg of I-Flu plus 1x105 GFP-VRP at weeks 0 and 4.  At day  
3 post-boost DLN and contralateral lymph node (CLN) culture supernatants were evaluated  
for IgA antibodies by non-reducing western blot analysis (A).  D3 DLN supernatants were  
then mixed with influenza virus to form virus-antibody complexes and complexes were  
purified via ultracentrifugation prior to non-reducing western blot analysis for IgA (B).   
Groups of BALB/c mice were immunized in the rear footpads with 10 µg of OVA alone, or  
co-inoculated with 1x105 null VRP, or 1 µg of CpG DNA at weeks 0 and 4 and DLNs were  
harvested at day 3 and DLN PBS homogenates were evaluated for IgA antibodies by non- 
reducing western blot analysis as in A (C). 
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Figure 3-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4.  Antigen stimulation is required for DLN polymeric IgA production.  Groups 
of BALB/c mice were immunized in the rear footpads with at weeks 0 and 4 with10 µg of 
OVA, 10 µg of OVA co-inoculated with 1x105 IU of null VRP, PBS, or 1x105 IU of null 
VRP alone.  At day 3 post-boost, DLNs were harvested and PBS extracts were prepared and 
analyzed for the presence of IgA antibodies western blot under non-reducing conditions.   
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Figure 3-5 
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Figure 3-5.  Characterization of VRP DLN cells.  Groups of BALB/c mice were 
immunized in the rear footpads with at weeks 0 and 4 with1 µg of I-Flu alone, 1 µg of I-Flu 
co-inoculated with 1x105 IU of null VRP, or 1x105 IU of null VRP alone.  At day 0, 1, and 3 
post-boost, DLNs were harvested and weighed on an analytical balance and single cell 
suspensions were prepared by collagenase digestion.   The mass of each lymph node was 
determined (A), and total number of cells was determined by trypan blue exclusion (B).  The 
number of B cells (C), T cells (D), CD11b- DCs (E), and CD11b+ DCs (F) was evaluated by 
flow cytometry.    Values are presented as geometric mean +/- SEM.  
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Figure 3-6 
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Figure 3-6 
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Figure 3-6 
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Figure 3-6.  VRP induce the expression of the mucosal homing receptor on DLN B cells.  
Groups of animals were immunized in the rear footpad at weeks 0 and 4 with 10 µg of OVA 
alone of co-inoculated with 1x105 IU null VRP.  At days 1 and 3 post-boost, DLNs were 
harvested and stained with antibodies directed against CD19, B220, and the α4β7 integrin and 
analyzed by flow cytometry.  As a positive control, α4β7 integrin expression was examined on 
mesenteric lymph node (MLN) cells (A).  α4β7 integrin expression in both the B220 high and 
B220 low populations in the DLNs is shown in (B).  To confirm the upregulation of α4β7 
integrin expression specifically in the B220 low population following delivery of a viral 
antigen, α4β7 integrin expression was analyzed on DLN cells at day 0, 1, and 3 post-boost 
following delivery of 1 µg of I-flu alone, 1 µg of I-flu plus 1x105 IU null VRP, or 1x105 IU 
null VRP alone (C).  Values are presented as geometric mean +/- SEM. 
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Figure 3-7 
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Figure 3-7 
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Figure 3-7 
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Figure 3-7.  VRP upregulate MAdCAM-1 in the DLN.   
Groups of female BALB/c mice were immunized with at weeks 0 and 4 with 1 µg of I-Flu  
alone, 1 µg of I-Flu co-inoculated with 1x105 IU of null VRP, or 1 µg of I-Flu co-inoculated  
with 1 µg of CpG DNA and DLNs were harvested and snap frozen in OCT in liquid nitrogen  
at day 1, 2, and 3 post-boost.   MLN (A) and DLN sections were stained with antibodies  
directed against MAdCAM-1 (red) and PNAd (green) analyzed by confocal microscopy and  
visualized at 10 x (B) and 40x (C). 
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Figure 3-8 
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Figure 3-8.  VRP upregulate mucosal cytokine/chemokine production in the DLN.   
Groups of female BALB/c mice were immunized with at weeks 0 and 4 with 10 µg of OVA  
alone, OVA co-inoculated with 1x105 IU of null VRP, or 1 µg of CpG DNA and PBS  
homogenates were created from the DLN at 6 hrs, 12 hrs, and 24 hrs post-boost.  DLN  
homogenates were evaluated for the presence of IL-1β (A), IL-5 (B), IL-6 (C), TNF-α (D),  
IFN-γ (E), MIP-1 α (F), and RANTES (G) via LUMINEX.  Values are presented as  
geometric mean +/- SEM.   
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ABSTRACT 
 Alphavirus replicon particles induce potent antibody and CD8+ T cell responses to 
expressed antigens in numerous experimental systems.  We have recently demonstrated that 
Venezuelan equine encephalitis virus replicon particles (VRP) possess adjuvant activity for 
the activation of systemic and mucosal antibody responses.  In this report, we demonstrate 
that VRP induced a balanced serum IgG subtype response, with simultaneous induction of 
antigen-specific IgG1 and IgG2a antibodies and increased both systemic and mucosal CD8+ 
T cell responses directed towards a co-delivered antigen.  These responses significantly 
delayed the onset of tumor formation following challenge in a B16 melanoma model.  
Additionally, VRP further increased antigen-specific T cell immunity in an additive fashion 
following co-delivery with the TLR ligand, CpG DNA.    Moreover, VRP-induced immune 
activation appeared to function downstream of antigen acquisition/processing, as increased 
immunity also was observed following delivery of VRP with a processed peptide as antigen.  
VRP infection led to recruitment of CD8+ T cells into the mucosal compartment, potentially 
utilizing the mucosal homing receptor, as this integrin was upregulated on CD8+ T cells in 
the draining lymph node of VRP-infected animals.  This represents a novel activity of VRP, 
an adjuvant-mediated increased T cell response towards co-delivered antigen, and provides 
the potential to both define the molecular basis of alphavirus-induced immunity, as well as to 
improve alphavirus-based vaccines.   
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INTRODUCTION 
 Vaccination is the most effective strategy for protection against morbidity and 
mortality associated with numerous infectious agents (3).  The exact immunological 
mechanisms which serve as the critical protective factor/s vary widely depending upon the 
specific pathogen (38).  Likewise, the nature and makeup of the particular vaccine shapes the 
qualitative and quantitative aspects of the host immune response.  In general terms, 
protection is traditionally associated with either the induction of a neutralizing antibody 
response, the induction of a cell mediated immune response, or both (38).  There are a 
number of examples in which the immune correlates of protection has been identified 
[reviewed in (38)]; however, correlates have not been defined for important pathogens, such 
as human immunodeficiency virus (HIV) (23, 31).  Therefore, vaccination regimens capable 
of stimulating both broadly active antibody and cell mediated immunity represent a potential 
opportunity to intercede in the spread of such diseases.   
 Immunogen delivery systems based upon the alphaviruses have proven to be potent 
inducers of both neutralizing antibody responses as well as cell mediated immune responses 
to multiple antigens, including HIV antigens, expressed from the viral genome [reviewed in 
(14, 33, 34, 39, 41, 42, 46)].  The most promising results have come from replicon systems 
based upon Sindbis virus, Semliki forest virus (SFV), and Venezuelan equine encephalitis 
virus (VEE).  All three of these systems are actively under investigation as candidate HIV 
vaccine vectors in several laboratories.  Replicon particles harbor a modified genome; the 
viral non-structural genes which encode the proteins required to replicate the RNA genome 
are expressed from the 5’ two thirds of the genome, while the viral 26S subgenomic promoter 
catalyzes the transcription of the 3’ one third of the genome into a subgenomic mRNA (20).  
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The genome of replication-competent virus contains the viral structural genes, the capsid and 
E1 and E2 glycoprotein genes, expressed from the 26S promoter. This structural gene 
cassette has been replaced with a cloned antigen of interest in the vaccine replicon constructs 
(48).  In order to package replicon genomes into virus-like particles, the replicon RNA is co-
electroporated into permissive cells with two defective helper RNAs which together drive the 
expression of the structural components in trans.  However only the replicon RNA is 
incorporated into replicon particles, as the viral-specific packaging signal is deleted from the 
helper constructs (40).  VEE replicon particles (VRP) are currently under development as an 
HIV vaccine platform in a animal model systems (8, 13, 15, 16, 27).   
 We have recently identified a novel activity of VRP; they act as adjuvants for both 
systemic and mucosal antibody responses to antigens that were simply mixed with VRP that 
encode either an irrelevant or not transgene (49).  VRP significantly increased the systemic 
and mucosal IgG and IgA antibody responses to co-delivered antigen, however; the potential 
to increase T cell activation was not evaluated in that study.  Here we sought to determine 
whether VRP were capable of a T cell adjuvant effect, augmenting T cell mediated immune 
responses to co-delivered antigens.  As mentioned above, VRP induce potent T cell 
activation directed towards antigens expressed from the VRP genome.  When VRP are 
utilized as expression vectors, essentially all antigen positive cells are also VRP positive, and 
vice versa.  Following delivery of antigen mixed with VRP adjuvants, both VRP and antigen 
are likely to be sequestered to the same draining lymph node.  However, antigen may or may 
not be taken up by the same cells as those that are targets of VRP infection.  VRP target 
dendritic cells (DCs) following footpad delivery in mice (35); however, the precise subset of 
DCs that are initially infected has not yet been clearly determined.  Theoretically, it is quite 
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possible that co-delivered antigen could be processed in a very different manner compared to 
VRP-expressed antigen in the context of CD8+ T cell activation. 
CD8+ T cells are activated following presentation of peptide fragments in the context 
of major histocompatibility complex I (MHC I) and co-stimulatory molecule expression on 
antigen presenting cells (APCs) (7).  Understanding the factors which regulate antigen 
processing and presentation is an active area of investigation.  In general terms, endogenous 
cytosolic proteins are degraded by the 26S proteosome and ubiquitin pathways and gain 
access to the endoplasmic reticulum (ER) following transport via the transporter associated 
with antigen processing (TAP) (21).  Once in the ER these peptides are further processed by 
a number of ER-resident proteases, and are loaded into the peptide binding groove in MHC I 
molecules, displacing the peptide binding complex which protects “empty” class I molecules 
(28, 52).  Loaded peptide-MHC (pMHC) complexes are then transported to the cell surface 
for presentation to cognate CD8+ T cells (52).  An additional pathway of exogenous antigen 
loading, termed cross-presentation, also has been identified and involves the presentation of 
exogenous antigens into the class I pathway as a means to induce CD8+ T cell responses 
against pathogens which do not directly infect APCs (11, 44).   
Toll-like receptors (TLRs) are pattern recognition receptors which recognize 
conserved motifs, or pathogen associated molecular patterns (PAMPs) (1).  Recent evidence 
suggests that TLRs play a critical role in shaping both innate and adaptive immune responses 
(18, 26). Delivery of numerous TLR ligands promotes pro-inflammatory cytokine secretion 
and cross-priming (17).  Interestingly, simultaneous delivery of multiple TLR ligands 
synergistically activates both cytokine production and/or cross presentation (4, 37, 45, 51) at 
least in part through the type I interferon (IFN) pathway (17).  In this report we have assessed 
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the ability of VRP, either alone or in combination with a representative TLR ligand (CpG 
DNA), to activate cell-mediated immunity to a co-delivered antigen.  VRP infection 
produced an adjuvant effect, promoting increased CD8+ T cell immunity to co-delivered 
protein antigen, and an additive increase to both protein and peptide antigen in the presence 
of CpG DNA, as measured by IFN-γ secretion and antigen-specific pentamer analysis.  
Moreover, VRP-induced CD8+ T cell activation significantly delayed tumor onset in a B16-
OVA melanoma model.  Interestingly, nonmucosal VRP delivery resulted in a recruitment of 
CD8+ T cells into the mucosal compartment, as well as an increase in expression of the 
mucosal homing receptor on CD8+ T cells in the peripheral draining lymph node (DLN).  
Taken together these results suggest that VRP promote not only increased antibody responses 
(49), but also T cell responses to co-delivered antigens in both the systemic and mucosal 
compartments. 
 
MATERIALS AND METHODS 
VEE replicon constructs.  The VRP constructs utilized in this study were prepared and 
packaged as previously described (12, 40).  Briefly, in vitro-transcribed replicon RNA, along 
with two defective helper RNAs, which drive the expression of the viral structural genes in 
trans, were co-electroporated  into BHK-21 cells.  The viral-specific packaging signal is 
absent from the helper RNAs, therefore, only the replicon RNA is packaged into particles.  In 
this study, we have utilized a replicon which lacks a functional transgene downstream of the 
26S promoter (null VRP) (49).  Null VRP contain the viral nonstructural genes and the 26S 
promoter, a  14 nt stretch of VEE sequence downstream of the 26S mRNA transcription start 
site, a heterologous 43-nt long multiple cloning site, and the 118-nt 3' UTR (49).  Null VRP 
 184
were quantitated by immunocytochemistry of infected BHK cells with sera from mice 
inoculated with null VRP (49).  All replicon particles utilized in this study were packaged in 
the wild-type VEE (V3000) envelope.   
Animals and immunizations.  Seven-to-10-week-old female BALB/c or C57BL/6 mice 
were immunized in a 0.01 ml volume in the rear footpad(s) as previously described (49).  
Briefly, animals were immunized at week 0 and week 4 with antigen alone or antigen co-
inoculated with either VRP or CpG DNA as an adjuvant.   Chicken egg albumin (OVA) was 
purchased from Sigma and CpG DNA (ODN 1826) was purchased from Invivogen.  Diluent 
consisted of low endotoxin, filter-sterilized PBS.  For the peptide immunization experiments 
(presented in Figure 4-4), animals were immunized in both rear footpads in a 0.02 ml volume 
with the class I-restricted OVA peptide (SIINFEKL, New England Peptide) at weeks 0, 4, 
and 8.  Single cell suspensions were prepared from immunized animals 2 weeks following 
the last immunization and were analyzed for the presence of OVA-specific CD8+ T cells by 
IFN-γ ELISPOT and pentamer staining (see below). 
Serum collection.  All sample collection was prepared as previously described (49).  Blood 
was harvested from either the tail vein, following cardiac puncture, or from the 
submandibular plexus from individual animals and sera collected following centrifugation in 
microtainer serum separator tubes (Becton Dickinson).   
Flow Cytometric Analysis.  DLNs were harvested from immunized animals and the overall 
mass of the lymph nodes was determined by weighing individual lymph nodes on an 
analytical balance (Mettler).  Each lymph node was next disrupted with a razor blade and a 
hemostat, and single cell suspensions were created by agitating each lymph node in complete 
RPMI media [RPMI medium 1640 containing 10% (vol/vol) FBS, 2 mM L-glutamine, 50 
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µg/ml gentamicin, 100 units/ml penicillin, 100 µg/ml streptomycin, and 15 mM Hepes] 
containing 2.5 mg/ml Collagenase A (Roche Applied Science), 17 µg/ml DNase I (Roche 
Applied Science) for 30 minutes at 37ºC.  Single cell suspensions were then stained with 
antibodies directed against CD3, CD19, CD45 (B220), CD11c, CD11b (all purchased from 
ebioscience) as well as α4β7 integrin (LPAM-1, clone DATK32) purchased from BD 
Pharmingen and examined on a Becton Dickinson Facscaliber Flow cytometer and analyzed 
using Cellquest software. 
Enzyme Linked Immunosorbant Assay (ELISA). ELISAs for OVA-specific antibodies 
were performed on serum as previously described (49).   Briefly, a 1 mg/ml OVA solution (in 
PBS) was incubated in 96-well plates (Costar) overnight at 4°C to allow antigen to bind to 
the plate. Excess antigen was removed, and blocking solution [PBS 1x Sigmablock (Sigma)] 
was added overnight at room temperature. Following removal of blocking solution, plates 
were incubated at room temperature (RT) overnight with serial dilutions of individual 
samples diluted in the appropriate buffer. Plates were washed with a multi-channel plate 
washer (NUNC) and incubated for 1 hr with horseradish peroxidase-conjugated secondary 
goat anti-mouse IgG1 or IgG2a chain-specific antibodies (Southern Biotechnology 
Associates or Sigma). Finally, plates were again washed, and O-phenylenediamine 
dihydrochloride substrate was added for 30 mins, and the reaction was stopped with the 
addition of 0.1 M NaF. Antibody endpoint titers are reported as the reciprocal of the highest 
dilution that resulted in an OD450 ≥0.2. Data are presented as the geometric mean ± standard 
error of the mean (SEM). 
IFN-γ enzyme-linked immunospot assay (ELISPOT).  To evaluate the presence of OVA-
specific IFN-γ-secreting cells, single cell suspensions were prepared from both spleen and 
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the nasal epithelium.  Whole spleens were disrupted between frosted glass slides, and red 
blood cells were lysed either under hypo-osmotic conditions, or following addition of 
ammonium chloride buffer.  Cells were washed and banded on a Lympholyte-M density 
gradient (Accurate).  Banded cells were harvested, washed and counted. 
Nasal lymphocytes were prepared as previously described (49).  Briefly, nasal tissue 
from the tip of the nose to just anterior of the eye sockets was harvested from immunized 
animals, and the upper palate, including the NALT, was carefully removed prior to further 
processing.  Nasal tissue was physically and enzymatically disrupted by incubation at 37ºC 
for 2 hrs in a 50 ml Erlenmeyer flask in complete R-10 media [RPMI-1640 containing 10% 
(v/v) fetal bovine serum, 2 mM L-glutamine, 50 µg/ml gentamicin, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 15mM HEPES] containing 2.5mg/ml Collagenase A (Roche), 17 
µg/ml DNase I (Roche) and glass beads.  Following digestion, cells were filtered through a 
40 µm cell strainer (BD Falcon), washed, resuspended in 44% Percoll (Amersham) and 
layered on Lympholyte-M as described for spleen cells above.  Banded cells were harvested, 
washed, and counted.  Cells were pooled from two animals and typical yields were 
approximately 2.5x105 to 1x106 cells per animal.  Nitrocellulose membrane plates (96 well; 
Millipore) were incubated with 5 µg/ml of an anti-IFN-γ antibody (AN18, Mabtech) sodium 
bicarbonate buffer (pH 9.6) overnight at 4˚C.  Plates were then washed and blocked for 2 hrs 
with complete R-10 (10% serum) at RT.  Single cell suspensions from either spleen or nasal 
epithelium were then added to plates in duplicate in R-10 and incubated in the presence and 
absence of the class I-restricted OVA peptide (SIINFEKL, New England Peptide) for 24 hrs.  
Cells were removed from plates, plates were washed, a biotinylated anti-IFN-γ antibody (R4-
6A2, 1 µg/ml, Mabtech) was added to the plates, and the plates were incubated for 18 hours 
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at 4˚C.  Membranes were again washed, incubated with a streptavidin-alkaline phosphotase 
conjugate for 2 hrs at RT.  Plates were washed, and spots were developed following addition 
of BCIP/NBT substrate.  Spots were enumerated with a computerized ELISPOT plate reader 
(Immunospot).   Assay background values were obtained following incubation with either no 
peptide or an irrelevant peptide and were subtracted from specific peptide stimulated values.  
Data are presented as the number of antigen-specific IFN-γ-secreting-cells per 106 cells 
plated.  
Intracellular cytokine staining.  Single cell suspensions were prepared from spleen and 
nasal epithelium as described.  2x105 to 2x107 cells were incubated for 6-8 hours in 24 well 
or 48 well tissue culture plates with either media, 2 µg/ml of the class I-restricted OVA  
peptide (SIINFEKL), 2 µg/ml of an irrelevant peptide, or 5 µg/ml conA in the presence of 10 
µg/ml of Brefeldin A.  Cells were then washed and stained with antibodies against 
extracellular markers (CD8, CD4, CD3, etc) for 30 mins.  Cells were washed, fixed and 
permeabilized (Bectin Dickinson cytofix cytoperm), and stained with an antibody against 
IFN-γ (Mabtech).  Cells were washed and stored at 4˚C prior to analysis by flow cytometry. 
Pentamer staining.  Single cell suspensions prepared from animals immunized with the 
class I OVA peptide (SIINFEKL) were analyzed for the presence of OVA-specific cells via 
cell surface staining with antibodies against CD3, CD8, and the Kb-restricted SIINFEKL 
pentamer (Proimmune) according to manufacturer guidelines.  Stained cells were examined 
on a Becton Dickinson Facscaliber Flow cytometer and analyzed using Cellquest software.  
Data are reported as the percentage of CD3+, CD8+ cells which also stain positive with the 
OVA pentamer.  Values are presented as geometric mean +/- SEM. 
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Tumor challenge.  Protective OVA-specific CD8+ T cell responses were analyzed in the 
B16-OVA melanoma system.  Briefly, animals were immunized with OVA and VRP 
constructs as described above, and subsequently challenged subcutaneously with 5 x 104 
B16-OVA tumor cells in the flank.  Animals were examined and scored for the presence of 
tumors.   
Statistical Analysis. Antibody titers and cytokine values were evaluated for statistically 
significant differences by either the ANOVA or Mann-Whitney test (GraphPad INSTAT).  
Results are reported without adjustment for multiple comparisons.  A P value of ≤0.05 was 
considered significant. 
 
 
RESULTS 
 
VRP promote a balanced Th1/Th2 antibody profile.  We have previously demonstrated 
the ability of VRP to increase the systemic and mucosal antibody response to co-delivered 
antigens (Thompson et al., in preparation; (49).  Additionally, both Th1 and Th2 cytokines 
were induced in the VRP-draining lymph node at early times following VRP delivery 
(Thompson et al., in preparation).  Here we have further characterized the antigen-specific 
serum IgG antibody profile for the presence of IgG1 and IgG2a antibodies as an indirect 
measure of the Th1/Th2 cytokine profile following VRP immunization.  Groups of female 
Balb/c mice were immunized in the rear footpad at week 0 and week 4 with 10 µg OVA 
alone, or 10 µg of OVA mixed with either 1x105 IU of null VRP or 1 µg of CpG DNA.  Two 
weeks following the second inoculation, sera were collected and analyzed for the presence of 
OVA-specific IgG antibodies by ELISA.  These results were previously published online as 
supporting information in (49) in a different format, and are reprinted here for clarity.  As 
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shown in figure 4-1A, the inclusion of null VRP in the inoculum increased the OVA-specific 
IgG antibody response by approximately 40 fold.  Delivery of OVA plus CpG DNA as an 
adjuvant likewise induced an approximately 40 fold increase in the systemic IgG antibody 
response.  We next analyzed the same sera for the presence of OVA-specific IgG1 and IgG2a 
antibodies by ELISA.  Delivery of OVA alone resulted in a strong OVA-specific IgG1 
response relative to the IgG2a response, with an IgG1: IgG2a ratio of >20 (Figure 4-1B).  In 
contrast, inclusion of VRP as an adjuvant significantly increased the OVA-specific IgG2a 
response, while still inducing an OVA-specific IgG1 antibody titer similar to that of antigen 
delivery alone.  This resulted in a balanced IgG1: IgG2a ratio of 0.8 (Figure 4-1B).  A similar 
IgG1: IgG2a ratio was observed following delivery of OVA and CpG DNA (0.5), indicating 
a balanced Th1/Th2 response induced by both adjuvants.  These results suggest that VRP 
delivery significantly alters the systemic IgG subtype profile compared to delivery of antigen 
alone, and results in a balanced antibody response with the production of both Th1 and Th2 
IgG profiles (6, 43).   
VRP adjuvant activity for CD8+ T cell responses to co-delivered protein antigen.  As 
mentioned above, robust CD8+ T cell-mediated immune responses are evident following 
delivery of VRP as expression vectors, where the antigen of interest is encoded within the 
viral genome and therefore, expressed in all infected cells.  Here we sought to determine if 
VRP possess the ability to stimulate CD8+ T cell responses to co-delivered antigens.  Groups 
of female C57BL/6 mice were immunized in the rear footpad at week 0 and week 4 with 100 
µg OVA alone, 100 µg of OVA mixed with 1x105 IU of null VRP, 1 µg of CpG DNA, or 
both 1x105 IU of null VRP and 1 µg of CpG DNA simultaneously.  Two weeks following the 
second immunization, animals were sacrificed and single cell suspensions were prepared 
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from the spleen, as a characteristic systemic lymphoid organ, and from the nasal epithelium 
as a characteristic mucosal tissue.  Splenocytes and nasal lymphocytes were evaluated for the 
presence of IFN-γ-secreting cells following stimulation with the class I-restricted OVA 
peptide (SIINFEKL) in an IFN-γ ELISPOT assay.  As shown in figure 4-2, delivery of OVA 
alone resulted in low, but detectable levels of OVA-specific CD8+ T cell responses in both 
the spleen (figure 4-2A) and the nasal epithelium (figure 4-2B).  This response was increased 
approximately 12-fold in the spleen, and 7-fold in the nasal epithelium when VRP were 
included as an adjuvant.  Coimmunization with VRP induced a significant increase in 
antigen-stimulated IFN-γ producing cells compared to immunization with antigen alone in 
both the spleen and the nose (Mann-Whitney, p=0.0286).  CpG DNA also demonstrated an 
adjuvant effect in the systemic and mucosal compartments (Mann-Whitney, p=0.0286).  
When both VRP and CpG were combined as adjuvants, the OVA ELISPOT response was 
increased further, compared to either VRP or CpG DNA alone (Mann-Whitney, p=0.0286).  
Taken together, these results suggest that VRP as an adjuvant increases the CD8+ T cell 
response to soluble protein antigen and that combining VRP and CpG DNA provides and 
additive adjuvant effect. 
Functional activity of VRP-induced CD8+ T cells.  The data presented above, implicate 
VRP in the activation of CD 8 T cells specific for co-delivered antigens.  To determine if the 
T cell response to VRP-adjuvanted antigens was functional in vivo, we employed a B16-
OVA melanoma challenge model.  Groups of female C57BL/6 mice were immunized with 
100 µg of OVA protein alone, either 10 µg of OVA or 100 µg of OVA mixed with 1x105 IU 
of null VRP, or 1x105 IU of null VRP alone at week 0 and week 4.  Two weeks following the 
second inoculation, animals were challenged subcutaneously in the flank with 5 x 104 B16-
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OVA tumor cells and monitored for tumor formation.  As shown in figure 4-3, 100% of the 
animals immunized with either OVA alone, or VRP alone formed palpable tumors by day 25 
post challenge.  However, co-delivery of either the low or high dose of OVA in the presence 
of VRP induced a significant delay in tumor formation, with either 25% of animals (low 
OVA dose) or 50% of animals (high OVA dose) remaining tumor free.  These results suggest 
that VRP in fact induced a CD8+ T cell adjuvant effect in vivo that was functional in tumor 
suppression.     
VRP adjuvant activity for CD8+ T cell responses to co-delivered peptide antigen.  
Potential mechanism(s) by which VRP augmented CD8 T cell immunity include modulating 
antigen acquisition by antigen-presenting cells (APCs), promoting expression of MHC class I 
molecules on APCs, processing of whole protein into the immunogenic peptide fragments, 
enhancing expression of costimulatory molecules on APCs required for robust T cell 
activation, increasing the precursor frequency/activation status of antigen-specific CD8+ 
cells, as well as increasing the precursor frequency/activation status of Th1 CD4+ cells.  As a 
first step characterizing the T cell activation pathway in which VRP and CpG were active, 
the ability of VRP to augment CD8+ T cell responses was examined under experimental 
conditions which do not require antigen processing to individual peptides.  Groups of female 
C57BL/6 mice were immunized in the rear footpad at week 0 and week 4 with  20 µg of 
OVA peptide (SIINFEKL) alonefollowed by a third inoculation of 10 µg of peptide in hopes 
of boosting a CD8+ T cell response with peptide antigen alone.  In addition, mice were 
immunized with OVA peptide in the same amounts, and on the same dosing schedule mixed 
with either 1x105 IU of null VRP, 1 µg of CpG DNA, or both 1x105 IU of null VRP and 1 µg 
of CpG DNA.  Two weeks following the third immunization, animals were sacrificed and 
 192
single cell suspensions were prepared from the spleen and nasal epithelium.  Splenocytes 
were first examined for IFN-γ secretion by ELISPOT.  As shown in figure 4-4A, delivery of 
OVA peptide alone failed to induce a significant IFN-γ response the spleen, as measured by 
IFN- γ ELISPOT.  However, when VRP were co-inoculated with OVA peptide, IFN-γ-
secreting cells were detectable in the spleen at approximately 10-fold higher levels then 
present following delivery of peptide alone (Mann-Whitney, p=0.0286).  A similar increase 
was also observed following use of CpG as an adjuvant.  Moreover, delivery of OVA peptide 
in the presence of both VRP and CpG DNA resulted in a significantly stronger response than 
delivery of either adjuvant alone (Mann-Whitney, p=0.0286).  To further characterize the 
OVA-specific T cell response following peptide delivery, the OVA specific CD8+ T cells 
were evaluated by SIINFEKL/MHC I pentamer analysis.  Delivery of OVA peptide in the 
presence of both VRP and CpG resulted in an increased proportion of OVA-specific CD8+ T 
cells in both the spleen (figure 4-4B) and nasal epithelium (figure 4-4C); however, neither 
adjuvant alone induced a significant increase in antigen-specific cells as compared to OVA 
peptide alone.   Taken together, these results suggest that VRP, either alone or in 
combination with CpG DNA, increase the antigen-specific CD8+ T cell response to a peptide 
antigen.  
Nonmucosal VRP delivery results in increased numbers of mucosal CD8+ T cells.  Our 
initial experiments aimed at evaluating the role of VRP as T cell adjuvants entailed delivery 
of 10 µg of OVA in the presence and/or absence of 1x105 IU null VRP, and subsequent 
evaluation of spenocytes and nasal lymphocytes for the production of IFN-γ by intracellular 
cytokine staining following OVA peptide stimulation.  IFN-γ positive CD8+ T cells were 
detected in the nasal epithelium following low dose OVA administration in the presence of 
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VRP; however, the proportion of IFN-γ positive CD8+ T in the nasal epithelium was not 
significantly increased as compared to responses induced following delivery of OVA alone 
(0.010% +/- 0.004 vs. 0.016% +/- 0.002).   
Although the proportion of OVA-specific IFN-γ+ cells was not increased in the 
presence of VRP, the absolute number of such cells was increased.  Groups of female 
C57BL/6 mice were immunized with 10 µg of OVA in the presence and/or absence of 1x105 
IU null VRP at week 0 and week 4 and lymphocytes were prepared from the upper 
respiratory tract (URT) at two weeks post boost.  Interestingly, the inclusion of VRP in the 
inoculum resulted in a an approximately 5-fold increase in the proportion of viable nasal 
lymphocytes which were CD8+ (figure 4-5) (Mann-Whitney, p=0.0286).  This would result 
in an increase in the absolute number of OVA-specific CD8+ T cells in the nasal mucosa, 
even under conditions where the proportion of OVA-specific IFN-γ-secreting cells was not 
increased.  The proportion of viable spleen cells that were CD8+ was unaffected by VRP 
delivery (data not shown).  These results suggest that CD8+ T cells are recruited into the 
mucosal compartment when VRP are utilized as adjuvants.   
Nonmucosal VRP delivery upregulates the mucosal homing receptor on CD8+ T cells in 
the draining lymph node.  Local production of mucosal IgG and IgA antibodies has been 
demonstrated at multiple mucosal surfaces, including the nasal epithelium, following 
nonmucosal delivery of VRP and antigen (49).  Here we likewise demonstrate the stimulation 
of mucosal CD8+ T cell responses directed towards co-delivered antigen following 
nonmucosal VRP delivery.  VRP-induced IgA antibodies are first produced in the peripheral 
draining lymph node (DLN) following footpad inoculation (Thompson et al., in preparation, 
Chapter 3).  Furthermore, upregulated expression of the α4β7 integrin, or mucosal homing 
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receptor, also was demonstrated on DLN B cells, suggesting a potential mechanism by which 
VRP-activated cells gain access to the mucosal compartment.  In this study, levels of the α4β7 
integrin expressed on T cells present in the DLN were evaluated.  Groups of female Balb/c 
mice were immunized in the rear footpads with 10 µg of OVA in the presence and/or absence 
of 1x105 IU null VRP at week 0 and week 4.  DLNs were harvested at day 1 and day 3 
following the second inoculation (α4β7 integrin expression was upregulated on DLN B cells 
at day 1), and single cell suspensions were created by collagenase digestion.  Single cell 
suspensions were stained with antibodies against CD3, CD4, CD8, and the α4β7 integrin 
(LPAM-1).  As shown in figure 4-6, α4β7 integrin expression was increased on DLN CD8+ T 
cells at day 3 post boost following OVA plus VRP delivery, compared to delivery of OVA 
alone.  In contrast, expression levels of the α4β7 integrin were unchanged on DLN CD4 
positive T cells.  These results suggest that peripheral VRP immunization results in 
upregulation of proteins involved in licensing lymphocyte migration into the mucosal 
compartment.   
 
DISCUSSION 
Cell-mediated immune responses play a crucial role in protecting the host from 
invading pathogens.  Thus, the development of vaccination strategies which are capable of 
activating CD8+ T cells possess the potential to significantly influence the outcome of 
infection with harmful pathogens.  Viruses, and viral vectors induce potent CD8+ T cell-
mediated immunity in a number of experimental systems.  More importantly, gaining a 
mechanistic understanding of both the immunological and virological basis of T cell 
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activation may in the long run allow for the optimization of viral vectors as vaccine delivery 
tools.   
Alphavirus expression vectors based on Sindbis virus, Semliki forest virus, and 
Venezuelan equine encephalitis virus induce strong CD8+ T cell responses against antigens 
which are expressed from the viral genome [reviewed in (14, 33, 34, 39, 41, 42, 46)].  Under 
these conditions, all productively infected cells would also be antigen positive, providing a 
means for virally-expressed proteins/peptide fragments to gain access to the MHC class I 
pathway in the same cells that receive viral activation signals.  Viral signals in general, and 
alphavirus signals specifically (10, 47), appear to stimulate cross priming, or loading of 
exogenous antigens into the class I pathway in DCs.  The activation of cross priming by SFV 
is dependent upon the TLR adaptor molecule MyD88, suggesting that TLR signaling is 
critical for licensing exogenous antigen delivery into the class I pathway.  Production of type 
I IFN, which occurs following TLR ligation, appears to be at least partially responsible for 
viral-induced cross priming (17, 29, 30).   
Here we demonstrate the ability of VRP, as an adjuvant, to induce activation of CD8+ 
T cell responses to a co-delivered antigen.  It is possible that this T cell activation results 
from the interaction of CD8+ T cells with APCs that were both infected by VRP, and had 
taken up exogenous antigen.  VRP are known to upregulate both co-stimulatory molecule 
expression and pro-inflammatory cytokine production in infected human DC cultures (36) 
and promote CD8+ T cell responses to antigens which are encoded in the VRP genome.  
Conversely, as VRP and OVA may target distinct APC subsets, VRP may provide an 
adjuvant signal for CD8+ T cells through the secretion of soluble mediators in the DLN.   
Consistent with this idea, VRP induce the production several inflammatory mediators in the 
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DLN including IFN-β, TNF-α, IL-6, RANTES, and MIP1-β (Thompson et al., in preparation, 
Konopka et al., in preparation).  Virus-induced type I interferon is known to mediate cross-
priming in DCs (30), suggesting a potential mechanism by which VRP may increase CD8+ T 
cell responses to co-delivered antigens. 
We have demonstrated that VRP specifically infect DCs in the lymph node draining 
the infection site (35), and preliminary experiments suggest that CD11b+ DCs represent the 
major target of VEE infection (West, A., Whitmore, A., and Johnston, R., unpublished).  
Interestingly, CD11b+ DCs have been implicated in the induction of Th1 CD4+ T cell 
responses in a number of model systems (19, 25, 53), [reviewed in (24, 26)], raising the 
possibility that VRP-infected CD11b+ DCs promote the activation of CD8+ T cell-mediated 
immunity by driving helper CD4+ T cells towards a Th1 phenotype in vivo.  We have recently 
demonstrated that incubation of peripheral blood mononuclear cells with VRP-infected DCs 
in vitro represents a potent method for expanding antigen-specific CD8+ T cell responses 
(36).  We are currently evaluating the capacity of various subsets of DCs isolated from the 
DLN of VRP-infected animals to stimulate co-cultured, antigen-specific CD8+ T cells, in an 
attempt to define the exact DC subsets involved in immune induction in the VRP system (2, 
5). 
 The increased stimulation of CD8+ T cell responses in the VRP adjuvant system 
could occur at various steps in the activation pathway including enhanced antigen acquisition 
by APCs, increased expression of MHC class I molecules on APCs, enhanced antigen 
processing, increased expression of costimulatory molecules on APCs, increased precursor 
frequency and/or activation status of antigen-specific CD8+ T cells.  While the precise 
explanation has yet to be elucidated, we suggest that VRP potentially act downstream of 
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antigen acquisition and antigen processing, as increased IFN-γ secretion by CD8+ T cells was 
observed following delivery of OVA peptide in the presence of VRP.  This delivery 
circumvents both antigen uptake and processing to the immunogenic peptide, narrowing our 
focus on the events occurring subsequent to peptide loading into MHC molecules following 
delivery of VRP adjuvants.   
Our studies clearly demonstrate that VRP possess intrinsic T cell adjuvant activity; 
however, the question of whether our experimental system is optimized for T cell activation 
has not been fully addressed.  The inoculation regimen utilized in these studies was based 
upon our experience with using VRP to induce serum IgG responses directed against 
expressed antigens.  We have not yet explored the possibility that the optimal dosing 
schedule for the induction of T cell adjuvant activity may be different than that for serum 
antibody responses; such experimentation may allow for the optimization of VRP T cell 
adjuvant activity.  We are actively pursuing methods to augment the VRP T cell adjuvant 
effect. 
One such method has been the utilization of VRP as adjuvants in combination with 
other known T cell adjuvants.  Our studies demonstrated stronger T cell adjuvant effects 
following co-delivery of both VRP and CpG together, as compared to delivery of either 
adjuvant alone.  Synergy has been documented following delivery of multiple TLR agonists 
in terms of either proinflammatory cytokine production or T cell activation  (4, 37, 45, 51).  
However, increased CD8+ T cell responses appeared to be additive as opposed to synergistic 
following co-delivery of VRP and CpG DNA.  One possible explanation of this result that 
VRP induced a more robust stimulation of the signaling pathways which lead to T cell 
activation in the presence of CpG DNA, suggesting that the signaling pathways induced by 
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both stimuli may be partially, or completely overlapping.  Conversely, it is possible that the 
additive effect of VRP and CpG results from stimulation of intracellular signaling pathways 
by VRP which are distinct from those activated by CpG DNA.  It will be interesting to 
determine whether VRP activate intracellular signaling pathways which are similar to those 
induced by CpG DNA.  Another possibility is that VRP- and CpG-induced signaling occurs 
in distinct temporal waves, and delivery of VRP and CpG in a different temporal fashion may 
provide a synergistic effect.  In support of this idea, the kinetics of proinflammatory cytokine 
production in the DLN appeared to differ between VRP and CpG DNA, with VRP-induced 
responses peaking approximately 18 hours prior to the peak induced by CpG DNA 
(Thompson et al., in preparation, Chapter 3)  We are currently evaluating the stimulatory 
effect of antigen delivery in the presence of VRP and CpG when delivered simultaneously, as 
compared to staggering the timing of delivery of the two adjuvants.  Additionally, it will be 
interesting to determine whether synergistic T cell activation occurs following delivery of 
VRP in the presence of other TLR ligands.   
Here we demonstrate that nonmucosal VRP delivery resulted in a significant increase in the 
proportion of viable cells in the nasal mucosa that were CD8+, suggesting that VRP mobilize 
CD8+ T cell migration into the mucosal compartment.  The mechanism underlying this 
phenomenon is unclear at present.  One explanation is that VRP delivery induces the antigen-
independent migration of CD8+ T cells into the mucosal compartment.  An alternative 
explanation is that the increase in mucosal CD8+ T cells in the mucosal compartment is in 
fact due to the influx of antigen-specific cells, specific for antigens other than OVA.  While 
VRP preparations are purified over a sucrose gradient, “contaminating” proteins may in fact 
be present in VRP preps at levels sufficient for such proteins to serve as an antigen.  VRP 
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may in turn adjuvant the antigen-specific CD8+ T cell response to “contaminating” antigens, 
accounting for CD8+ cell influx into the mucosal compartment.  Additional experiments will 
be required to distinguish between these possibilities.  It will be interesting to determine the 
ratio of mucosal CD8+ T cells in the nasal epithelium following delivery of ultra purified 
VRP.  Additionally, antigen-independent migration may be evaluated by determining the 
ability VRP to induce mucosal migration of adoptively transferred CD8+ T cells with a 
specificity distinct from that of the immunizing antigen.  Regardless of mechanism, it will be 
important to determine whether this property is unique to the nasal mucosa, or if other 
mucosal surfaces likewise harbor increased numbers of CD8+ T cells. 
 Activation of mucosal IgA responses following nonmucosal VRP delivery has also 
been observed (22, 32, 49).  Interestingly, IgA antibodies were first produced in the 
peripheral draining lymph node, consistent with a model in which tissue plays a role in the 
inductive process following nonmucosal VRP delivery (Thompson et al., in preparation, 
Chapter 3).  Upon further characterization of the VRP DLN, a population of B cells with 
increased expression of the α4β7 integrin was discovered, suggesting a role for the mucosal 
homing receptor in VRP-induced mucosal antibody activation (Thompson et al., in 
preparation).  This integrin promotes lymphocyte migration into the mucosal compartment, 
especially in the gut (9).   
Here we demonstrate that CD8+ T cells present in the VRP DLN also upregulated the 
α4β7 integrin, here by approximately 3-fold.  Furthermore, Gupta et al. demonstrated α4β7 
integrin expression on antigen-specific, IFN-γ-secreting cells both in the DLN and at the 
vaginal mucosal surface following nonmucosal prime and mucosal boost of an alphavirus 
replicon chimera encoding the VEE RNA, providing additional support for this pathway in 
 200
alphavirus replicon mucosal immune induction.   Further experimentation, such as VRP 
adjuvant experiments in β7 integrin knock out mice (50), will be required to definitively 
implicate this pathway in VRP-induce mucosal immunity; however, we speculate that the 
α4β7 integrin pathway plays a significant role in VRP-induced mucosal T cell immunity.   
 In summary, we describe a novel activity of VRP to augment CD8+ T cell responses 
to co-delivered antigen alone and in concert with a TLR agonist.  To our knowledge, this is 
the first demonstration of T cell adjuvant activity with alphavirus vectors.  VRP-induced 
activation in the presence of CpG DNA appeared to occur downstream of antigen processing, 
as increased immunity was observed following delivery of peptide antigens.  Additionally, 
VRP delivery resulted in increased homing of CD8+ T cells into the mucosal compartment, 
potentially via the mucosal homing receptor.  These studies provide a framework which 
should allow for the identification of the critical viral factors and signaling pathways which 
are responsible for the activation of T cell responses to co-delivered antigens.  In turn, such 
knowledge could lead to more efficacious vaccines based on viral vectors.   
  
ACKNOWLEDGEMENTS 
We thank Mark Heise, Clayton Beard, and Nancy Davis for critical review of the manuscript, 
and members of the Carolina Vaccine Institute for helpful discussions. Additionally, we 
acknowledge Martha Collier for preparation of VRP utilized in these studies.  This work was 
supported by National Institutes of Health Grants P01-AI46023 and R01-AI51990 (to R.E.J.). 
 
 
 
 201
REFERENCES 
1. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen Recognition and Innate 
Immunity. Cell 124:783-801. 
 
2. Allan, R. S., C. M. Smith, G. T. Belz, A. L. van Lint, L. M. Wakim, W. R. Heath, 
and F. R. Carbone. 2003. Epidermal viral immunity induced by CD8alpha+ 
dendritic cells but not by Langerhans cells. Science 301:1925-8. 
 
3. Andre, F. E. 2003. Vaccinology: past achievements, present roadblocks and future 
promises. Vaccine 21:593-595. 
 
4. Bagchi, A., E. A. Herrup, H. S. Warren, J. Trigilio, H.-S. Shin, C. Valentine, and 
J. Hellman. 2007. MyD88-Dependent and MyD88-Independent Pathways in 
Synergy, Priming, and Tolerance between TLR Agonists. J Immunol 178:1164-1171. 
 
5. Belz, G. T., C. M. Smith, D. Eichner, K. Shortman, G. Karupiah, F. R. Carbone, 
and W. R. Heath. 2004. Cutting edge: conventional CD8 alpha+ dendritic cells are 
generally involved in priming CTL immunity to viruses. J Immunol 172:1996-2000. 
 
6. Boom, W. H., D. Liano, and A. K. Abbas. 1988. Heterogeneity of helper/inducer T 
lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on 
resting B lymphocytes. J. Exp. Med. 167:1350-1363. 
 
7. Braciale, T. J., L. A. Morrison, M. T. Sweetser, J. Sambrook, M. J. Gething, and 
V. L. Braciale. 1987. Antigen presentation pathways to class I and class II MHC-
restricted T lymphocytes. Immunol Rev 98:95-114. 
 
8. Burkhard, M. J., L. Valenski, S. Leavell, G. A. Dean, and W. A. F. Tompkins. 
2002. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats. 
Vaccine 21:258-268. 
 
9. Butcher, E. C. 1999. Lymphocyte Homing and Intestinal Immunity, p. 507-522. In P. 
L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee 
(ed.), Mucosal Immunology, 2nd ed. Academic Press, London. 
 
10. Chen, M., C. Barnfield, T. I. Naslund, M. N. Fleeton, and P. Liljestrom. 2005. 
MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens 
from Infected Cells. J. Virol. 79:2964-2972. 
 
11. Cresswell, P., A. L. Ackerman, A. Giodini, D. R. Peaper, and P. A. Wearsch. 
2005. Mechanisms of MHC class I-restricted antigen processing and cross-
presentation. Immunological Reviews 207:145-157. 
 
12. Davis, N. L., I. J. Caley, K. W. Brown, M. R. Betts, D. M. Irlbeck, K. M. 
McGrath, M. J. Connell, D. C. Montefiori, J. A. Frelinger, R. Swanstrom, P. R. 
 202
Johnson, and R. E. Johnston. 2000. Vaccination of Macaques against Pathogenic 
Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus 
Replicon Particles. The Journal of Virology 74:371-378. 
 
13. Davis, N. L., I. J. Caley, K. W. Brown, M. R. Betts, D. M. Irlbeck, K. M. 
McGrath, M. J. Connell, D. C. Montefiori, J. A. Frelinger, R. Swanstrom, P. R. 
Johnson, and R. E. Johnston. 2000. Vaccination of macaques against pathogenic 
simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon 
particles. J Virol 74:371-8. 
 
14. Davis, N. L., and R. E. Johnston. 2004. RNA Virus Replicon Vaccines, p. 337-351. 
In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, and M. F. Good (ed.), New 
Generation Vaccines, 3rd ed. Marcel Dekker, New York. 
 
15. Davis, N. L., A. West, E. Reap, G. MacDonald, M. Collier, S. Dryga, M. 
Maughan, M. Connell, C. Walker, K. McGrath, C. Cecil, L. H. Ping, J. 
Frelinger, R. Olmsted, P. Keith, R. Swanstrom, C. Williamson, P. Johnson, D. 
Montefiori, and R. E. Johnston. 2002. Alphavirus replicon particles as candidate 
HIV vaccines. IUBMB Life 53:209-11. 
 
16. Dong, M., P. F. Zhang, F. Grieder, J. Lee, G. Krishnamurthy, T. VanCott, C. 
Broder, V. R. Polonis, X.-F. Yu, Y. Shao, D. Faix, P. Valente, and G. V. 
Quinnan, Jr. 2003. Induction of Primary Virus-Cross-Reactive Human 
Immunodeficiency Virus Type 1-Neutralizing Antibodies in Small Animals by Using 
an Alphavirus-Derived In Vivo Expression System. J. Virol. 77:3119-3130. 
 
17. Durand, V., S. Y. Wong, D. F. Tough, and A. Le Bon. 2006. IFN-alpha/beta-
dependent cross-priming induced by specific toll-like receptor agonists. Vaccine 24 
Suppl 2:S2-22-3. 
 
18. Durand, V., S. Y. C. Wong, D. F. Tough, and A. Le Bon. 2004. Shaping of 
adaptive immune responses to soluble proteins by TLR agonists: A role for IFN-
alpha/beta. Immunol Cell Biol 82:596-602. 
 
19. Filippi, C., S. Hugues, J. Cazareth, V. Julia, N. Glaichenhaus, and S. Ugolini. 
2003. CD4+ T Cell Polarization in Mice Is Modulated by Strain-specific Major 
Histocompatibility Complex-independent Differences within Dendritic Cells. J. Exp. 
Med. 198:201-209. 
 
20. Frolov, I., T. A. Hoffman, B. M. Pragai, S. A. Dryga, H. V. Huang, S. 
Schlesinger, and C. M. Rice. 1996. Alphavirus-based expression vectors: Strategies 
and applications. Proceedings of the National Academy of Sciences 93:11371-11377. 
 
21. Gromme, M., and J. Neefjes. 2002. Antigen degradation or presentation by MHC 
class I molecules via classical and non-classical pathways. Molecular Immunology 
39:181-202. 
 203
22. Harrington, P. R., B. Yount, R. E. Johnston, N. Davis, C. Moe, and R. S. Baric. 
2002. Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated 
with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like 
Particles. The Journal of Virology 76:730-742. 
 
23. Heeney, J. L., and S. A. Plotkin. 2006. Immunological correlates of protection from 
HIV infection and disease. Nat Immunol 7:1281-4. 
 
24. Itano, A. A., and M. K. Jenkins. 2003. Antigen presentation to naive CD4 T cells in 
the lymph node. Nat Immunol 4:733-9. 
 
25. Itano, A. A., S. J. McSorley, R. L. Reinhardt, B. D. Ehst, E. Ingulli, A. Y. 
Rudensky, and M. K. Jenkins. 2003. Distinct Dendritic Cell Populations 
Sequentially Present Antigen to CD4 T Cells and Stimulate Different Aspects of Cell-
Mediated Immunity. Immunity 19:47-57. 
 
26. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive 
immune responses. Nat Immunol 5:987-95. 
 
27. Johnston, R. E., P. R. Johnson, M. J. Connell, D. C. Montefiori, A. West, M. L. 
Collier, C. Cecil, R. Swanstrom, J. A. Frelinger, and N. L. Davis. 2005. 
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine 
encephalitis virus replicon particle vectors followed by a mucosal challenge with 
SIVsmE660. Vaccine 23:4969-79. 
 
28. Kloetzel, P. M. 2004. Generation of major histocompatibility complex class I 
antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5:661-9. 
 
29. Le Bon, A., V. Durand, E. Kamphuis, C. Thompson, S. Bulfone-Paus, C. 
Rossmann, U. Kalinke, and D. F. Tough. 2006. Direct Stimulation of T Cells by 
Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming. J Immunol 
176:4682-4689. 
 
30. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, 
and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced 
type I interferon. Nat Immunol 4:1009-15. 
 
31. Letvin, N. L. 2006. Progress and obstacles in the development of an AIDS vaccine. 
Nat Rev Immunol 6:930-939. 
 
32. LoBue, A. D., L. Lindesmith, B. Yount, P. R. Harrington, J. M. Thompson, R. E. 
Johnston, C. L. Moe, and R. S. Baric. 2006. Multivalent norovirus vaccines induce 
strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 
24:5220-5234. 
 
33. Lundstrom, K. 2002. Alphavirus-based vaccines. Curr Opin Mol Ther 4:28-34. 
 204
34. Lundstrom, K. 2003. Alphavirus vectors for vaccine production and gene therapy. 
Expert Rev Vaccines 2:447-59. 
 
35. MacDonald, G. H., and R. E. Johnston. 2000. Role of Dendritic Cell Targeting in 
Venezuelan Equine Encephalitis Virus Pathogenesis. The Journal of Virology 
74:914-922. 
 
36. Moran, T. P., M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. 
Serody. 2005. A Novel Viral System for Generating Antigen-Specific T Cells. The 
Journal of Immunology 175:3431-3438. 
 
37. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. 
Selected Toll-like receptor agonist combinations synergistically trigger a T helper 
type 1-polarizing program in dendritic cells. Nat Immunol 6:769-76. 
 
38. Plotkin, S. A. 2001. Immunologic correlates of protection induced by vaccination. 
Pediatr Infect Dis J 20:63-75. 
 
39. Polo, J. M., J. P. Gardner, Y. Ji, B. A. Belli, D. A. Driver, S. Sherrill, S. Perri, M. 
A. Liu, and T. W. Dubensky, Jr. 2000. Alphavirus DNA and particle replicons for 
vaccines and gene therapy. Dev Biol (Basel) 104:181-5. 
 
40. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. 
Smith. 1997. Replicon-Helper Systems from Attenuated Venezuelan Equine 
Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization 
against Heterologous Pathogens in Vivo. Virology 239:389-401. 
 
41. Rayner, J. O., S. A. Dryga, and K. I. Kamrud. 2002. Alphavirus vectors and 
vaccination. Rev Med Virol 12:279-96. 
 
42. Riezebos-Brilman, A., A. d. Mare, L. Bungener, A. Huckriede, J. Wilschut, and 
T. Daemen. 2006. Recombinant alphaviruses as vectors for anti-tumour and anti-
microbial immunotherapy. Journal of Clinical Virology 35:233-243. 
 
43. Rizzo, L. V., R. H. DeKruyff, and D. T. Umetsu. 1992. Generation of B cell 
memory and affinity maturation. Induction with Th1 and Th2 T cell clones. J 
Immunol 148:3733-3739. 
 
44. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and 
role in immune surveillance. Immunological Reviews 207:166-183. 
 
45. Roelofs, M. F., L. A. Joosten, S. Abdollahi-Roodsaz, A. W. van Lieshout, T. 
Sprong, F. H. van den Hoogen, W. B. van den Berg, and T. R. Radstake. 2005. 
The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is 
increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic 
cytokine production by dendritic cells. Arthritis Rheum 52:2313-22. 
 205
46. Schlesinger, S., and T. W. Dubensky. 1999. Alphavirus vectors for gene expression 
and vaccines. Current Opinion in Biotechnology 10:434-439. 
 
47. Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, 
Y.-T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. 2005. Toll-like 
receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887-892. 
 
48. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, 
replication, and evolution. Microbiol.Rev. 58:491-562. 
 
49. Thompson, J. M., A. C. Whitmore, J. L. Konopka, M. L. Collier, E. M. B. 
Richmond, N. L. Davis, H. F. Staats, and R. E. Johnston. 2006. Mucosal and 
systemic adjuvant activity of alphavirus replicon particles. PNAS 103:3722-3727. 
 
50. Wagner, N., J. Lohler, E. J. Kunkel, K. Ley, E. Leung, G. Krissansen, K. 
Rajewsky, and W. Muller. 1996. Critical role for [beta]7 integrins in formation of 
the gut-associated lymphoid tissue. Nature 382:366-370. 
 
51. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. 
Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic 
cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. 
Blood 108:544-50. 
 
52. Zhang, Y., and D. B. Williams. 2006. Assembly of MHC class I molecules within 
the endoplasmic reticulum. Immunol Res 35:151-62. 
 
53. Zhao, X., E. Deak, K. Soderberg, M. Linehan, D. Spezzano, J. Zhu, D. M. Knipe, 
and A. Iwasaki. 2003. Vaginal Submucosal Dendritic Cells, but Not Langerhans 
Cells, Induce Protective Th1 Responses to Herpes Simplex Virus-2. J. Exp. Med. 
197:153-162. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 206
Figure 4-1 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1.  VRP promote a balanced Th1/Th2 antibody profile.  Groups of female  
Balb/c mice were immunized in the rear footpad at week 0 and week 4 with 10 µg OVA  
alone, or 10 µg of OVA mixed with either 1x105 IU of null VRP or 1 µg of CpG DNA.  Two  
weeks following the second inoculation, sera were collected and analyzed for the presence of  
OVA-specific total  IgG antibodies (A) or OVA-specific IgG1 and IgG2a antibodies (B) by  
ELISA.  Values represent the geometric mean +/- SEM. 
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Figure 4-2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2.  VRP promote CD8+ T cell immunity to co-delivered soluble antigen. Groups  
of female C57BL/6 mice were immunized in the rear footpad at week 0 and week 4 with 100  
µg OVA alone, or 100 µg of OVA mixed with either 1x105 IU of null VRP, 1 µg of CpG  
DNA, both 1x105 IU of null VRP and 1 µg of CpG DNA .  Two weeks following the second  
inoculation, splenocytes (A) and nasal lymphocytes (B) were analyzed for the presence of  
IFN-γ-secreting cells following stimulation with the OVA class I-restricted peptide in an  
IFN-γ ELISPOT assay.  Values represent the geometric mean +/- SEM. 
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Figure 4-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3.  VRP-induced CD8+ T cells delay tumor onset.  Groups of female C57BL/6  
mice were immunized with 100 µg of OVA protein alone, both 10 µg and 100 µg of OVA  
mixed with 1x105 IU of null VRP, or 1x105 IU of null VRP alone at week 0 and week 4.   
Two weeks following the second inoculation, animals were challenged subcutaneously in the  
flank with TM 1/5 x 104 B16-OVA tumor cells and monitored for tumor formation.   
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Figure 4-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4.  VRP promote CD8+ T cell immunity to co-delivered peptide antigen.   
Groups of female C57BL/6 mice were immunized in the rear footpad at weeks 0, 4, and 8 
with OVA peptide (SIINFEKL, 20 µg /20 µg/10 µg respectively) alone, or mixed with either  
1x105 IU of null VRP, 1 µg of CpG DNA, both 1x105 IU of null VRP and 1 µg of CpG  
DNA.  Two weeks following the last inoculation, splenocytes (A) were analyzed for the  
presence of IFN-γ-secreting cells following stimulation with the OVA class I-restricted  
peptide in an IFN-γ ELISPOT assay.  Additionally, splenocytes (B) and nasal lymphocytes  
(C) were analyzed for the presence pMHC-specific CD8+ T cells by pentamer staining.   
Values represent the geometric mean +/- SEM. 
 210
Figure 4-5 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5.  VRP recruit CD8+ T cells to the upper respiratory tract (URT).  Groups of  
Female C57BL/6 mice were immunized in the rear footpad at weeks 0 and 4 with 10 µg of  
OVA alone, or mixed with either 1x105 IU of null VRP, 1 µg of CpG DNA, both 1x105 IU of  
null VRP and 1 µg of CpG DNA .  Two weeks following the last inoculation, splenocytes  
(A) and nasal lymphocytes (B) were analyzed for the presence pMHC-specific CD8+ T cells 
 by pentamer staining.  Values represent the geometric mean +/- SEM. 
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Figure 4-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6.  VRP upregulate the mucosal homing receptor on DLN CD8+ T cells.   
Groups of female Balb/c mice were immunized in the rear footpads at weeks 0 and 4 with 10  
µg of OVA alone, or mixed with either 1x105 IU of null VRP.  Day 3 following the last  
inoculation, single cell suspensions were prepared from the DLN and CD4 and CD8+ T cells  
were analyzed for the presence of the α4β7 integrin and CCR9 by flow cytometry.  Shown are  
the proportion of α4β7 integrin positive cells.   
CHAPTER FIVE 
 
THE CONTRIBUTION OF TYPE I INTERFERON SIGNALING TO MUCOSAL 
 IgA RESPONSES INDUCED BY ALPHAVIRUS REPLICON VACCINES AND 
ADJUVANT PARTICLES 
 
 
Joseph M. Thompson1,2, Alan C. Whitmore2, Herman F. Staats3, and Robert Johnston1,2 
 
Department of Microbiology and Immunology1, and Carolina Vaccine Institute2, University 
of North Carolina, Chapel Hill NC 27599; and Department of Pathology, and Human 
Vaccine Institute3, Duke University Medical Center, Durham NC 27710 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 213
ABSTRACT 
The type I interferon (IFN) system is critical for protecting the mammalian host from 
numerous virus infections.  Much is known regarding the signal transduction pathways and 
antiviral effector genes which are activated by IFN, and a growing body of evidence suggests 
that IFN also plays a key role in shaping anti-viral adaptive immune response.  In this report, 
the importance of type I IFN signaling was assessed in a mouse model of alphavirus-induced 
humoral immune induction. Venezuelan equine encephalitis virus replicon particles (VRP) 
expressing the hemagglutinin (HA) gene from influenza virus (HA-VRP) were used to 
vaccinate both wildtype and IFN α/β receptor knockout (RKO) mice.  HA-VRP vaccination 
induced equivalent levels of flu-specific systemic IgG antibodies, mucosal IgG antibodies, 
and systemic IgA antibodies in both wildtype and IFN RKO mice.  In contrast, HA-VRP 
vaccination of IFN RKO mice failed to induce significant levels of flu-specific mucosal IgA 
antibodies at multiple mucosal surfaces, including the upper respiratory tract, the 
gastrointestinal tract, and the urogenital tract.  We have recently demonstrated that VRP 
which do not encode a foreign antigen in the replicon genome (null VRP) activate systemic 
and mucosal immune responses to co-delivered antigens.  The role of IFN signaling was also 
analyzed with respect to the VRP adjuvant effect.  Delivery of ovalbumin (OVA) protein in 
the presence of null VRP increased levels of both OVA-specific systemic IgG antibodies and 
mucosal IgA antibodies in both wildtype and RKO mice, suggesting that type I IFN signaling 
is not required for the VRP adjuvant effect.  Taken together, these results suggest that, 1) at 
least in regard to IFN signaling, the mechanisms which regulate VRP-induced responses in 
the expression vector system differ from those that regulate responses in the presence of VRP 
used as an adjuvant, and 2) type I IFN signaling is required for the induction of mucosal IgA 
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antibodies directed against VRP-expressed antigen.  These results potentially shed new light 
on the regulatory networks which promote immune induction, and specifically mucosal 
immune induction, with alphavirus vaccine vectors. 
 
INTRODUCTION 
The type I interferons (IFNs) are a family of pleiotropic cytokines which were 
originally classified as proteins that interfere with virus replication (14), and are now known 
to provide the first line of defense against numerous viral pathogens (43).   Type I IFNs, 
which include IFNα and IFNβ, signal through a common receptor, the type I IFN receptor, 
expressed on almost all cell types (44).  Signaling through the IFN receptor involves a 
complex cascade of events which translates extracellular signals into an increased antiviral 
state by upregulating the expression of interferon-stimulated genes, or ISGs (11).  The 
importance of IFN signaling in antiviral defense is evidenced by the fact that animals with an 
engineered genetic deficiency in the IFNα/β receptor (IFNα/β receptor knockouts, or RKOs) 
are acutely susceptible to numerous viral infections (7, 13, 34, 49).   
Recent evidence suggests that in addition to affecting innate immunity, type I IFN 
signaling also plays an important role in the activation of adaptive immune responses (2, 15, 
22, 45, 47).  Type I IFN promotes the differentiation of human monocytes into dendcritic 
cells (DCs) (40) and provides a powerful activation signal to differentiated DCs, promoting 
co-stimulatory molecule expression and their antigen-presenting-cell (APC) function (22).  
Interferon-treated DCs upon interacting with B cells, activate immunoglobulin (Ig) class 
switch recombination and Ig secretion (20) to multiple isotypes, including IgA.  This effect is 
due, at least in part, to the release of TNF family ligands from IFN-activated DCs (25).   IFN 
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also promotes cross-priming, the activation of CD8+ T cell responses directed against 
exogenous antigens, in DCs (19).  In addition to effects on DCs, IFN signaling is directly 
required for complete activation of B cells (21), CD4+ T cells (9), CD8+ T cells (17), and 
natural killer cell activity (3).   
The goal of vaccination is to stimulate an immune response within an individual 
which will protect that individual from morbidity and mortality associated with a natural 
pathogen challenge.  Vaccine vectors based on the alphavirus, Venezuelan equine 
encephalitis virus (VEE), have proven to be potent inducers of antigen-specific immunity in 
several pre-clinical vaccination models (6, 27, 28, 35, 38, 39, 42), and are currently under 
evaluation in human clinical trials.  The alphaviruses contain a message-sense, single-
stranded RNA genome of approximately 12 kb (46).  The viral nonstructural genes, which 
encode the enzymatic activity required for RNA replication are encoded at the 5’ end of the 
genome, while the viral structural genes are expressed from a subgenomic 26S promoter at 
the 3’ one third of the genome.  The most well characterized members of this family are 
Sindbis virus (SIN), Semliki forest virus (SFV), and VEE.  Several types of VEE-based 
vaccine technologies have been developed.  One such technology, termed VEE replicon 
particles (VRP), functions as an expression vector, encoding a modified genome in which the 
structural genes are replaced with a heterologous antigen (37).  Following VRP infection, the 
replicon RNA encoding the transgene is expressed at very high levels; however, progeny 
virions are not produced as the structural components are absent from the genome.  Thus, 
VRP are single-cycle vectors capable of only one round of replication.  VRP are potent 
inducers of both systemic and mucosal antibody responses directed against the antigen which 
is carried in the viral genome (8, 26, 48).   
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We have recently identified a novel activity of VRP; to serve as adjuvants for the 
activation of humoral immune and cell-mediated immune responses directed against a co-
delivered antigen (48) (Thompson et al., in preparation, Chapter 4).  Null VRP, which lack a 
heterologous transgene downstream of the 26S promoter, acting as adjuvants, were capable 
of stimulating systemic and mucosal immune responses following nonmucosal delivery, 
similar to our observations with VRP expression vectors (8, 26, 48).  The finding that VRP, 
acting as both expression vectors and as adjuvants, stimulate local antibody synthesis 
following nonmucosal vaccination is significant, as nonmucosal vaccine delivery methods 
typically fail to induce authentic mucosal immunity (30-32).  We have recently demonstrated 
the presence of several characteristics of mucosal lymphoid tissues, including antigen-
specific polymeric IgA antibodies, in the draining lymph node (DLN) of VRP-vaccinated 
mice, suggesting that this lymphoid tissue may serve as a component of the mucosal 
inductive pathway stimulated by nonmucosal VRP delivery (Thompson et al., in preparation, 
Chapter 3).  These results suggest that VRP are potent stimulators of the adaptive immune 
system. 
A specific role for type I IFN signaling in alphavirus-induced adaptive immunity has 
previously been established.  The activation of B and T lympocytes (as measured by 
upregulated CD69 expression) was significantly impaired in IFNα/β RKO mice, suggesting 
that alphavirus-induced lymphocyte activation is incomplete in the absence of IFN signaling 
(1).  An additional alphavirus vaccine technology has been developed in which the replicon 
RNA is delivered, not from a virus particle, but instead encoded on a bacterial plasmid as a 
DNA replicase-based vaccine [reviewed in (41)].  These alphavirus vaccines are highly 
immunogenic in several mouse models, including murine models of tolerance.  Leitner et al. 
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demonstrated a role for type I IFN signaling in a replicase-based vaccine, as this vaccine 
induced immunity to a “self” tolerant antigen in wildtype animals; however, failed to induce 
immunity to the same tolerant antigen in IFNα/β RKO mice (23).  An additional study 
performed by Restifo and colleagues suggested that the ability of replicase-based vaccines to 
break immunological tolerance was dependent upon a single ISG, RNaseL (24).  Moreover, 
Hidmark et al. recently demonstrated that the systemic IgG adjuvant effect of SFV replicon 
particles was dependent upon type I IFN signaling, as SFV replicons failed to augment serum 
IgG responses in IFNα/β RKO mice.     
In this report we have evaluated the role of type I IFN signaling in the stimulation of 
systemic and mucosal antibody responses by VRP as expression vectors, expressing the 
hemagglutinin (HA) gene from influenza (flu) virus (HA-VRP), and as adjuvants, following 
co-delivery of null VRP with soluble ovalbumin (OVA).  HA-VRP induced equivalent flu-
specific systemic IgG and systemic IgA antibody responses in both wildtype (wt) and IFNα/β 
RKO mice.  In contrast, while HA-VRP vaccinated, wt mice produced strong flu-specific 
IgA responses at several mucosal surfaces, mucosal IgA responses were barely detectable in 
IFNα/β RKO mice. Interestingly, null VRP significantly augmented OVA-specific serum 
IgG and fecal IgA antibodies in both wt and IFNα/β RKO mice.  These results suggest that 
type I IFN signaling plays an important role in VRP expression vector-induced mucosal IgA 
responses; however, only a minimal role in the VRP adjuvant effect.  This analysis should 
allow for a more basic understanding of the precise role of IFN in alphavirus-induced 
immunity.   
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MATERIALS AND METHODS 
VEE replicon constructs.  The construction and packaging of VRP was performed as 
previously described (5, 37).  Briefly, confluent monolayers of BHK-21 cells were co-
electroporated with three separate in-vitro-transcribed RNAs; namely the replicon genome 
RNA, and two defective helper RNAs which drive the expression of the viral structural genes 
in trans.  Only the replicon genome RNA is packaged into VRP, as the helper RNAs lack the 
viral packaging signal.  In this study, two different replicon constructs were utilized: 1) 
replicons expressing the HA gene from the A/PR/8/34 strain of influenza virus (HA-VRP); 
and 2) replicons which lack a functional transgene downstream of the 26S promoter (null 
VRP) (48).  Null VRP contain the viral nonstructural genes, a  14 nt stretch  of VEE 
sequence downstream of the 26S mRNA transcription start site, a heterologous 43-nt long 
cassette containing multiple restriction sites for cloning into the replicon backbone, and the 
118-nt 3' UTR.  HA-VRP and null VRP were quantitated by immunocytochemistry of 
infected BHK cells with anti-sera against HA (37) and null VRP (48), respectively.  All 
replicon particles utilized in this study were packaged in the wild-type (V3000) envelope.   
Animals and immunizations.  Eight-to-16-week-old 129 Sv/Ev and 129 Sv/Ev IFN α/β 
receptor knockout (RKO) mice were immunized in a 0.01 ml volume in the rear footpad as 
previously described (48).  129 Sv/Ev animals were bred under specific pathogen free 
conditions.  Breeder pairs were obtained from Dr. Barbara Sherry, North Carolina State 
University, or were purchased from Taconic Laboratories.  Breeder pairs of the RKO animals 
were obtained from Dr. Herbert Virgin, Washington University, and bred under specific 
pathogen free conditions.   Animals were immunized at week 0 and week 4 with either HA-
VRP or antigen (chicken egg albumin, ovalbumin) in the presence or absence of null VRP as 
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an adjuvant.   Ovalbumin (OVA) was purchased from Sigma.  Diluent consisted of low 
endotoxin, filter-sterilized PBS. 
Antibody-Secreting-Cell enzyme-linked immunospot assay (ASC ELISPOT).  To 
evaluate the presence of OVA-specific ASCs, single cell suspensions were prepared from 
both spleen and the nasal epithelium.  Whole spleens were disrupted between frosted glass 
slides, and red blood cells were lysed either under hypo-osmotic conditions, or following 
addition of ammonium chloride buffer.  Cells were washed and placed on a Lympholyte-M 
density gradient (Accurate).  Banded cells were harvested, washed and counted. 
For preparation of nasal lymphocytes, nasal tissue from the tip of the nose to just 
anterior of the eye sockets was harvested from immunized animals, and the upper palate, 
including the NALT, was carefully removed prior to further processing.  Nasal tissue was 
physically disrupted and incubated at 37ºC for 2 hrs in a 50 ml Erlenmeyer flask in complete 
R-10 media [RPMI-1640 containing 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 50 
µg/ml gentamicin, 100 U/ml penicillin, 100 µg/ml streptomycin, and 15mM HEPES] 
containing 2.5mg/ml Collagenase A (Roche), 17 µg/ml DNase I (Roche) and glass beads.  
Following digestion, cells were filtered through a 40 µm cell strainer (BD Falcon), washed, 
resuspended in 44% Percoll (Amersham) and layered on Lympholyte-M as described for 
spleen cells above.  Banded cells were harvested, washed, and counted.  Cells were pooled 
from two animals, and typical yields were approximately 2.5x105 to 1x106 cells per animal.  
ASC ELISPOT analysis was modified from previous reports (24),(25).  Briefly, 96-well 
nitrocellulose membrane plates (Millipore) were incubated with 1 mg/ml OVA in PBS 
overnight at 4˚C.  Plates were then washed and blocked for 2 hrs with complete R-10 (10% 
serum).  Two fold dilutions of single cell suspensions were then added to plates in duplicate 
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in R-10 and incubated overnight.  Plates were washed, and bound spots were detected by the 
addition of HRP-conjugated secondary goat anti-mouse γ or α chain-specific antibodies 
(Southern Biotechnology Associates), followed by addition of 3-amino-9-ethylcarazole 
(AEC, Sigma), and enumerated with a computerized ELISPOT plate reader (Immunospot).   
Data are presented as the number of antigen-specific ASCs per 106 cells plated.  
Lymphoid Organ Cultures.  Lymphoid cultures were prepared as previously described (26, 
48).  Briefly, draining popliteal lymph nodes were harvested from immunized animals and 
placed in Eppendorf tubes containing 1 ml of wash buffer (Hanks’ balanced salt solution 
containing 100 units/ml penicillin, 100 µg/ml streptomycin, 110 mM Ca2+, 50 mM Mg2+, and 
15 mM Hepes) and washed three times by aspiration and resuspension.  Draining lymph 
nodes (DLNs) were placed in individual wells in a 96-well tissue culture plate in 0.1 mls of 
media [RPMI medium 1640 (GIBCO) containing 15 mM Hepes, 10% FBS, 100 units/ml 
penicillin, 100 µg/ml streptomycin, 50 µg/ml gentamicin, 2 mM L-glutamine (GIBCO), and 
0.25 µg/ml amphotericin B] Plates were incubated at 37ºC for 7 days to allow antibody 
secretion from tissue-resident B cells into the supernatant.  Following incubation, 
supernatants were collected, clarified by centrifugation at 4ºC, and analyzed for the presence 
of antigen-specific antibodies by ELISA (see below).  
Sera, Fecal Extracts, and Vaginal Washes.  All sample collection was prepared as 
previously described (48).  Blood was harvested from individual animals either from the tail 
vein, following cardiac puncture, or from the submandibular plexus, and sera collected 
following centrifugation in microtainer serum separator tubes (Becton Dickinson).  For fecal 
extracts, fresh fecal pellets (5-8, ≈ 100-150 mg) were isolated from individual animals and 
placed in a 1.5 ml Eppendorf tube containing 1 ml of fecal extract buffer buffer [PBS 
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containing10% (vol/vol) normal goat serum and 0.1% (vol/vol) Kathon CG/ICP (Supeleco)].  
Samples were vortexed for at least 10 mins until all pellets were disrupted into a homogenous 
mixture.  Samples were vortexed and clarified by centrifugation at 4ºC, and supernatants 
were transferred to fresh tubes and stored at -20 ºC prior to analysis in ELISA assay (see 
below).  Vaginal washes were performed by lavaging the exterior vaginal opening with 0.07 
mls of PBS 8-10 times.  Lavage samples were stored at -20 ºC and clarified at 4ºC prior to 
ELISA analysis (see below).   
Enzyme Linked Immunosorbant Assay (ELISA).  ELISAs for influenza- and OVA-
specific antibodies were performed on serum, fecal extracts, vaginal washes, and lymphoid 
culture supernatants as previously described (48).   Briefly, antigen solutions (either 250 
ng/ml of influenza virus in carbonate buffer, or 1 mg/ml of OVA in PBS) were incubated in 
96-well plates (Costar) overnight at 4°C to allow antigens to bind to the plate. Excess antigen 
was removed, and blocking solution [PBS containing 5% milk for flu, or 1× Sigmablock 
(Sigma) for OVA] was added for 2 h for flu or overnight for OVA, at room temperature. 
Following removal of blocking solution, plates were incubated at room temperature for 2 h 
(flu) or overnight (OVA) with serial dilutions of individual samples diluted in the appropriate 
blocking buffer. Plates were washed with a multi-channel plate washer (NUNC) and 
incubated for 1 h with horseradish peroxidase-conjugated secondary goat anti-mouse γ or α 
chain-specific antibodies (Southern Biotechnology Associates or Sigma). Finally, plates were 
again washed, and O-phenylenediamine dihydrochloride substrate was added for 30 min.  
The reaction was stopped with the addition of 0.1 M NaF. Antibody endpoint titers are 
reported as the reciprocal of the highest dilution that resulted in an OD450 ≥ 0.2. Data are 
presented as the geometric mean ± standard error of the mean (SEM). 
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Statistical Analysis. Antibody titers and cytokine values were evaluated for statistically 
significant differences by either the ANOVA or Mann-Whitney test (GraphPad INSTAT). A P 
value of ≤0.05 was considered significant. 
RESULTS 
Type I IFN signaling is not required for expression-vector-induced systemic immunity.  
Systemic and mucosal immunity can be induced by VRP used in two different modalities.  In 
the first instance, VRP express an antigen encoded in the VRP genome (expression vectors).  
In the second, the antigen is supplied separately with the VRP contributing a mucosal and 
systemic adjuvant effect.  We have examined the requirement for a functional type I IFN 
system for systemic and mucosal immunity induced by both VRP modalities.  Groups of 
wildtype 129 Sv/Ev and IFN receptor knockout (RKO) mice were immunized in the rear 
footpad at weeks 0 and 4 with 1x105 infectious units (IU) of VRP expressing the HA gene 
from influenza virus (HA-VRP).  Two weeks following the second immunization, animals 
were sacrificed, and flu-specific systemic immune responses were measured by serum IgG 
ELISA and by IgG and IgA spleen ASC ELISPOT assay (figure 5-1).  As shown in figure 5-
1A, HA-VRP induced equivalent levels of flu-specific IgG antibodies in the serum of both 
wildtype and RKO mice.  Consistent with this finding, similar numbers of flu-specific IgG- 
and IgA-secreting cells were evident in the spleens of both wildtype and RKO mice (figure 
5-1B and 5-1C).  Together, these results suggest that type I IFN signaling is not required for 
the induction of systemic immunity, both IgG and IgA, directed against VRP-expressed 
antigens. 
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Type I IFN signaling is required for expression-vector-induced mucosal IgA responses.  
We have recently demonstrated that VRP expression vectors induce local mucosal IgA 
responses at multiple mucosal surfaces in mice including the upper respiratory tract (URT) 
(48), the gastrointestinal tract (8, 26, 48), and the urogenital tract (48) even when inoculated 
at a nonmucosal site.  Mucosal antibody responses were measured in wildtype and IFN RKO 
animals in the URT (ASC ELISPOT), gastrointestinal tract (ELISA on fecal extracts), and 
urogenital tract (ELISA on vaginal washes) (figure 5-2).  As with systemic IgG, mucosal IgG 
appeared to be unaffected by the absence of type I IFN signaling with VRP expression 
vectors, evidenced by the observation that HA-VRP induced equivalent levels of flu-specific 
IgG-secreting cells in the URT in both wildtype and RKO mice.  In RKO mice however, HA-
VRP induced significantly reduced levels of IgA-secreting cells in the upper respiratory tract 
of RKO mice (figure 5-2B).  To determine if the mucosal IgA defect in the URT of RKO 
mice was limited to this single mucosal surface or was also true of other mucosal surfaces, 
flu-specific mucosal IgA responses were analyzed at two additional mucosal surfaces.  HA-
VRP-inoculated RKO mice also generated reduced IgA antibody responses in fecal extracts 
(figure 5-2C) and vaginal wash fluids (figure 5-2D), representative of the gastrointestinal and 
urogenital tracts, respectively.  These results suggest that type I IFN signaling plays a critical 
role in VRP expression-vector-induced mucosal IgA immunity, while playing only a minimal 
role, if any, in systemic immunity under the same experimental conditions.   
VRP expression-vector-induced IgA production in the draining lymph node.  The 
immunological mechanism(s) underlying the induction of mucosal IgA after nonmucosal 
inoculation of VRP expressing an antigen, remain unclear.  One hypothesis suggests that 
cytokines induced by the replication of VRP RNA convert the DLN into the functional 
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equivalent of a mucosal inductive site (Thompson et al., in preparation, Chapter 3).  A 
cardinal feature of such sites is the production of antigen-specific IgA antibodies, and this 
characteristic is observed in the DLN following inoculation of VRP expressing an antigen.  
 Here we sought to determine if type I IFN signaling affects the production of DLN 
IgA antibodies.  Groups of wildtype 129 Sv/Ev and RKO mice were immunized in the rear 
footpad at weeks 0 and 4 with 1x105 IU of HA-VRP.  At day 3 post boost (the timepoint at 
which VRP-induced IgA antibodies peaked in the DLN of BALB/c mice; Thompson et al., in 
preparation), DLNs were harvested and incubated in media in a lymphoid organ culture assay 
as described (48).  DLN culture supernatants were evaluated for the presence of flu-specific 
IgA antibodies by ELISA (figure 5-3).  As shown in figure 5-3A, equivalent levels of flu-
specific IgA antibodies were produced in wildtype and RKO mice.  In the same experiment, 
HA-VRP also induced similar levels of flu-specific IgG antibodies in the DLNs of both 
wildtype and RKO mice (data not shown).  These results suggest that the defect in mucosal 
IgA production at the mucosal surface following VRP expression vector delivery is not due 
to a lack of antigen-specific IgA antibodies in the DLN. 
Type I IFN signaling is not required for VRP adjuvant-induced immunity.  VRP, when 
used as an adjuvant, enhance systemic and mucosal antibody responses to co-delivered 
antigen (48).  The systemic adjuvant effect of replicon particles derived from a related 
alphavirus, Semliki forest virus, was dependent upon type I IFN signaling (10).  Therefore, 
the role of type I IFN signaling on VRP adjuvant activity was also evaluated.  Groups of 
wildtype and RKO animals were immunized at week 0 and week 4 with 10 µg of OVA alone, 
or with 10 µg of OVA co-immunized with 1x105 IU null VRP (no transgene) as an adjuvant.  
Two weeks following the boost, animals were evaluated for the presence of OVA-specific 
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IgG antibodies in the serum and OVA-specific IgA antibodies in fecal extracts (Table 5-1).  
The inclusion of VRP in the inoculum as an adjuvant significantly increased the OVA-
specific systemic IgG response in both wildtype and RKO mice, suggesting that IFN 
signaling does not play a critical role in systemic immune induction with VRP adjuvants.  
Likewise, VRP significantly increased fecal IgA responses to the same extent in both 
wildtype and RKO animals, suggesting that while IFN clearly plays a critical role in mucosal 
IgA induction when the antigen is expressed from the VRP genome, IFN signaling is not 
required for the induction of either mucosal IgA or systemic IgG when VRP are utilized as an 
adjuvant.  
 
DISCUSSION 
 Alphavirus replicon particles are potent stimulators of adaptive immune responses, 
and provide a powerful model system for the study of host factors involved in the regulation 
of viral immunity.  While the utility of VRP as a component of successful vaccines has 
clearly been established, little is known regarding the critical immunological factors which 
regulate VRP-induced immune induction.  The type I IFN system has been implicated in 
several models of alphavirus-induced immunity.  Here we present evidence that type I IFN 
signaling plays an important role in VRP-induced immune stimulation; specifically in the 
induction of mucosal IgA responses directed towards VRP-expressed antigen.   
 Our studies suggest that, at least in regard to the IFN system, the mechanisms which 
regulate immune induction to antigens expressed from alphavirus replicon particles are 
distinct from the immunoregulatory mechanisms operative when replicon particles are 
utilized as adjuvants.  This notion is supported by the results presented here that mucosal IgA 
 226
responses induced by VRP expression vectors are significantly impaired in RKO mice; 
however, mucosal IgA responses directed against VRP adjuvanted antigen in RKO were 
equivalent to wildtype mice.  Although Hidmark et al. did not measure mucosal IgA 
responses, they also report a different effect of the RKO defect on replicon expressed 
compared to replicon adjuvanted vaccines.  The authors demonstrated that serum IgG 
responses directed against expressed antigen were equivalent between wildtype and RKO 
animals; however, the serum IgG adjuvant effect with SFV replicon particle was abrogated in 
RKO mice (10).  Together, these results are consistent with a model in which alphavirus 
replicon particles rely on distinct mechanisms for immune induction when utilized as 
expression vectors as compared to adjuvants.   
 While work with both the VEE replicon particles and SFV replicon particles reveals a 
distinction between their use as expression vectors and adjuvants, there are important 
differences between results obtained with the two systems as well. The SFV replicon 
adjuvant effect in serum IgG was abrogated in RKO mice (10).  This was not the case in the 
VEE system, as serum adjuvant activity was observed in RKO mice.  To date, the 
mechanistic explanation regarding the differences between VEE and SFV have yet to be 
determined; however, several possibilities exist.  One plausible explanation is that the initial 
targets of infection shape the IFN dependence for immune induction.  VRP efficiently infect 
DCs both in vitro (33) and in vivo (29), (West, A., Whitmore, A., Moran, T., and Johnston, 
R., unpublished).  In contrast, SFV does not appear to efficiently infect DCs in vitro, even at 
an MOI as high as 1000 (12).  Additionally, while SFV infection has been shown to induce 
DC migration in vivo (16), infection of DCs by SFV has yet to be reported.   
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Other more subtle effects could also account for the differences observed between 
VEE and SFV.  For example, both viruses induce type I IFN, however a careful comparison 
of the absolute levels induced by both viruses has not been carried out. Additionally, 
mammals encode multiple IFN α genes (47) and it is unclear exactly what role each 
individual α gene plays both in antiviral defense and activation of adaptive immunity.  It is 
possible that both the absolute amount of IFN induced by VEE and SFV, as well as the 
distribution of the different α genes is different between the two viruses.  Future 
experimentation will be required to fully elucidate the role of IFN in vaccine-induced 
immunity with VEE and SFV replicon particles. 
 Further study is required to discover the mechanism by which IFN specifically 
promotes mucosal IgA responses following delivery of VRP expression vectors.  We have 
recently demonstrated that nonmucosal VRP delivery induces numerous characteristics of 
mucosal lymphoid tissues in the peripheral draining lymph, node including antigen-specific 
polymeric IgA antibodies, a population of B cells which express upregulated levels of the 
mucosal homing receptor, increased mucosal cytokine/chemokine expression, and expression 
of the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) (Thompson et al., in 
preparation, Chapter 3).  These results are supportive of a model in which the draining lymph 
node is converted into the functional equivalent of a mucosal inductive site.   
The question of whether IFN exerts its effect at the level of the draining lymph node 
is still unclear; however, results presented here suggest that IFN is operative downstream of 
IgA class switch, as levels of both antigen-specific systemic IgA and DLN IgA were 
unaffected in RKO mice following VRP delivery.  Instead, IFN may play a role in regulating 
VRP-induced cytokine responses in general, upregulation of the α4β7 integrin, MAdCAM-1, 
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or a yet unidentified critical component.  These results are consistent with a model in which 
IFN regulates the migration of VRP-activated IgA-secreting cells, promoting migration of 
IgA-secreting cells into the mucosal compartment.  It has been reported that IgA-secreting 
cell migration occurs via the selective upregulation of specific integrins and chemokine 
receptors which may be affected by the production of type I IFN (18).  It will be important to 
examine the VRP DLN in RKO mice for additional characteristics of mucosal lymphoid 
tissue, such as expression of MAdCAM-1 on the high endothelial venules and the α4β7 
integrin on DLN B cells as a means to identify the precise mechanism by which IFN 
promotes VRP expression vector-induced mucosal IgA responses.   
 The observation that IFN serves as a potent adjuvant for the induction of antibody 
responses to co-immunized antigen is consistent with a role for IFN in alphavirus-induced 
immunity (4, 20, 36); however, whether IFN plays a direct or indirect role in the VRP system 
remains to be determined.  The direct role of IFN has been examined in studies using 
recombinant IFN as an adjuvant.  In one report, increased IgA responses were not observed 
following IFN adjuvant treatment (20).  It is possible that a specific subset of IFN α genes 
directly promote mucosal IgA responses in the VRP system, and this subset was not present 
in the recombinant preparations studied as an adjuvant in Le Bon et al. (20).   In another 
study, recombinant IFN did promote mucosal IgA responses following nasal delivery in an 
influenza vaccine model (4, 36).  It will be interestesting to examine the role of individual 
IFN α genes in the activation of mucosal IgA responses in general, and specifically in the 
VRP expression vector system.    
An important point to consider in the interpretation of immune induction experiments 
in RKO mice is the differences in the level of antigen expression between wildtype and RKO 
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mice.  It is known that alphavirus vector-expressed antigen is markedly increased in animals 
lacking the type I receptor [(23) and White et al., in preparation], suggesting that, in wt mice, 
autocrine and paracrine IFN signaling limit alphavirus vector antigen expression (23).  In 
experiments presented here, we concluded that IFN was not required for expression-vector-
induced systemic immunity; however, this interpretation includes the caveat that equivalent 
systemic immune responses against the encoded antigen were induced under conditions in 
which antigen expression levels were markedly different.  However, in the case of mucosal 
IgA responses induced in RKO mice with VRP expression vectors, a significant defect was 
observed in RKO mice even though much more antigen was present, demonstrating that 
increased antigen levels cannot replace the function of IFN signaling in this system. 
In this report we provide further evidence for the role of the type I IFN system in 
regulating virus-induced adaptive immunity.  Type I IFN played a critical role in the 
activation of mucosal IgA responses following delivery of VRP expression vectors.  These 
results suggest a specific role for type I IFN in VRP-induced immunity, potentially the 
regulation of migration of IgA-secreting-cells into the mucosal compartment.  Identification 
of the precise mechanism by which IFN promotes VRP-induced mucosal IgA should lead to 
both a basic understanding of the factors involved in virus-induced immunity as well as new 
strategies to increase the efficacy of VRP as mucosal vaccine vectors.   
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Figure 5-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1.  Type I IFN signaling is dispensable for expression-vector-induced systemic  
immunity.  Groups of wildtype (wt) and IFN α/β receptor knockout (RKO) mice were 
immunized in the rear footpad at weeks 0 and 4 with 1x105 IU of HA-VRP.  Two weeks 
following the boost, flu-specific serum IgG (A) antibodies were evaluated by ELISA.  
Additionally, flu-specific IgG- (B) and IgA (C) -secreting cells were evaluated by ASC 
ELISPOT.  Values represent the geometric mean +/- SEM.  No statistically-significant 
differences exist between responses induced in wt and RKO animals. 
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Figure 5-2 
 
 
 
 
 
 
Figure 5-2.  Type I IFN signaling is required for expression-vector-induced mucosal 
IgA responses.  Groups of wildtype (wt) and IFN α/β receptor knockout (RKO) mice were 
immunized in the rear footpad at weeks 0 and 4 with 1x105IU of HA-VRP.  Two weeks 
following the boost, flu-specific IgG- (A) and IgA- (B) were analyzed by ASC ELISPOT of 
URT cells.  Also, flu-specific IgA antibodies were evaluated in fecal extracts (C) and vaginal 
washes (D) by ELISA.  Values represent the geometric mean +/- SEM.  IgA responses in wt 
mice are all statistically greater than IgA responses in RKO mice (Mann-Whitney). 
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Figure 5-3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3.  Type I IFN signaling is not necessary for expression-vector-induced DLN 
IgA.  Groups of wildtype (wt) and IFN α/β receptor knockout (RKO) mice were immunized 
in the rear footpad at weeks 0 and 4 with 1x105 IU of HA-VRP.  Three days following the 
boost lymphoid cultures where established from the DLNs and supernatants were assayed for 
the presence of flu-specific IgA antibodies by ELISA.  Values represent the mean +/- SEM.   
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Table 5-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1.  Type I IFN signaling is not required for VRP adjuvant-induced immunity.  
Groups of wildtype (wt) and IFN α/β receptor knockout (RKO) mice were immunized in the 
rear footpad at weeks 0 and 4 with OVA alone, or OVA plus 1x105 IU of nullVRP.  Two 
weeks following the boost, OVA-specific serum IgG and fecal IgA- antibody responses were 
evaluated by ELISA.  Values represent the geometric mean +/- SEM.   
 
 
 
CHAPTER SIX 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 241
 The development of successful vaccines against human pathogens, such as smallpox 
and polio, is one of the most significant accomplishments in the field of medical intervention 
in the last 200 years.  While traditional vaccination methods have proven effective in 
numerous cases, new vaccine technologies will be required to combat the continued threats 
posed by infectious diseases.  Here we describe one such technology, alphavirus replicon 
particles, and present the viral and cellular components involved in alphavirus-induced 
immunity.  A paucity of information exists regarding the definitive mechanisms by which 
vaccines induce protective immunity.  Thus, we have attempted to delineate the viral 
trigger(s) of immune induction as well as the immunological pathways which lead to 
protection/immunity following vaccination.   
 
Molecular Mechanisms of Alphavirus-induced Immunity 
 Role of DC targeting in VRP-induced immunity.  Infection with alphaviruses, as is 
the case with most infectious agents, initiates a multi-pronged, overlapping cascade of events 
in infected cells, and in the animal or vaccinee.  Because of this, defining a causative 
relationship between a single cellular pathway and the induction of an immunological 
response has proved elusive.  Venezuelan equine encephalitis virus replicon particles display 
several features which potentially contribute to their potent immunogenicity.  Targeting 
experiments in the mouse model suggest that VRP preferentially infect DCs following 
parenteral inoculation (26).  Indeed, MacDonald and Johnston proposed that skin-derived 
Langerhans cells represent the early targets of VEE infection.  An understanding of the 
specific cellular targets of VEE infection may provide valuable information regarding the 
critical immune inductive mechanisms operating in the context of VRP vaccines.  The studies 
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presented here suggest that VRP infection promotes a massive influx of DCs into the VRP-
infected draining lymph node.  VRP infection promoted a preferential recruitment of CD11b+ 
DCs to the DLN, although CD11b- DCs were also significantly increased.  Interestingly, this 
increase was manifested by a significant increase in both the total cellularity of the DLN (8-
fold), as well as a 10-fold increase in the proportion of CD11b+ DCs in the DLN.  Combined, 
these effects result in a dramatic increase in the total number of CD11b+ DCs in the VRP-
infected DLN.   
 While VRP infection dramatically affects the APC makeup in the DLN, it will be 
important to determine which cells are targeted by VEE.  Our initial studies suggest that 
CD11b+ DCs represent the major early target of VRP infection.  Next, it will be important to 
determine the relationship between the VRP-infected DCs in the DLN and the DCs which 
present viral antigen and activate viral immunity.  Interestingly, following skin infection of 
mice with HSV, influenza virus, and vaccinia virus, Langerhans cells, while critical for 
transferring viral antigens to the DLN, were incapable of stimulating antigen-specific CD8+ 
T cells in vitro.   Instead, the CD8+ dermal DCs were found to be the only DC subset in the 
lymph node capable of stimulating antigen-specific CD8+ T cells in vitro (2, 3).  Belz et al. 
suggested a model in which Langerhans cells take up and transport viral antigens to the DLN 
following cutaneous viral infection and transfer these antigens to the dermal DCs where they 
initiate adaptive immunity (5).  We are currently testing this model in the VRP system by 
evaluating the subset of DCs which are targeted by VRP and comparing this to the DC 
subset(s) capable of stimulating in vitro CD8+ T cell responses specific for both encoded and 
co-delivered antigens.  It is possible that the DC subsets involved in the activation of CD8+ T 
cell responses under conditions in which antigens are encoded in the viral genome are 
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different than when VRP are used as an adjuvant, and antigen is not necessarily present in 
every VRP-infected cell.  Such analysis should shed new light on the role of DC targeting 
and DC APC function in alphavirus-induced immunity. 
 
 Immunostimulatory properties of VRP.  In addition to targeting vaccine antigens to 
DCs in vivo, VRP possess several other properties which may also play a role in their potent 
immunogenicity, including high level antigen expression in infected cells.  Alphavirus 
replicons express heterologous antigens under the control of the 26S subgenomic promoter, 
which is significantly stronger than the commonly utilized cytomegalovirus (CMV) promoter 
(13).  It is possible that high level transgene expression is the dominant mechanism of 
replicon-induced immune induction.  However, here we demonstrate that VRP possess 
intrinsic immunostimulatory properties which are independent of antigen expression, as VRP 
promote potent immune induction to non-VRP-expressed antigens.  These observations 
suggest that while high level antigen expression most likely does play a role in alphavirus 
expression-vector-induced immunity, the host innate immune response to the infection is 
critical for immune induction to both expressed and co-delivered antigens.   
 The induction of strong innate immune responses as a means to stimulate adaptive 
immunity is a developing theme in several experimental systems (15, 20, 23, 33).  Here we 
have begun to characterize the early inflammatory pathways which are activated by 
alphavirus infection.  VRP infection resulted in a significant increase in several 
proinflammatory and immunoregulatory factors in the DLN such as IL-1β, IL-6, TNF-α, 
IFN-γ, MIP-1β, and RANTES, consistent with the idea that VRP activate a strong innate 
immune response.  Whether immune induction with VRP is dependent upon any or all of 
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these cytokines and/or chemokines remains to be determined.  It is possible that VRP-
induced immunity is dependent upon the induction of a single cytokine or chemokine, or 
conversely, it is more likely that immune induction is a cumulative property of a suite of 
inflammatory responses.  It is also important to consider in this context that an individual 
cytokine or group of cytokines may play a more dominant role in the activation of one arm of 
the adaptive response versus another.  For example, VRP-induced IFN-γ, while critical for 
the activation of T cell responses to either VRP-expressed or co-delivered antigens, may or 
may not be required for activation of humoral immunity.  An additional consideration in this 
regard is the idea that a single cytokine or group of cytokines may have differential 
requirements for immune induction when using VRP as expression vectors as compared to 
VRP adjuvants.  Consistent with this idea, type I interferon signaling was required for the 
induction of mucosal IgA responses with VRP expression vectors, but not with VRP 
adjuvants.  The next step in the process should involve further immune induction 
experiments with both alphavirus expression vectors and adjuvants in animals either 
genetically devoid, or antibody depleted, of candidate cytokines involved in immune 
induction.  These studies should allow the identification of critical host responses involved in 
alphavirus-induced immune induction.  Any host immunological factors implicated in 
alphavirus-induced immunity in these studies would also serve as prime targets for cellular 
components which contribute to alphavirus pathogenesis (see below). 
 
 Alphavirus PAMP recognition.  While we are beginning to understand the 
inflammatory mediators that are induced by alphavirus infection, the upstream recognition 
and signaling pathways which initiate these responses have yet to be determined.  We have 
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speculated that an alphavirus-specific pathogen-associated molecular pattern (PAMP) is 
contained within replicon particles, or produced within replicon-infected cells (39).  We first 
sought to address this question by evaluating the role of VRP RNA replication in the 
adjuvant effect.  It is not feasible to evaluate RNA replication as a component of immune 
induction in the expression vector system, as mutations and/or treatments which would affect 
RNA replication, would also impact antigen expression, clouding the interpretation of such 
studies.  We found that UV-treated VRP failed to induce an adjuvant effect in both the 
systemic and mucosal compartments.  These results are consistent with a model in which 
VRP RNA replication is recognized by a cellular sentinel molecule which, once activated, 
initiates an immunological cascade which ultimately culminates in immune induction to co-
delivered antigen.  We are currently evaluating VRP-induced immunity, both in the adjuvant 
and expression vector systems, in animals genetically deficient for several candidate sentinel 
molecules such as TLR3 (1), MyD88 (7, 17), MDA5 (43), and MAVS (37).  Such analysis 
should allow us identify an alphavirus PAMP(s) and to assess the role of both the major 
intracellular viral RNA recognition pathways in alphavirus-induced immunity, as well as in 
alphavirus pathogenesis. 
 Our studies with UV-treated VEE replicon particles suggest that the alphavirus 
adjuvant effect is UV sensitive, and therefore most likely dependent upon VRP RNA 
replication as a trigger for immune induction.  However, Hidmark et al. recently 
demonstrated a serum IgG adjuvant effect with UV-treated replicons derived from the related 
alphavirus, Semliki forest virus (18).  The mechanistic explanation for this discrepancy in the 
VEE and SFV systems is unclear at this point; however, several explanations are plausible.  
A significant complication in the interpretation is the fact that it is impossible to determine 
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the exact amounts of UV applied to both replicon particles, as they were treated under 
different experimental conditions.  One potential explanation is that the UV treatment in the 
VEE system was sufficiently strong as to affect not only the structure of the nucleic acid, but 
also the conformation of the glycoproteins on the particle surface, functionally inhibiting 
binding, entry, and/or uncoating.  Conversely, it is possible that the UV treatment in the SFV 
system, while sufficient to inhibit the viral protein expression in vitro, did not fully abrogate 
RNA replication in vivo.   In support of this idea, we have demonstrated that the mouse is at 
least 10-fold more sensitive to VRP than cell lines in vitro.  This conclusion stems from the 
observation that, following subcutaneous delivery of 0.1 BHK cell IUs of HA-expressing 
VRP, seroconversion occurred in 100% of the immunized animals.  This observation is 
consistent with a model in which animals did not seroconvert to less then 1 IU of VRP, but 
instead, at least 10 times more mouse infectious units are present in VRP preparations than 
BHK cell infectious units.  Therefore, it will be important to assess the effects of a UV dose 
titration on VEE and SFV replicon RNA replication in vivo to clarify this issue.  A third 
explanation is that New World and Old World alphaviruses rely on distinct immunological 
pathways for immune induction.  Support for this idea stems from the VEE and SFV studies 
in type I interferon receptor knockout mice.  In the SFV system, type I interferon signaling 
was critical for the serum IgG adjuvant effect (18); however, VEE replicons exerted an 
adjuvant effect in type I interferon receptor knockout mice (Thompson et al., in preparation, 
Chapter 5).  It is possible that VEE induces additional cytokines which substitute for type I 
interferon whereas SFV does not.  Further experimentation will be necessary to clarify these 
issues and should provide important insights into alphavirus-induced immune induction in 
general, and the potential to optimize alphavirus-vectored vaccines.   
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The VRP Alternative Pathway for Mucosal Immune Induction 
 While we have performed the initial characterization of both the early targets of VRP 
infection, as well as the phenotype of the VRP-induced mucosal immune response, the 
molecular details of the intervening events have yet to be fully elucidated.  We are currently 
attempting to define the individual steps which occur following infection of DCs and prior to 
the presence of antibodies in mucosal secretions.  Although mucosal antigen delivery appears 
to be the most efficient method for generating a mucosal immune response (28, 29), a 
growing body of evidence supports the existence of a pathway capable of inducing mucosal 
immune responses following nonmucosal delivery [reviewed in (8, 40), (Thompson et al., in 
preparation, Chapter 3)].  Our studies suggest that the VRP DLN is a critical component of 
the alternative mucosal immune induction pathway (Thompson et al., in preparation, Chapter 
3).  Several markers of mucosal lymphoid tissues were present in the VRP-infected DLN 
including antigen-specific polymeric IgA antibodies, B and T lymphocytes bearing the 
mucosal homing receptor, expression of MAdCAM-1 on the high endothelial venules, and 
increased mucosal cytokine secretion.  However, the precise mechanism by which the VRP 
DLN activates mucosal immune responses has not been fully elucidated. 
 
VRP-induced mucosal homing.  The migration of lymphocytes into the mucosal 
compartment represents a critical regulatory step in the mucosal inductive pathway (10).  
Much is known regarding the individual components which promote mucosal homing (10).  
As mentioned previously, the α4β7 integrin, termed the mucosal homing receptor plays a 
dominant role in homing to the gut mucosa.  Our studies demonstrate that VRP induce a 
significant increase in α4β7 integrin expression on B cells and CD8+ T cells present in the 
 248
DLN.  This suggests that the α4β7 integrin-MAdCAM-1 pathway plays a role in mediating 
mucosal migration in the VRP system; however, this has not been proven.  It will be 
interesting to determine whether VRP promote mucosal immune induction in β7 integrin-
deficient animals (41) or if this pathway is not functionally required, despite the fact that it 
appears to be activated in the DLN.  If β7 integrin-deficient animals do in fact have defects in 
VRP-induced mucosal immunity, it would suggest that at least some components of the 
peripheral VRP pathway and the natural pathway are overlapping.  Other mediators of 
mucosal migration, especially in the gut, include CCR9-TECK and CCR10-MEC 
interactions. Evaluation of VRP mucosal immune induction in both CCR9 and CCR10 
knockouts would likewise provide important insights into the VRP alternative pathway.   
Again, the finding of a defect in mucosal immune induction with VRP in one or more of 
these mouse models would warrant the further evaluation of such proteins in VEE 
pathogenesis.   
Classical mucosal homing experiments involved harvesting lymphocytes from 
mucosal inductive tissues, such as the PPs and/or MLN, and monitoring homing to the 
mucosal compartment following adoptive transfer.  In fact, lympocytes of mucosal origin do 
repopulate the mucosal compartment following adoptive transfer (27, 35).  If the VRP DLN 
is truly converted into the functional equivalent of a mucosal inductive site, then one might 
predict that cells isolated from the DLN of VRP-immunized mice may have the capacity to 
home to mucosal tissues following adoptive transfer.  These experiments are underway and, 
if positive, will provide a strong functional significance for the role of the VRP-infected 
DLN in mucosal immune induction. 
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VRP-induced DLN IgA.  Our studies suggest that the DLN is a very early source of 
VRP-induced IgA antibodies, as antigen-specific IgA is detected in the DLN prior to 
detection in mucosal secretions.  A significant proportion of the DLN IgA antibodies were 
found to be dimeric or polymeric in nature.  These are characteristics of IgA antibodies 
produced at mucosal sites (6, 12, 31) and further support the notion of the DLN as part of a 
mucosal inductive pathway.  It will be interesting to determine if the VRP-induced DLN 
polymeric IgA antibodies are functionally transported into mucosal secretions.  We are 
currently evaluating the ability of DLN IgA to be recognized and transported through 
polarized epithelial cells expressing the pIgR (19) as a model system for in vivo mucosal 
transport.  Additionally, it would be interesting to measure the ability of VRP to induce IgA 
antibodies in both the DLN as well as at the local mucosal surface in animals which have 
been genetically engineered to produce an increased monomeric to polymeric IgA ratio, such 
as J chain knockout mice or pIgR knockout mice.  The results of such studies should further 
characterize the mucosal characteristics of DLN IgA and provide an additional test to the 
VRP alternative pathway model (21). 
While the presence of IgA in the DLN of VRP-vaccinated mice is not disputed, the 
anatomical location in which IgA class switch occurs has yet to be determined.  It is 
theoretically possible that the cells producing IgA antibodies in the DLN at day 3 post boost 
received the IgA class switch signals somewhere other then the DLN (such as the PP) and 
then migrated back to the inflamed DLN to initiate IgA secretion.  Or conversely, that IgA 
class switch occurred in the DLN just prior to IgA secretion.  As a first step in addressing 
whether IgA class switch occurs in the VRP-infected DLN, we are evaluating whether the 
cytokines present in the DLN of VRP-immunized mice possess the capacity to promote IgA 
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class switch in vitro.  Several cytokines which we have shown to be present in the DLN, such 
as IL-5 (22), IL-6 (22), and TNF-α, are known to promote either IgA class switch or 
secretion from IgA-switched cells.  We are currently utilizing DLN PBS extracts as a source 
of cytokines driving IgA class switch of LPS-treated B cells in culture (4).  If VRP DLN 
extracts in fact promote IgA class switch, the stimulating cytokine(s) will be identified in a 
series of blocking studies with monoclonal antibodies directed against specific cytokines 
(32).   
 
VRP-induced mucosal IgG/IgA ratio.  A large body of evidence supports the notion 
that antibodies of the IgA isotype are the most abundant antibodies present in mucosal 
secretions, although IgG and IgM antibodies are also found in mucosal secretions at much 
reduced levels compared to IgA  (11, 28-30).  Our studies clearly demonstrate that VRP 
stimulate the production of antigen-specific IgA antibodies at the mucosal surface.  However, 
an interesting finding in our analysis of VRP-induced mucosal immune induction is that VRP 
consistently stimulate the production of greater than 10-fold more antigen-specific IgG 
antibodies than IgA antibodies in mucosal secretions.  This observation holds true in the 
upper respiratory tract (nasal washes, nasal lymphocyte ASC ELISPOT, nasal epithelium 
lymphoid cultures), the gastrointestinal tract (fecal extracts, LPL ASC ELISPOT, gut 
lymphoid cultures), the urogenital tract (vaginal lavage fluids) (16, 24, 39), (Thompson J. M., 
Richmond, E. M., and Johnston, R. E., unpublished) as well as in the VRP DLN (Thompson 
et al., in preparation, Chapter 3).  It has been proposed that IgG antibodies in mucosal 
secretions may play an important role in mucosal defense (9, 36).  In fact, significant levels 
of IgG antibodies are found in secretions from the female reproductive tract  (9, 36).  The 
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exact signals which promote an increased ratio of mucosal IgG to IgA in the VRP system as 
compared to the IgG to IgA ratio following, for example, nasal antigen delivery in the 
presence of CT remain to be determined.   
Irrespective of the inductive mechanism(s) responsible for mucosal IgG production, 
we speculate that VRP-induced mucosal IgG antibodies may play a significant role in 
mediating protection from mucosal challenge in the alphavirus system.  We have 
demonstrated recently that HA-expressing VRP not only protect animals from the overt signs 
of disease following intranasal challenge with influenza virus, but also limit challenge virus 
replication to levels below the limits of detection by plaque assay as well as HA-specific in 
situ hybridization (Richmond E. M., Thompson, J. M., Davis, N. L., Brown, K., West, A. C., 
and Johnston, R. E., unpublished).  It will be interesting to determine what respective roles 
nasal IgG and IgA antibodies play in mediating this protective effect.  Several models of 
mucosal IgA deficiency exist including J chain knockouts (25) and pIgR knockouts (21); 
however, we propose to utilize local depletion of either nasal IgG and/or IgA by intranasal 
installation of anti-mouse IgG and/or IgA antibodies as developed by Renegar and Small 
(34), in combination with our nasal influenza challenge model, to identify the protective 
isotype(s).  The results of these studies should significantly improve our knowledge of VRP-
induced protective immunity.   
 
Implications for VEE Pathogenesis 
Role of DC targeting in VEE pathogenesis.  The studies described here clearly 
demonstrate the utility of VRP as components of successful vaccines and provide a powerful 
model system for the study of viral immunology.  Our findings may also have implications 
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for the pathogenesis of VEE as well.  While a thorough examination of all the individual 
APC subsets present in the lymph node following VRP delivery has yet to be performed, our 
studies clearly demonstrate that VRP infection leads to a significant recruitment of DCs to 
the DLN.  One possibility is that recruitment is a generalized host response to an 
inflammatory environment in the DLN.  Consistent with this idea, VEE promotes the strong 
induction of several inflammatory mediators in the DLN such as IL-1β, TNF-α, and IL-6.  A 
second possibility is that VEE specifically recruits its own cellular targets of infection to the 
DLN as a means to promote spread in the animal.  However, it is not immediately apparent 
exactly why this would be advantageous to the virus, as virus replication occurs in nearly 
every organ in the animal at later times post infection, suggesting the cellular targets of 
infection are not limiting.  Why the first round of infection, as modeled by VRP delivery, 
demonstrates preferential infection of DCs and not infection of the downstream visceral 
organs is unclear at this point.  It is possible that DC-derived viruses are somehow better 
suited for either infection of, or replication within, downstream tissues in vivo.  Glycosylation 
patterns in DCs could potentially give rise to viruses with an altered infectivity profile for 
downstream tissues, an enhanced ability to cross the blood-brain barrier, or the capability to 
evade the next wave of host innate immune responses.  Shabman et al. recently demonstrated 
that the cell type in which alphaviruses are grown dramatically affects both the infectivity of 
progeny virions for DCs as well as their ability to interfere with the type I interferon response 
(38).  This hypothesis presents a testable model.  It would be interesting to evaluate the 
replication kinetics and in vivo pathogenesis of DC-grown virus as compared to fibroblast-
grown virus following intraveneous inoculation to bypass the DC targeting steps. 
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It is also possible that VEE recruits DCs to the lymph node as a means to cripple their 
APC function.  VEE causes significant apoptosis in DC cultures (Moran et al., submitted), 
and recruitment of DCs to the pro-inflammatory environment of the DLN could hinder APC 
function directly through the activation cell death pathways in infected cells, or indirectly 
through cytokine and/or chemokine signals to neighboring, uninfected cells.  Alternatively, 
virus-induced recruitment may not affect the viability or functionality of DCs, but instead 
provide a mechanism to sequester DCs in the DLN, blocking their function in anti-viral 
defense by limiting access to viral antigen and cells of the adaptive immune system in 
downstream tissues.  Consistent with this idea, recruitment of DCs to the DLN following 
VRP delivery continued through day 3 post infection; a timepoint in which downstream 
tissues are already infected following delivery of replicating virus.  A more careful 
examination of the kinetics of DC recruitment to the DLN following VRP delivery may help 
to determine what role, if any, viral recruitment of DCs to the DLN plays in VEE 
pathogenesis.   
 
Role of lymphocyte migration in VEE pathogenesis.  One of the most common 
clinical manifestations of VEE disease in humans, horses, and mice is an acute lymphopenia 
(42).   The exact mechanisms responsible for this clinical outcome have not been clearly 
elucidated (14).  One potential explanation is that lymphocytes undergo programmed cell 
death as a result of direct or indirect signals provided by virus infection.  Alternatively, 
clinical presentation of lymphopenia could also occur following virus-induced lymphocyte 
migration to sites which would preclude their detection systemically.  Our studies suggest the 
VRP infection dramatically affects cellular migration and trafficking patterns of lymphocytes 
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in vivo.  VRP induced a significant influx of lymphocytes into the draining lymph node at 
early times post infection (Chapter 3) and migration of lymphocytes into the mucosal 
compartment at later times post infection (Chapter 4).  These results are consistent with the 
idea that VEE infection dramatically affects the migratory properties of lymphocytes and 
begs the question of whether VRP promote the mobilization of lymphocyte migration into 
the mucosal compartment in a non-specific manner.  It remains to be determined if this is 
really the case.  It will be interesting to determine if VRP infection promotes mucosal 
migration of lymphocytes with a defined, unrelated specificity, to the VRP-associated 
antigen or if the observed migration is activation of cells specific for “contaminating” 
antigens in VRP preparations.  While the quantitative analysis of cells present in the URT 
following VRP delivery does suggest that the URT is the single reservoir of systemic 
lymphocytes, it is possible that mucosal lymphocyte migration contributes to the 
lymphopenia observed following natural VEE infection.  We are currently evaluating 
whether VRP infection promotes lymphocyte migration to other mucosal surfaces in addition 
to the URT.  Further experimentation will be required to evaluate the role of mucosal 
lymphocyte homing in VEE pathogenesis; however, these studies typify the interplay 
between pathogenesis and vaccine development in the alphavirus system. 
 
Optimization of VRP Vaccines 
 The primary focus of the studies presented here has been the identification of the viral 
and immunological factors which regulate alphavirus-induced immunity.  The discovery of 
the alphavirus adjuvant effect has provided a powerful experimental system which has turned 
out to be extremely useful in this regard.  We are also pursuing VRP as vaccines in a number 
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of systems.  In fact, a phase I human trial has recently been completed utilizing VRP 
expressing HIV antigens.  Therefore, regardless of the immune inductive pathways 
stimulated by VRP, the ability of VRP to promote protective immunity may significantly 
improve human vaccines.  Thus, the optimization of VRP-induced immunity represents an 
important area of development.   
 The dosing schedule utilized in these studies was based upon our experience 
optimizing serum IgG responses induced by VRP expression vectors.  Additional schedules 
including multiple dosing as well as combining several routes should be explored as a means 
to improve the utility of VRP vaccines, with special emphasis on induction of mucosal 
immunity.  Additionally, here we have focused on the characterization of VRP adjuvant 
activity.  Future work should combine the various alphavirus vaccine platforms (expression 
vectors, adjuvants, DNA-launched expression vectors) into a single immunization protocol.  
Furthermore, in order to identify immunological mechanisms involved with alphavirus-
mediated immune induction we have focused on single modality studies; however, VRP may 
prove to perform better as components of successful combination vaccines.  In support of this 
idea, VRP and CpG worked together in an additive manner to increase immunity to co-
delivered antigen.  Future studies should expand to test other modalities in combination with 
VRP in search of synergistic effects.  This search should include other TLR agonists, both 
old and new vaccine technologies, as well as potentially delivering VRP in the skin through 
transcutaneous immunization.  We believe that further dosing and combinational 
optimization has the potential to significantly improve the utility of VRP-based vaccines and 
adjuvants, and may enable successful vaccination protocols for the production of anti-
pathogen immunity in humans.   
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